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Abstract 
Major Depressive Disorder (MDD) is a leading cause of global morbidity and mortality, 
and is associated with impaired functioning and a poorer quality of life. It is 
increasingly recognised that individuals with MDD are at greater risk of chronic health 
conditions such as obesity and cardiometabolic disease, however the pathways linking 
MDD to chronic disease risk factors are not well understood. An integrated 
biopsychosocial approach may improve the understanding of the links between MDD 
and chronic health conditions, potentially leading to more effective treatments. Changes 
in appetite and weight are symptoms of MDD and may be a pathway between MDD and 
chronic disease risk factors. Indeed, problematic eating behaviours, such as emotional 
eating and food addiction, have been linked to depressogenic weight gain. Further, 
hormones implicated in food intake and eating behaviours such as the satiety hormone 
leptin, hunger hormone ghrelin, energy balance hormone serotonin and sympathetic 
stress response hormone dopamine may be dysregulated in MDD. However, the nature 
of problematic eating behaviours, and whether peripheral hormones are directly related 
to problematic eating and health indices, has not been systematically studied in MDD. 
Therefore, this thesis examined relationships between problematic eating behaviours, 
peripheral hormones, health indices such as body mass index (BMI) and waist 
circumference, and symptom profiles in MDD to elucidate possible pathways between 
MDD and chronic health conditions. In Study 1, plasma leptin was compared between 
individuals with MDD (n = 63) and healthy controls (n = 60), by sex and symptom 
profile. The relationship between leptin and problematic eating was assessed in a subset 
of individuals with MDD (n = 33). Leptin was higher in females with increased versus 
decreased or unchanged appetite and weight, with the opposite effect found in males. 
Problematic eating was more prevalent in depressed females than depressed males, and 
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positively correlated with leptin concentrations. In Study 2, problematic eating, appetite 
and weight symptoms, and plasma leptin and ghrelin concentrations were examined in a 
new cohort of individuals with MDD (n = 60) and healthy controls (n = 60). 
Problematic eating was more prevalent in MDD compared to controls, and in females 
compared to males. Females had higher leptin than males. Leptin correlated positively 
and ghrelin negatively with overeating. In the same cohort, Study 3 examined plasma 
serotonin in relation to symptom profiles and weight changes in MDD, and 
relationships between serotonin, problematic eating and depressive symptoms. Plasma 
serotonin was higher in MDD than controls and in males than females, but did not differ 
by appetite and weight symptom profile. Serotonin did not correlate with overeating or 
health indices, however it was positively associated with low mood, negative thinking 
and insomnia, particularly in males. Study 4 evaluated plasma dopamine and 
depressogenic overeating, particularly food addiction, in an extended cohort of 
individuals with MDD (n = 80) and healthy controls (n = 60) by sex. Participants with 
MDD who met food addiction criteria had poorer health indices and greater 
psychopathology than those who did not meet these criteria. Depressed males who met 
food addiction criteria had lower dopamine than those who did not meet food addiction 
criteria, whereas dopamine did not vary by food addiction status in females. Dopamine 
correlated with overeating positively in females and negatively in males. Following the 
individual assessment of hormones in relation to depressogenic overeating, Study 5 
assessed the extent to which leptin, ghrelin, serotonin and dopamine accounted for 
unique variance in problematic eating behaviours, depressive symptom severity and 
BMI in MDD and control participants from Studies 2 to 4 (n = 140), with Sex as a 
moderating variable. Leptin and dopamine accounted for a significant amount of 
variance in Emotional eating, whereas serotonin accounted for a significant amount of 
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variance in depressive symptom severity. Leptin and ghrelin further predicted adiposity 
across sexes, with leptin in particular accounting for a greater amount of variance in 
BMI in females compared to males. In all studies, problematic eating and hormones 
correlated with higher BMI and waist circumference values. This thesis provides 
evidence that individuals with MDD, particularly females, experience greater 
problematic eating behaviours which are related to peripheral hormones and indices of 
health risk. The hormonal results suggest that insensitivity or resistance to peripheral 
hormones, particularly leptin, is significantly associated with overeating in MDD. These 
findings provide new insight into the nature of depressogenic overeating, and indicate 
greater hormonal involvement in MDD than previously recognised. These findings 
present possible avenues for further research into novel and integrated treatments to 
reduce the risk of chronic health conditions in those affected by MDD, particularly 
females. 
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Thesis Overview 
Individuals with Major Depressive Disorder (MDD) are at an increased risk of 
developing chronic health conditions, including obesity and cardiometabolic disorders 
(Luppino et al., 2010; Penninx, 2017). Despite this risk, the associations between MDD 
and such conditions are not clearly understood. While MDD is characterised by 
symptoms spanning psychological and physiological domains, existing approaches in 
MDD research tend to have a predominantly psychological or physiological focus, 
which limits comprehensive analyses of the potential factors underlying the relationship 
between MDD and poor physical health. These approaches also fail to account for the 
heterogeneous nature of depressive symptom profiles which may further obscure 
potential pathways (Abreu & Santos, 2008). Biological, psychological and behavioural 
factors may influence the relationships between MDD, obesity and cardiometabolic 
disease, however integrated research that combines these factors while accounting for 
heterogeneity is lacking (Milaneschi et al., 2019). 
Weight gain is one of the proposed links between MDD and chronic health 
conditions. A core symptom of MDD is appetite and weight dysregulation, where 
individuals can experience either increases or decreases to their appetite and weight 
(American Psychiatric Association, 2013). Notably, the prevalence of depressogenic 
weight gain is increasing in concert with the increasing prominence of obesogenic 
environments (Blanco et al., 2012). Problematic eating behaviours, such as emotional 
eating and food addiction, may be relevant to weight gain in MDD since such 
behaviours are risk factors for obesity, which is in turn a risk factor for cardiometabolic 
disease (Romero-Corral et al., 2010). Additionally, peripheral hormones play a crucial 
role in eating behaviour by regulating satiety, hunger, weight, energy balance and 
sympathetic stress, and may therefore also contribute to depressogenic weight gain and 
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chronic health condition risk (Arora & Anubhuti, 2006). However, problematic eating 
in MDD is not well understood, and research assessing the relationships between 
peripheral hormones, eating behaviours and health risk indices in MDD is lacking. 
Accordingly, this thesis applied an integrated biopsychosocial approach to empirically 
investigate the nature of problematic eating behaviours in MDD, and how such 
behaviours relate to psychological measures of depressive symptoms such as appetite 
and weight change, physical health indices such as BMI and peripheral hormones linked 
to satiety, hunger, weight regulation and energy balance. These interrelationships were 
assessed with a view of extending the existing knowledge regarding MDD, obesity and 
cardiometabolic disease risk. Notably, this is the first program of research to 
simultaneously examine peripheral hormones, depressive symptom profiles and 
physical health indices in MDD.  
In this thesis research, several types of problematic eating were 
psychometrically quantified, including emotional eating, restrained eating, external 
eating and food addiction. The depressive symptom profile of most interest was self-
reported appetite and weight gain compared to appetite and weight loss. Other 
depressive symptoms which may influence problematic eating and weight gain in MDD 
were also measured, including depressive symptom severity, psychological distress 
related to mood, anxiety and stress, insomnia and negative thoughts. The physical health 
indices measured included weight, BMI, waist circumference, blood pressure and heart 
rate. Peripheral hormones implicated in the regulation of appetite and weight were also 
examined, which may be relevant to cardiometabolic disturbances and overeating in 
MDD. Leptin and ghrelin were examined due to their respective roles in satiety and 
hunger, in addition to energy balance and adiposity. Plasma serotonin was investigated 
Preamble – Thesis Overview xviii 
due to its links to mood, obesity and energy balance, and plasma dopamine was 
assessed due to its roles in energy balance and the sympathetic stress response. 
 The opening chapter of this thesis (Chapter 1) provides a comprehensive review 
of existing literature. The literature review outlines MDD and its symptomology, the 
chronic conditions that are associated with MDD and the role of weight gain in these 
conditions. Also outlined in the literature review are potential pathways to 
depressogenic weight gain, including problematic eating behaviours and the relevant 
peripheral hormones. Chapter 1 concludes with a statement of the specific thesis aims. 
Study 1 (Chapter 2) investigated the role of leptin in appetite and weight 
changes in MDD (total n = 120; 60 MDD, 60 healthy controls). Problematic eating 
behaviours, including emotional eating and food addiction, and their links to leptin 
concentrations were examined in a small subset of the larger study (n = 33). Leptin was 
linked to appetite and weight change patterns in MDD, which differed by sex, with 
higher leptin concentrations in depressed females who reported increased appetite and 
weight, and in depressed males who reported decreased appetite and weight. Leptin 
correlated positively with problematic eating behaviours in MDD, providing some of 
the first evidence that problematic eating in MDD is related to a peripheral hormone. 
Study 2 (Chapter 3) extended on the previous pilot investigation to compare 
problematic eating behaviours in MDD compared to controls in a new, larger cohort 
(total n = 120; 60 MDD, 60 healthy controls). Sex differences and the relationships 
between leptin, the hunger hormone ghrelin, problematic eating behaviours and 
appetite/weight changes were also assessed. High levels of problematic eating 
behaviours were found in MDD, particularly among those who reported appetite and 
weight gain, and females, supporting that problematic eating behaviours occur 
frequently in MDD and vary as a function of symptom profile and sex. Leptin correlated 
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positively, and ghrelin negatively, with problematic eating behaviours and BMI, 
providing additional evidence that appetite and weight hormones are related to 
overeating and biometric health indices in MDD. 
Having established links between hunger and satiety hormones and problematic 
eating behaviours in MDD, Study 3 (Chapter 4) examined the energy balance hormone 
serotonin in MDD compared to controls, in the same cohort as Study 2. Differences in 
plasma serotonin concentration by sex and appetite/weight changes were measured, and 
relationships between plasma serotonin, problematic eating behaviours and other 
depressive symptoms such as low mood, psychological distress, depressogenic thinking 
and insomnia were assessed. Plasma serotonin was significantly higher in those with 
MDD than controls, and in males than females. Serotonin correlated with greater 
depressive symptom severity, depressogenic thinking and anxiety in males, but only 
with agitation in females. Plasma serotonin did not differ by appetite and weight 
symptom profile in MDD and was not associated with problematic eating. While 
serotonin was not directly linked to overeating, it may be an important factor to other 
symptom profiles in MDD featuring low mood, negative thinking and insomnia 
disturbances, particularly in males. 
Following the high prevalence of problematic eating behaviours identified in 
participants with MDD relative to controls in Studies 1 and 2, Study 4 (Chapter 5) 
aimed to assess the extent of overeating and food addiction in MDD, and examine the 
potential role of peripheral dopamine in these behaviours, in an extended cohort to 
Studies 2 and 3 (total n = 140; 80 MDD, 60 healthy controls). Participants with MDD 
were more likely to meet the criteria for food addiction than controls, with those 
meeting criteria for both MDD and food addiction demonstrating greater indices of 
health risk and psychopathology than depressed individuals who did not meet food 
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addiction criteria. Plasma dopamine was higher in males compared to females, and 
correlated positively with problematic eating behaviours in females, and negatively in 
males. The results of this study provide further support to indicate that problematic 
eating behaviours in MDD are related to hormones, and also suggests that relationships 
between plasma dopamine concentrations and overeating behaviours vary by sex. 
Following the findings that leptin, ghrelin, serotonin and dopamine were 
associated with depressogenic problematic eating behaviours and physical health risks 
in Studies 1-4, Study 5 investigated the combined and individual relative contributions 
of each of these peripheral hormones to variance in problematic eating behaviours, 
depressive symptom severity and BMI, and the potential role of Sex in moderating these 
relationships (total n = 140; 80 MDD, 60 healthy controls). Across sexes, leptin and 
dopamine predicted problematic eating behaviours, whereas serotonin predicted overall 
depressive symptom severity. Leptin significantly predicted adiposity as indicated by 
BMI, with effects being more pronounced in females compared to males. These 
findings highlight the relative importance of individual hormones in relation to 
problematic eating behaviours and depressive symptom severity, and that hormones 
accounted for greater variance in adiposity associated with MDD, as indicated by BMI, 
in females compared to males. 
The final chapter of this thesis (Chapter 7) summarises the overall thesis 
findings and their collective implications, in addition to discussing the significance of 
the research. Methodological limitations, directions for future research and general 
conclusions are also discussed. 






General Introduction and Literature Review 
 
1.1 Major Depressive Disorder 
1.1.1 Prevalence 
Major Depressive Disorder (MDD) is a multifaceted and heterogeneous mental 
illness that is a leading cause of morbidity and mortality worldwide, and also the 
leading contributor to the global disease burden (World Health Organisation, 2017). 
Approximately 322 million individuals, or 4.5% of the global population, were 
estimated to be living with MDD in 2017, which affected 5.5% of females and 3.6% of 
males (World Health Organisation, 2017). In 2018, the 12-month prevalence rate of 
MDD in Australia was 10.4%, which affected 11.6% of females and 9.1% of males 
(Australian Bureau of Statistics, 2018). The global prevalence of MDD rose by 18.4% 
in the decade between 2005 and 2015, with prevalence rates continuing to rise annually 
(World Health Organisation, 2017). The rising prevalence of MDD has been attributed 
to increased stress, which can be defined a psychological or physiological response to 
an experience where situational demands are interpreted to be greater than the resources 
an individual has to cope (Kogler et al., 2015). These rises are further ascribed to 
increased endocrine dysregulation, or impaired hormone regulation, as well as an 
increased shift towards obesogenic lifestyles and environments. Such environments are 
characterised by increased food intake in response to salient and highly palatable food 
cues, poor nutrient intake, reduced physical activity and poor physical health (Hidaka, 
2012; World Health Organisation, 2017). 
 
1.1.2 Symptoms and Diagnosis 
According to the Diagnostics and Statistical Manual of Mental Disorders (DSM-
5), MDD is characterised by nine symptoms which broadly span psychological or 




physiological domains (American Psychiatric Association, 2013). A core psychological 
symptom of MDD is depressed mood, or a relatively constant negative affective state 
involving persistent sadness, tearfulness, irritability, pessimism, hopelessness or having 
a total absence of feeling (Beck et al., 1996). A second core psychological symptom is 
anhedonia, or the impaired ability to experience either pleasure or interest in activities 
found to be enjoyable in a pre-depressive state such as hobbies, social connections or 
sexual activities (Treadway & Zald, 2011). Other psychological symptoms include 
feelings of guilt or worthlessness that result from self-blame for minor failings or 
uncontrollable personal circumstances (McPherson et al., 2007); executive functioning 
impairments including indecisiveness, impaired attention and memory deficits 
(Paelecke-Habermann et al., 2005); and suicidal ideation, or suicidal thoughts that can 
either be passive without intent to act, or active with intention to see a suicide plan 
through to completion (American Psychiatric Association, 2013).  
Physiological symptoms of MDD often present dichotomously in different 
symptom profiles. These include appetite and weight dysregulation, which presents as 
either hypophagia and weight loss, or hyperphagia and weight gain (American 
Psychiatric Association, 2013); sleep disturbances of insomnia, which encompasses 
difficulty falling asleep, difficulty staying asleep or repeatedly waking too early, and 
hypersomnia, a daily excess of 10 hours of sleep that is often not restful, resulting in 
increased sleepiness when awake (Geoffroy et al., 2018); and psychomotor disturbances 
presenting as either agitation or retardation, whereby agitation manifests as an inability 
to sit still, talkativeness or distractibility, and retardation is the slowing of thoughts and 
behaviours (Sobin et al., 1998). The majority of depressed individuals also exhibit 
fatigue, or lethargy linked to mental or physical exertion (American Psychiatric 
Association, 2013). 




According to DSM-5 criteria, a diagnosis of MDD is based on an individual 
experiencing at least five out of the nine aforementioned symptoms for a minimum two-
week period, termed an ‘episode’, where one of the five symptoms is required to be 
either depressed mood or anhedonia (American Psychiatric Association, 2013). 
Additional diagnostic criteria include self-reported distress, worry or impairment in 
important areas of an individual’s life due to the presence of MDD symptoms, such as 
in social or occupational environments. Further, the symptoms experienced are required 
to not be attributable to substance use, a diagnosable medical condition or to another 
psychological disorder such as anxiety or schizophrenia (American Psychiatric 
Association, 2013). 
 
1.1.3 Prognosis and Impact 
MDD is a recurrent and progressive condition associated with a variable 
prognosis and course (Parekh et al., 2017). More severe depressive symptoms that are 
experienced for a longer period of time are linked to a poorer prognosis (Rubenstein et 
al., 2007). The median duration of a depressive episode is reported to be 24 weeks, 
however episodes can last from several weeks to several years (Ten Have et al., 2017). 
Sixty percent (60%) of individuals who experience one depressive episode go on to 
experience a second within 6 months of recovery from the first. Of these, 80% will 
experience a third episode, and 90% of those a fourth (American Psychiatric 
Association, 2013; Burcusa & Iacono, 2007). The highly recurrent nature of MDD can 
be explained using the ‘kindling effect’ (Post, 1992), which suggests that an initial 
depressive episode is triggered by major life stressors, which results in enduring 
neurochemical brain changes. Subsequent exposure to repeated or prolonged stressors 
combined with the neurochemical changes results in depressive episodes that are 




progressively less linked to specific triggers and more likely to occur without clear 
cause (Post, 1992). This indicates an increased vulnerability to further depressive 
episodes as more episodes occur (Post, 1992).  
MDD represents a significant physical, emotional and financial burden for those 
diagnosed, leading to impairment across various domains of inter- and intrapersonal 
functioning (Hammer-Helmich et al., 2018). Affected individuals often report reduced 
functional capacity or impairment in social or occupational environments (American 
Psychiatric Association, 2013), resulting in withdrawal from existing social 
connections, an inability to form and maintain new social relationships, and a loss of 
workplace productivity and capacity (Hammer-Helmich et al., 2018). This loss of 
functioning is associated with a decreased quality of life (IsHak et al., 2015), which is a 
risk factor for poor treatment outcomes and a greater likelihood of experiencing more 
recurrent and severe depressive episodes (Hirschfield et al., 2002). 
 
1.2 Obesity and Cardiometabolic Disease Risk and Impact in MDD 
 
A growing body of empirical evidence indicates that those with MDD are at a 
significantly greater risk of developing chronic health conditions, particularly obesity 
and cardiometabolic disease (Luppino et al., 2010; Rubin et al., 2013; Steiner et al., 
2019). Obesity is also a risk factor for cardiometabolic disease (Romero-Corral et al., 
2010). Cardiometabolic disease encompasses cardiovascular and metabolic disorders. 
Cardiovascular disease (CVD) broadly refers to conditions affecting heart and blood 
vessel health, including atherosclerosis and myocardial infarction (Penninx, 2017), 
while metabolic disorders include conditions that feature disturbances to insulin 
secretion, glucose regulation and lipid abnormalities, including metabolic syndrome 
(Garcia-Toro et al., 2016). The interaction between MDD and cardiometabolic 




conditions appears to be antagonistic with respect to health and functioning (Deschenes 
et al., 2015; Schmitz et al., 2007). Those with MDD with a cardiometabolic condition 
are at a significantly greater likelihood of disability, poor social and occupational 
functioning (Deschenes et al., 2015), morbidity, all-cause mortality (Ofei, 2005; 
Vaccarino et al., 2008), a reduced quality of life, a poorer prognosis and poor treatment 
outcomes (IsHak et al., 2015). Indicators of overweight or obesity include high BMI 
and waist circumference values (Romero-Corral et al., 2010). Risk factors for CVD 
include high resting heart rates and blood pressure (Gijon-Conde et al., 2015). 
There are noted bidirectional relationships between MDD and obesity (Luppino 
et al., 2010; Mannan et al., 2015). Obesity is characterised by the excessive 
accumulation of adipose tissue, particularly around the viscera, with this referred to as 
abdominal adiposity (Ofei, 2005). Clinical and epidemiological studies suggest that 
MDD increases the risk of obesity by 37-58%, and that obesity increases the risk of 
MDD by 18-55% (Luppino et al., 2010; Heiskanen et al., 2013; Mannan et al., 2015). 
MDD is associated with higher BMI and waist circumference values compared to 
controls (Kloiber et al., 2007; Zhao et al., 2009), with these effects being more 
pronounced in females than males (Li et al., 2017; Zavala et al., 2018). More severe 
depressive symptoms are also predictive of greater weight in MDD as indexed by BMI 
(Heiskanen et al., 2013).  
MDD is also associated with an increased risk for developing CVD (Rubin et 
al., 2013; Penninx, 2017). Depressive symptom severity is a predictor of future CVD 
onset (Rubin et al., 2013), with a clinical diagnosis of MDD increasing the risk of CVD 
by approximately 50-90% (Hare et al., 2014). MDD has been associated with high 
resting heart rates linked to poor emotional regulation (Agelink et al., 2002) and 
elevated blood pressure (Rubio-Garcia et al., 2013), both of which are associated with 




increased sympathetic nervous system activity and increased CVD risk (Nabi et al., 
2011). Greater depressive symptom severity has also been correlated with higher blood 
pressure values (Rubio-Garcia et al., 2013).  
 
1.2.1 Considerations for Understanding the Links Between MDD, Obesity and 
Cardiometabolic Disease 
Despite the increasingly reported associations between MDD, obesity and 
cardiometabolic disease, the specific pathophysiological pathways between MDD and 
such conditions are not clear. Some factors which have been implicated in the onset of 
these conditions in MDD include psychological and physiological stress, unhealthy 
lifestyles such as increased sedentary activity, changes in diet (Luppino et al., 2010), 
consistent low-grade inflammation (Knol et al., 2006), weight gain (Rubin et al., 2013), 
problematic eating behaviours (van Strien et al., 2016) and hormones related to the 
regulation of food intake (Arora & Ahubhuti, 2006). However, a clear understanding of 
these mechanisms and associations is complicated by the heterogeneous nature of 
MDD, as well as a lack of integrated conceptual models for MDD. 
 
1.2.1.1 Heterogeneity in MDD Symptoms 
There is substantial heterogeneity in MDD symptom profiles. The requirement 
of low mood or anhedonia, in addition to another four symptoms, are required for a 
DSM-5 diagnosis of MDD (American Psychiatric Association, 2013) allows for 
considerable variability in symptom presentation. Accounting for the dichotomous 
presentations of appetite/weight dysregulation, sleep disturbances, psychomotor 
disturbances and suicidal ideation, in addition to any of the other symptoms being 
present or absent, there are over 227 potential different presentations of MDD that 
qualify for DSM-5 diagnosis (Zimmerman et al., 2015). There is also a high degree of 




variation in treatment responsiveness, as individuals with the same diagnosis but 
different symptom profiles may respond differently to various treatment types, such as 
psychological interventions or antidepressant medications (Uher et al., 2011). The cause 
of this heterogeneity is hypothesised to be a complex interaction between the 
aetiological factors related to MDD, including changes to the brain and neurochemistry, 
dysregulation in the hypothalamic-pituitary-adrenal (HPA) axis (Keller et al., 2016), 
genetics (Lohoff, 2010), environmental factors such as stressful life events or 
socioeconomic status (Fava & Kendler, 2000), and the various interrelationships 
between depressive symptoms (Bridwell et al., 2015). Therefore, diverse MDD 
symptom patterns need to be considered with respect to risk factors for obesity and 
cardiometabolic disease. However, existing research tends to have combined symptom 
profiles without consideration of differing presentations. For example, examining 
weight changes generally without examining the direction of change could mask 
differences in obesity and cardiometabolic disease risk among particular subgroups of 
individuals with particular MDD symptom profiles (Fried & Nesse, 2015a).  
 
1.2.1.2 Conceptual Models for MDD 
The current dominant models for the pathogenesis and treatment of MDD tend 
to be divided between those that focus primarily on either psychological factors such as 
dysfunctional thought patterns, or physiological factors such as dysregulation in brain 
neurochemistry (Abreu & Santos, 2008; Berton & Nestler, 2006). Psychological models 
of MDD, including Beck’s Cognitive Model (Beck, 1967) suggest that MDD is the by-
product of systematic negative biases in thoughts and perceptions. An interaction 
between early stressful life events and genetic factors is associated with the 
development of negative cognitive schemas, or stable cognitive frameworks which are 




used to interpret the self, the world and the future (Beck, 1967). Negative cognitive 
schemas are activated in response to biological factors such as stress, and once activated 
result in a pessimistically distorted perception of reality which contributes to negative 
mood and behaviour (Beck, 1967). Recurrent activation of these cognitive schemas is 
associated with an attentional bias towards negative stimuli, consistent low mood and 
perception, memory and problem-solving deficits (Beck, 1967). Cognitive Behavioural 
Therapy (CBT; Beck, 1967), developed as a result of Beck’s model, is a first line 
treatment for MDD (RANZCP, 2015). CBT relies on rationalising negative thoughts 
and replacing such thoughts with more realistic ones through techniques such as 
monitoring negative thought processes, cognitive restructuring and psychoeducation 
(Beck, 1967; Powell et al., 2008). CBT has demonstrated efficacy in being able to 
reduce MDD symptoms after six to twelve therapy sessions (Busch & Sandberg, 2012), 
however both CBT approaches and Beck’s Cognitive Model, while acknowledging a 
role of genetic factors in the pathogenesis of MDD, have a limited consideration of 
physiological factors which may be important to MDD. Beck’s model was revised in 
2008 to outline how biological factors could be incorporated into the existing CBT 
framework, however this model was largely hypothetical and to date there has been 
very little research examining the interaction between biological and psychological 
factors (Beck, 2008; Thomas & Larkin, 2020).  
The dominant physiological model of MDD is the monoamine hypothesis, 
which postulates that low levels of monoamine neurotransmitters in the central nervous 
system (CNS) are related to depressive symptoms, including serotonin (Charney, 1998). 
Serotonin has been implicated in the pathogenesis of MDD following the accidental 
discovery that antipsychotic medications designed to increase serotonergic functioning 
in schizophrenia were more effective in alleviating depressive than psychosis-related 




symptoms (Schildkraut, 1965). The premise of low CNS-serotonin in individuals with 
MDD led to the development of selective serotonin-reuptake inhibitor (SSRI) 
medications, where the purported mechanism of action is to block reuptake of serotonin 
at the neuronal synapses and increase the quantity of serotonin available, with effects on 
mood (O’Neill et al., 2008). SSRIs have modest efficacy in alleviating symptoms in 
mild to moderate cases of MDD (Berton & Nestler, 2006), however they are associated 
with low remission rates, high treatment resistance (Bartolomucci & Leopardi, 2009) 
and a delayed onset of action. SSRIs are required to be taken for some weeks before 
effects become evident, resulting in the mechanism of action being questioned, since a 
quicker response should occur if low CNS-serotonin underlies depressogenic symptoms 
(Andrews et al., 2015). Notably, the premise of the monoamine hypothesis is difficult to 
empirically validate, as synaptic levels of serotonin cannot be measured directly 
(Andrews et al., 2015). As such, CNS-serotonin is commonly estimated in cerebrospinal 
fluid (CSF) obtained via a lumbar puncture. However, this procedure is highly invasive, 
requires a large volume of CSF for an accurate reading, and reflects post-
neurotransmission serotonin concentrations, which does not indicate original levels in 
the brain (Andrews et al., 2015; Nishizawa et al., 1997). Similarly to the limitations 
associated with the psychological models, the monoamine hypothesis can be criticised 
for a lack of focus on psychosocial factors in the pathogenesis of MDD. 
 
1.2.2 The Need for Integrated Approaches 
MDD is a heterogeneous disorder, with diverse psychological and physiological 
symptoms and aetiological factors. Dominant approaches to conceptualising MDD tend 
to focus on one potential pathogenesis pathway, with treatment approaches similarly 
oriented towards addressing either psychological or physiological factors as opposed to 




taking an integrated approach (Abreu & Santos, 2008). Considering that MDD consists 
of both psychological and physiological symptoms, failure to consider both perspectives 
in combination may result in potential interactions between these factors being 
overlooked. Examining depressogenic symptom profiles from a biopsychosocial 
perspective is warranted to provide a more complete understanding of MDD as a 
disorder, and to develop a clearer account of the associations between MDD, obesity 
and cardiometabolic diseases (Chen et al., 2000). An integrated approach may allow for 
the development of tailored intervention methods for depressed individuals at risk of 
chronic health conditions, in turn improving the prognosis of affected individuals. Such 
an approach would be advantageous if it can account for unique symptom presentations 
and pathogenesis factors (Bridwell et al., 2015). However, at present there is a lack of 
research applying these approaches. 
 
1.3 Pathways between MDD and Cardiometabolic Diseases: Weight Gain 
Weight gain, as a precursor to obesity, is a proposed pathway between MDD and 
cardiometabolic diseases, with increased appetite/weight being the primary depressive 
symptom explored in the current thesis. A core symptom of MDD is appetite and 
weight dysregulation, with the direction of appetite/weight changes often varying as a 
function of MDD subtype (American Psychiatric Association, 2013). MDD has 
historically been associated with appetite and weight loss, which is symptomatic of 
melancholia. Melancholic MDD is more prevalent in males than females (Woelfer et al., 
2019), and is also characterised by non-reactive mood, blunted emotional responses, 
pervasive anhedonia, insomnia, loss of libido (American Psychiatric Association, 2013) 
and HPA axis hyperactivity which is associated with excess cortisol release (Baumeister 
& Parker, 2012).  




However, a growing number of individuals with MDD experience excessive 
eating and weight gain, which is characteristic of atypical MDD (American Psychiatric 
Association, 2013). In contrast to melancholic MDD, atypical MDD is more prevalent 
in females than males (Parker & Thase, 2007; Thase, 2007) and is associated with low 
mood reactivity, hypersomnia, leaden paralysis, increased sensitivity to interpersonal 
rejection, excess seeking of interpersonal reassurance (American Psychiatric 
Association, 2013) and HPA axis hypoactivity featuring a blunted cortisol stress 
response (Baumeister & Parker, 2012). Individuals with atypical MDD have an elevated 
risk of weight gain (Lassere et al., 2014), with atypical MDD also associated with 
higher adiposity and waist circumference values (Jantaratnotai et al., 2016). 
Epidemiological studies indicate that depressogenic weight gain as part of atypical 
MDD is now more than 40% more prevalent than weight loss as part of melancholic 
MDD, likely as result of the increasing prominence of obesogenic diets and 
environments, and sedentary lifestyles (Blanco et al., 2012). Consistent weight gain and 
obesity is associated with insulin dysregulation, hypertension, sleep apnoea and high 
cholesterol, which in turn increase the likelihood of cardiometabolic diseases such as 
cardiovascular disease and metabolic syndrome (Kearns et al., 2014). Accordingly, 
individuals with MDD who experience weight gain are at a greater risk of developing 
these conditions (Kearns et al., 2014; Zhao et al., 2009). 
 
1.3.1 Problematic Eating Behaviours 
MDD has been linked to appetite disturbances and associated problematic eating 
behaviours, which may act as conduits to depressogenic weight gain. Problematic eating 
behaviours are conceptualised as consisting of emotional eating, restrained eating, 
external eating and food addiction (Gearhardt et al., 2009, 2016; van Strien et al., 2016). 




These problematic eating behaviours can be measured using self-report measures such 
as the Dutch Eating Behaviours Questionnaire (DEBQ; van Strien et al., 1986) and the 
Yale Food Addiction Scale (YFAS; Gearhardt et al., 2016).  
 
1.3.1.1 Emotional Eating 
Emotional eating refers to an increase in food intake in response to negative 
feelings, which is popularly conceptualised as ‘comfort eating’ due to its motivation in 
relieving emotional distress (Finch & Tomiyama, 2015; van Strien et al., 2016). 
Emotional eating may not be a conscious process, as poor interoceptive awareness of 
internal satiety signals or physiological distress is associated with emotional eating in 
response to any arousal state (van Strien & Ouwens, 2007). More severe depressive 
symptoms have been linked to increased emotional eating (Goossens et al., 2009; Paans 
et al., 2018; van Strien et al., 2016), particularly the increased intake of carbohydrates 
and energy dense foods (Christensen & Pettijohn, 2001; Konttinen et al., 2010). In 
addition, females have higher rates of emotional eating than males (Bailly et al., 2012). 
As a result of increased food intake, emotional eating is associated with weight gain 
(Keller & Siegrist, 2015; Porter & Johnson, 2011; van Strien et al., 2016), particularly 
in atypical MDD (Konttinen et al., 2010).  
 
1.3.1.2 Restrained Eating 
Restrained eating is the deliberate and conscious restriction of food intake, with 
the motivation to limit or sustain a preferred body weight (van Strien et al., 2016). 
Restrained eating behaviours have been reported in MDD (Sevincer et al., 2017), with 
greater depressive symptom severity associated with greater dietary restraint (Paans et 
al., 2018). Increased restrained eating behaviours have also been associated with greater 
anxiety (Appleton & McGowan, 2006) and lower life satisfaction (Remick, Pliner & 




McLean, 2009). Higher levels of restrained eating have also been reported in females 
compared to males (Bailly et al., 2012). Seemingly counterintuitively, restrained eating 
is often accompanied by binge eating behaviours, which may act as a compensatory 
response for any psychological or physiological stress experienced as a result of caloric 
restriction or hunger (Lowe & Kral, 2006). As a result of these compensatory eating 
behaviours, restrained eating may be associated with higher body weight (van Strien et 
al., 2016). 
 
1.3.1.3 External Eating 
External eating is defined as the tendency to selectively attend to food cues, 
such as the sight and smell of food, resulting in increased food intake (Hou et al., 2011; 
van Strien et al., 2016). In external eating, food intake is largely regulated by the 
external food environment, with little influence from internal physiological eating 
signals such as hunger (Ouwens et al., 2009). Individuals who have a greater tendency 
to engage in external eating also often have a lower degree of control over these eating 
behaviours (Heaven et al., 2001; Hou et al., 2011). Increased food intake in response to 
sensory food cues is a prominent feature of obesogenic environments (Hidaka, 2012). 
MDD has been linked to external eating in response to highly-palatable-food cues 
(Ouwens et al., 2009; Sevincer et al., 2017), with the onset of external eating behaviours 
occurring independently of depressive symptom severity (Paans et al., 2018). More 
frequent instances of external eating have been related to lower self-esteem (Braet & 
van Strien, 1997). Similarly to emotional and restrained eating, external eating is also 
associated with weight gain and obesity as a result of increased food intake (Song, Lee 
& Sung, 2014). 
 
 




1.3.1.4 Food Addiction 
Food addiction is an emerging type of problematic eating behaviour that is 
defined as the development of addiction-like behaviours associated with the increased 
intake of highly-palatable foods; particularly those high in sugars or fats (Piccinni et al., 
2015). Food addiction is proposed to occur on a continuum of overeating behaviours, 
ranging from normal eating patterns to addiction (Piccinni et al., 2015). Neuroimaging 
studies have demonstrated that neural pathways associated with the reward 
neurotransmitter dopamine are activated in response to highly palatable foods, with 
repeated exposure to these foods resulting in addiction-like behaviours similar to 
general substance use disorders such as a greater tolerance to increased food intake and 
withdrawal when these foods are not consumed (Gearhardt et al., 2009; Gearhardt et al., 
2011; Volkow et al., 2012). Food addiction is not currently recognised as a diagnosable 
disorder; however, criteria have been developed to assess this based on substance use 
criteria in the DSM-5, including the YFAS (Gearhardt et al., 2016). 
The concept of food addiction is currently considered controversial. Food is 
necessary for survival, whereas the targets of other addictions such as psychoactive 
substances are not (Onaolapo & Onaolapo, 2018; Ziauddeen & Fletcher, 2013). 
Similarly, food addiction may also be more appropriately defined as ‘additive 
addiction’, as it has been reported that the addictive behaviours occur in response to the 
sugar or fat content of the foods as opposed to the food as a whole (Onaolapo & 
Onaolapo, 2018). Many modern foods have been altered to have a higher fat and sugar 
content compared to naturally occurring foods to increase their palatability (Leigh & 
Morris, 2018). This in turn increases the likelihood of excessive consumption of these 
foods and therefore weight gain (Johnson & Wardle, 2014).  




Based on YFAS criteria, a 5-10% prevalence of food addiction has been 
reported in general community samples, and 25% in obese populations (Meule & 
Gearhardt, 2014). While a prevalence rate of food addiction has not previously been 
reported in MDD, food addiction has been linked to depressive symptomology. Obese 
individuals who meet YFAS criteria have greater depressive symptoms than obese 
controls (Gearhardt et al., 2012). Further, depressive symptoms have been positively 
associated with the increased consumption of high sugar and fat foods (Crawford et al., 
2011; Martins et al., 2019), and the chronic overconsumption of fast food is associated 
with an increased risk of MDD up to 6 years later (Sanchez-Villegas et al., 2012). It is 
therefore possible that food addiction may be related to depressogenic weight gain, 
however this has not yet been evaluated. 
 
1.3.2 Mechanisms Underlying Problematic Eating Behaviours 
The motivation to engage in problematic eating behaviours in MDD is widely 
perceived to be psychologically based. Such problematic eating behaviours, particularly 
emotional eating and food addiction, may be a coping mechanism used to reduce 
negative emotions (Finch & Tomiyama, 2015). Despite this conceptualisation, evidence 
indicates that problematic eating behaviours may occur in response to both 
psychological and physiological factors, particularly stress (Finch & Tomiyama, 2015; 
Mouchacca et al., 2013). The physiological stress response is produced by the 
hypothalamic-pituitary-adrenal (HPA) axis, with elevated HPA axis activity being a 
common feature of MDD (Keller et al., 2016). The increased preference for highly 
palatable foods during periods of emotional distress is thought to be a consequence of 
the ability of some foods to dampen the HPA axis stress response by reducing 
glucocorticoid activity (Dallman et al., 2003; Hoch et al., 2015). Attenuation of HPA 




axis activity facilitates the alleviation or reduction of negative emotions such as low 
mood, anger or boredom, and their potential replacement by more positive feelings 
(Gearhardt, et al., 2009). However, evidence indicates that mood-improving effects 
associated with highly palatable food intake are only temporary (Finch et al., 2019), 
suggesting that increased food intake in response to emotions may occur to mitigate 
physiological stress in order to prolong transient mood effects; which may be relevant to 
the high prevalence of problematic eating behaviours in MDD (Finch et al., 2019). This 
indicates a potential physiological element to problematic eating behaviours, despite the 
typical emphasis on its psychological nature only. However, while MDD has been 
linked to disordered eating (van Strien et al., 2016) and weight gain (Zhao et al., 2009), 
the psychological and physiological factors involved and relationships between them 
remain to be elucidated.  
 
1.4 Neuroendocrine Function 
Changes to neuroendocrine function, including peripheral hormones, may 
explain the relationships between MDD, problematic eating behaviours, weight gain 
and cardiometabolic disease risk. Homeostatic regulation of the endocrine system is 
essential for optimal mental and physical health (Blevins & Rio, 2013). MDD is 
associated with prominent neuroendocrine changes, with alterations to neurotransmitter, 
neuropeptide, thyroid and androgen hormones linked to disturbances in processes such 
as mood, stress regulation, sleep onset and sleep quality, which are symptoms of MDD 
(Blevins & Rio, 2013; Chavez-Castillo et al., 2019). The neuroendocrine change most 
frequently reported and researched in MDD is cortisol dysregulation linked to altered 
HPA axis activity (Keller et al., 2016). Hypercortisolemia is a risk factor for MDD 
onset (Herbert, 2012), and individuals with MDD often demonstrate elevated morning 




(Keller et al., 2016; Thomas & Larkin, 2018), and wakening (Bhagwagar et al., 2005; 
Kabia et al., 2015) cortisol concentrations compared to controls, however no differences 
have also been reported (Steiner et al., 2019). Higher cortisol concentrations are 
associated with increased stress (Vreeburg et al., 2009), fatigue (Krishnan & Nestler, 
2010) and deficits in cognitive functioning (van Londen et al., 1998). In addition, 
cortisol concentrations are noted to vary as a function of MDD subtype, with 
hypercortisolemia characteristic of melancholic MDD and hypocortisolemia associated 
with atypical MDD (Carroll et al., 2007).  
However, other peripheral hormones related to the regulation of hunger, satiety, 
weight, energy balance and the sympathetic stress response, including leptin, ghrelin, 
serotonin and dopamine, may have key roles in the psychological and physiological 
mechanisms underpinning eating behaviours, and the regulation of appetite and weight 
(Arora & Anubhuti, 2006). Changes in the concentrations of these peripheral hormones 
may be involved in problematic eating behaviours and weight gain in MDD; however, 
at present there has been little research conducted to test this hypothesis.  
 
1.4.1 Leptin 
Leptin is an adipokine hormone secreted by adipocyte cells (Zhang et al., 1994), 
with significant roles in regulating fat mass and body weight as part of energy 
homeostasis (Lu, 2007; Maffei et al., 1995). Leptin also has an important anorexigenic 
influence as it acts as an appetite suppressant during periods of energy excess (Elmquist 
et al., 1998). While leptin concentrations have been observed to decrease in response to 
fasting (Nuttall et al., 2016) and increase post-prandially (Korek et al., 2013) as part of 
the satiety response, previous research comparing leptin in fasted and non-fasted blood 
samples have identified no overall difference between concentrations (Hancox & 




Landhuis, 2011). Notably, non-fasting blood sampling protocols have been utilised in 
several leptin studies (Ge et al., 2013; Hafner et al., 2012; Rubin et al., 2002), which 
may reduce the burden on participants (Kearney et al., 2011). 
Leptin is secreted in proportion to adipose tissue mass and encourages 
adipogenesis to account for excess energy intake (Maffei et al., 1995), with plasma 
leptin concentrations positively associated with BMI and waist circumference values 
(Chen et al., 2016; Jow et al., 2006; Morris et al., 2012). Subcutaneous administration 
of leptin is associated with reduced food intake and weight loss (Jow et al., 2006), 
however the use of leptin as a weight management strategy has not demonstrated long-
term success (Heymsfield et al., 1999; Levin & Dunn-Meynell, 2002). This effect may 
be explained by leptin resistance, a condition where chronically elevated plasma leptin 
is associated with desensitisation of leptin receptors, resulting in reduced satiety signals, 
increased food intake and weight gain (Pan et al., 2014). Leptin resistance is a risk 
factor for obesity, CVD and metabolic syndrome, where it is linked to weight gain 
(Maffei et al., 1995; Pan et al., 2014) and hypertension (Gijon-Conde et al., 2015).  
Leptin dysregulation has been observed in MDD (Antonijevic et al., 1998; 
Ozsoy et al., 2014; Westling et al., 2004). In particular, elevated leptin concentrations 
have been reported in individuals with atypical MDD compared to those with 
melancholia and controls (Gecici et al., 2005; Milaneschi et al., 2017a), suggesting that 
leptin resistance may be implicated in a subset of individuals with MDD who 
experience appetite and weight gain. Leptin has also been linked to low mood through 
its role in regulating HPA axis activity (Hirano et al., 2007; Kim et al., 2006). Leptin 
secretion is associated with inhibited glucocorticoid production and a suppressed stress 
adaptation response, which have in turn been linked to greater depressive symptoms 
(Roubos et al., 2012). Leptin concentrations are sexually dimorphic, with females 




exhibiting higher leptin than males (Antonijevic et al., 1998; Rubin et al., 2002) since 
females naturally store more body fat for reproduction (Blaak, 2001). Despite the 
associations between leptin, MDD and weight gain, there are no reports on the 
relationships between leptin in problematic eating behaviours. Given its role in satiety, 
and potential leptin resistance in atypical MDD, leptin may be related to problematic 
eating behaviours in MDD. 
 
1.4.2 Ghrelin 
Ghrelin is a 28-amino acid hormone secreted from the stomach and 
gastrointestinal tract (Kojima et al., 1999), with important orexigenic roles in 
stimulating appetite, and increasing food intake (Wren et al., 2000), adiposity (Tschop 
et al., 2001) and growth hormone release (Akamizu et al., 2004). Ghrelin exists in two 
forms: acyl or ‘active’ ghrelin accounts for approximately 10% of circulating ghrelin 
concentrations and promotes feeding effects, while desacyl or ‘inactive’ ghrelin 
constitutes about 90% of plasma ghrelin and encourages adipogenesis to ensure 
adequate energy stores during times of energy insufficiency (Patterson et al., 2005; 
Thompson et al., 2004).  
Ghrelin concentrations fluctuate in response to food intake, with higher ghrelin 
observed prior to eating and reduced levels post-food intake (Akamizu et al., 2004). 
However, meal-related fluctuations in ghrelin concentrations are noted to occur in both 
fasted and non-fasted states (Natalucci et al., 2005), suggesting that diurnal rhythms 
may have a greater influence on ghrelin than fasting status (Nuttall et al., 2016). 
However, few studies have directly compared ghrelin concentrations in fasted and non-
fasted blood samples. Ghrelin is also released during periods of stress, and is implicated 
in stress-induced weight gain by promoting the intake of highly palatable foods to 




mitigate the stress response (Buss et al., 2014). Central and peripheral administration of 
ghrelin is associated with increased feeding and weight gain (Tschop et al., 2000; Wren 
et al., 2000), however such feeding and weight changes have not been reported to occur 
in obese populations (Atalayer et al., 2013). Low ghrelin concentrations have also been  
associated with risk factors for CVD, particularly high blood pressure and 
atherosclerosis (Zhang et al., 2010). 
Ghrelin dysregulation has been reported in MDD (Barim et al., 2009; Ozsoy et 
al., 2014), with more severe MDD associated with higher ghrelin concentrations (Algul 
& Ozcelik, 2017). Ghrelin is also specifically associated with mood (Lutter et al., 2008; 
Kluge et al., 2011), with one study reporting that 33% of participants reported mood 
elevations following ghrelin administration (Schmid et al., 2005). Ghrelin is reported to 
be higher in females compared to males (Soriano-Guillen et al., 2016). However, 
whether ghrelin concentrations differ as a function of appetite/weight gain or loss in 
MDD is yet to be determined. Further, the relationship between ghrelin and problematic 
eating behaviours in MDD has not been examined. Due to its role in food intake, it is 
possible that ghrelin may be involved in the onset or increased prevalence of 
problematic eating behaviours in MDD, however similarly to leptin, this has not been 
assessed in existing ghrelin research. 
 
1.4.3 Serotonin 
Serotonin is a monoamine neurotransmitter primarily synthesised by 
enterochromaffin cells in the GI tract. Peripheral pools of serotonin are separated from 
central pools in the CNS by the blood brain barrier (Andrews et al., 2015). Impairment 
of the blood brain barrier has previously been postulated in MDD (Steiner et al., 2011) 
potentially linked to elevated peripheral serotonin concentrations, which may lead to 




crosstalk between the two pools (Maurer-Spurej, 2005). Peripheral serotonin has 
important roles in modulating GI health, cardiovascular function (Amireault et al., 
2013) and metabolic homeostasis (El-Merahbi et al., 2015). Peripheral serotonin also 
been linked to affect and behaviour regulation via the gut-brain axis, where it acts as a 
signalling molecule for the vagus nerve afferents that connect the cognitive and 
affective areas of the brain with the GI tract (O’Mahony et al., 2015; Jenkins et al., 
2016). Plasma serotonergic dysregulation has been observed in MDD (Holck et al., 
2019; Tyano et al., 2006) and linked to low mood (Messaoud et al., 2018; Paul-Savoie 
et al., 2011), and these effects reportedly do not differ by sex (Demerdash et al., 2018). 
There is a lack of research examining peripheral serotonin in relation to other depressive 
symptoms, including problematic eating behaviours and depressogenic weight gain. In 
humans, increased carbohydrate intake (Blum et al., 1992) and higher BMI values 
(Young et al., 2018) have been linked to increased plasma serotonin release. Further, 
higher plasma serotonin has been associated with metabolic disturbances, increased 
inflammation, immune activation and pain sensitivity (Shajib & Khan, 2015).  
In the CNS, serotonin is implicated in the regulation of mood, sleep, cognition, 
reward, and HPA axis activity (Berger et al., 2009). Neuroimaging and CSF studies 
have implicated CNS-serotonin in the control of appetite and food intake (Breum et al., 
2003), with elevated concentrations of CNS-serotonin associated with reduced appetite 
(Kurhe & Mahesh, 2015) and reduced CNS-serotonin related to greater disinhibition 
with respect to food intake (Bonnet et al., 2017). Serotonergic dysregulation in the CNS 
has been heavily implicated in the pathogenesis of several psychological disorders, 
including MDD (Schildkraut, 1965; Jonnakuty & Gragnoli, 2008). Although there are 
limitations with measuring serotonin directly in the brain (Andrews et al., 2015), studies 
estimating CNS-serotonin in CSF or using neuroimaging techniques have reported both 




lowered (Gao et al., 2008) or elevated (Lemonde et al., 2003) serotonin concentrations 
in MDD relative to controls. Given that the majority of serotonin is synthesised 
peripherally, and its links to food intake, weight and chronic health conditions, 
peripheral serotonin may be related to problematic eating behaviours and weight gain 
risk in MDD, however these relationships have not yet been examined. 
 
1.4.4 Dopamine 
Dopamine is a catecholamine neurotransmitter predominantly synthesised in the 
periphery by the adrenal medulla where, similarly to peripheral serotonin, peripheral 
pools are separated from central ones by the blood-brain barrier (Rubi & Maechler, 
2010). Peripheral dopamine has important endocrine roles in the homeostatic regulation 
of blood pressure, plasma glucose concentration, respiration, gastrointestinal motility 
and circadian rhythms (Rubi & Maechler, 2010). Peripheral dopamine has also been 
linked to the stress response, with higher levels of physiological stress associated with 
greater peripheral dopamine release (Rubi & Maechler, 2010), suggesting that 
dopamine may reflect HPA axis dysregulation in MDD (Dallman et al., 2003). Plasma 
dopamine dysregulation has been observed in MDD (Fajardo et al., 2003; Pan et al., 
2018), and is associated with greater depressive symptom severity (Tomei et al., 2007) 
and increased psychological stress (Hamner & Diamond, 1996). There is no apparent 
sexual dimorphism in plasma dopamine concentrations (Fajardo et al., 2003; Pan et al., 
2018).  
In the CNS, dopamine has important roles in movement, memory and executive 
function regulation (Drozak & Bryla, 2005). Dopamine is also the primary 
neurotransmitter implicated in substance use disorders, as it signals hedonic stimuli and 
motivates individuals to obtain them via neural reward pathways (Treadway & Zald, 




2011). In addition to psychoactive substances, dopaminergic reward pathways can be 
activated in response to highly palatable foods (Meule & Gearhardt, 2014), supporting a 
possible role for dopamine in the pathogenesis of problematic eating behaviours such as 
food addiction. CNS-dopamine signals the desire to eat and creates anticipation of 
reward-driven eating, which is associated with weight gain (Meguid et al., 2000). 
Hypodopaminergic states in the CNS are associated with low mood and anhedonia in 
MDD (Belujon & Grace, 2017; Cannon et al., 2009). However, considering that the 
majority of dopamine is synthesised peripherally and its associations with energy 
balance and the stress response, it is possible that peripheral dopamine may be related to 
depressogenic problematic eating behaviours, including food addiction; however, no 
study to date has examined these factors. 
 
1.5 Summary and Importance 
In summary, there are several factors that may be implicated in depressogenic 
weight gain and therefore cardiometabolic disease risk among individuals with MDD. 
Previous studies have considered the separate effects of problematic eating behaviours 
(Paans et al., 2018) or peripheral hormones (Milaneschi et al., 2017a) on depressogenic 
weight gain, however there is limited research that considers the interrelationships 
between these factors. This review of the literature indicates that problematic eating 
behaviours may be related to peripheral hormones including leptin, ghrelin, serotonin 
and dopamine. While the majority of neuroendocrine research in MDD is oriented on 
the HPA axis, peripheral hormones related to the regulation of hunger, satiety, weight, 
energy balance and the sympathetic stress response may be more relevant to 
understanding problematic eating behaviours and weight changes in MDD. However, 
there is a lack of research that adequately accounts for the heterogeneity in MDD 




symptom profiles, or incorporates psychological and physiological factors into an 
integrated framework. Examining these relationships from an integrated perspective 
while accounting for heterogeneity is necessary to better understand the associations 
between MDD, obesity and cardiometabolic disease, with such findings having the 
potential to influence how MDD and associated health issues are treated. 
Chronic health problems in at-risk individuals have historically been addressed 
with large-scale and multifaceted public health interventions, such as in the case of 
smoking and lung-cancer risk. Such interventions, including tax increases on cigarettes, 
mass-media anti-smoking campaigns, helplines, biological interventions and the 
implementation of smoke-free zone legislation, have been associated with a substantial 
reduction in the incidence of smoking and lung cancer diagnoses (Australian 
Department of Health, 2013). However, despite the risk of weight gain, obesity and 
cardiometabolic disease in individuals with MDD, there is currently a notable absence 
of integrated treatment or prevention strategies in the literature for individuals with 
MDD who are at greater risk of weight gain and health problems in Australia or 
elsewhere in the world. The responsibility for addressing weight gain is often viewed to 
be an individual, rather than a public, issue (Brownell et al., 2010), with existing 
treatment options for depressogenic weight gain including generic weight loss 
approaches such as dieting, exercise or pharmacotherapy regimes. However, such 
approaches do not demonstrate long-term success without consistent motivation and 
maintenance, which is often reduced in MDD (Firth et al., 2016; Jacka & Berk, 2012). 
There are also considerable social stigmas placing blame for weight gain on an 
individual’s lack of willpower (Brownell et al., 2010). Antidepressant medications, 
which are commonly prescribed to treat MDD, can also compound the risk of weight 
gain as this is a common side effect (Moret et al., 2009). The popular perception of 




comfort eating and weight gain being psychologically driven is also limiting, as 
therapeutic approaches may tend to focus on the purported emotional issues inciting an 
individual to overeat (beyondblue, 2018) while overlooking physiological influences, 
due to a lack of evidence linking emotional eating to both psychological and 
physiological factors (Finch & Tomiyama, 2015; Mouchacca et al., 2013). The long-
term success of treatments for depressogenic weight gain may also be influenced by 
peripheral hormones implicated in food intake. Further, the sex differences evident in 
the incidence of MDD, its subtypes and in peripheral hormones indicate that treatments 
specific to each sex may also have utility (Smith et al., 2008).  Current treatment 
approaches may be improved if the underlying pathways to depressogenic weight gain 
are better elucidated, prompting the need for integrated biopsychosocial research to 
examine these factors. This in turn may result in the increased efficacy of current 
interventions, and lead to novel preventative measures in order to reduce the likelihood 
of obesity and cardiometabolic disease in at-risk individuals with MDD. 
 
1.6 Thesis Aims and Hypotheses 
The broad aim of the current thesis was to examine the nature of problematic 
eating behaviours and their relationship to peripheral hormones, health indices and 
different depressive symptom profiles, in order to better understand the pathways 
between MDD, obesity and cardiometabolic disease risk. Such research may lead to 
refined biopsychosocial models of MDD and chronic disease risk, which in turn may 
lead to improved, tailored interventions for MDD and associated health conditions. 
To address these aims, four studies were conducted to investigate associations 
between problematic eating behaviours, depressive symptoms and symptom profiles, 
indices of obesity, cardiovascular measures, and peripheral hormones associated with 




hunger, satiety, mood and energy balance in MDD. In this thesis, problematic eating 
behaviours refer to emotional eating, restrained eating and external eating as measured 
using the DEBQ (van Strien et al., 1986) and food addiction-related symptoms as 
measured by the YFAS (Gearhardt et al., 2016). Depressogenic appetite and weight 
changes were defined as increased appetite and weight compared to decreased or 
unchanged appetite and weight and were determined using the MINI International 
Neuropsychiatric Interview (Sheehan, 2015). Other depressive symptoms, including low 
mood, sleep disturbances and negative thinking, were measured using questionnaires 
such as the Beck Depression Inventory (BDI-II; Beck et al., 1996); Depression, Anxiety 
and Stress Scale (DASS-21; Lovibond & Lovibond, 1995); Automatic Thoughts 
Questionnaire (ATQ; Hollon & Kendall, 1980) and the Insomnia Severity Index (ISI; 
Morin et al., 2009). Obesity indices included BMI and waist circumference values, and 
cardiovascular measures included blood pressure and heart rate. The peripheral 
hormones that were quantified were leptin, ghrelin, serotonin and dopamine. 
Study 1 examined leptin concentrations in participants with MDD and healthy 
controls, with its relationships to problematic eating behaviours assessed in a pilot 
study. Study 2 extended on Study 1 by assessing relationships between leptin, ghrelin 
and depressogenic problematic eating behaviours and health indices in a larger study. 
Study 3 assessed the role of peripheral serotonin in relation to depressive symptoms, 
including problematic eating behaviours and low mood. Study 4 investigated the role of 
peripheral dopamine in depressogenic problematic eating behaviours and low mood, 
with a particular emphasis on the concept of food addiction. Finally, Study 5 assessed 
the overall and unique contribution of leptin, ghrelin, serotonin and dopamine to 
problematic eating behaviours, depressive symptom severity and BMI.






2.1 Introductory Comments 
 
This first study examined the relationships between weight changes, problematic 
eating behaviours and leptin concentrations in MDD. Appetite changes and problematic 
eating behaviours, including emotional and restrained eating, have been documented in 
MDD and represent potential pathways to depressogenic weight gain. Leptin may have 
a role in this pathway, due to its relationship with adiposity and role in satiety. 
However, there has been no direct assessment of the relationships between leptin, 
problematic eating behaviours and physiological symptoms of MDD with respect to 
weight change direction. Understanding these relationships may offer insight into the 
prevalence of obesity, and consequently cardiometabolic disease risk, in MDD. 
Plasma leptin concentrations, biometric measurements including BMI, and 
psychometric indices of depressive symptoms were compared between 63 individuals 
with MDD and 60 healthy controls. All participants were further sub-categorised into 
those with increased, reduced or unchanged appetite/weight for a comparison of the 
variables of interest by appetite/weight symptom profile. Following anecdotal reports of 
emotional eating and loss of control around food by some participants in the MDD 
cohort, the relationships between leptin, biometrics and problematic eating behaviours 
were examined in a subset of MDD participants as part of a pilot investigation. 
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Background: Appetite and weight changes are core symptoms of Major Depressive 
Disorder (MDD), and those with MDD are at increased risk of obesity, cardiovascular 
disease and metabolic disorders. Leptin promotes satiety, with leptin dysregulation and 
resistance noted in obesity. However, the role of leptin in weight changes in MDD is 
not established. This study investigates leptin levels in relation to appetite and weight 
changes and problematic eating behaviours in MDD. 
Methods: Plasma leptin levels, psychopathology and biometrics were compared 
between participants meeting DSM-5 diagnostic criteria for MDD (n = 63) and healthy 
controls (n = 60). Depressed participants were also sub-categorised according to 
increased, decreased or unchanged appetite and weight. The Dutch Eating Behaviour 
Questionnaire and Yale Food Addiction Scale were examined in a subset of participants 
with MDD. 
Results: Females with increased appetite/weight had higher leptin levels than those with 
stable or reduced appetite/weight, however males showed the opposite effect. Leptin 
levels were positively correlated with problematic eating behaviours. One quarter of the 
depressed subset, all females, met the Yale criteria for food addiction, approximately 
double the rates reported in general community samples. 
Limitations: The study is limited by a cross sectional design and a small sample size in 
the subset analysis of eating behaviours. 
Conclusions: The results provide new information about associations between leptin, 
sex-specific weight and appetite changes and problematic eating behaviours, which may 
be risk factors for cardiovascular and metabolic diseases in MDD, particularly in 
females. Future longitudinal research investigating leptin as a risk factor for weight gain 




in MDD is warranted, and may lead to early interventions aimed at preventing weight 
gain in at-risk individuals. 





The global prevalence of Major Depressive Disorder (MDD) is rising annually, 
with this rise currently being attributed to increasing stress, endocrine dysfunction, 
modern lifestyle characteristics and dietary patterns (Hidaka, 2012). Altered eating 
behaviours, and appetite and weight dysregulation, are central diagnostic criteria of 
MDD (American Psychiatric Association, 2013). MDD is a risk factor for obesity, 
cardiovascular disease and metabolic syndrome (Cassano & Fava, 2002; Penninx et al., 
2013), with a key risk factor being increased appetite; which can occur in MDD 
(American Psychiatric Association, 2013). Identifying biological and behavioural 
pathways between MDD and changes in appetite and weight could improve 
interventions. The hormone leptin is relevant due to its relationship with adiposity and 
role in satiety, however its relationship to MDD-related weight changes is not properly 
understood. 
There are bidirectional influences between MDD, appetite and weight 
dysregulation, as MDD increases the risk of becoming obese, and obese individuals are 
at an increased risk of developing MDD (Kloiber et al., 2007; Luppino et al., 2010). 
However, depressed individuals may experience either increases or decreases in their 
appetite and/or weight (Li et al., 2014; Paans et al., 2017); therefore, it is important to 
consider individual depressive symptom profiles in research relating to health risks. 
Increased appetite and weight gain are features of atypical MDD, a sub-type of MDD 




further characterised by hypersomnia, psychomotor slowing, increased mood reactivity 
and sensitivity to interpersonal rejection (American Psychiatric Association, 2013). 
Atypical MDD is further associated with higher body mass index (BMI; Lassere et al., 
2014), higher instances of metabolic syndrome (Lamers et al., 2016b) and increased 
endocrine dysregulation (Gecici et al., 2005; Lamers et al., 2016a; Milaneschi et al., 
2017a). There are also indications that weight gain and increased appetite, while 
previously referred to as ‘atypical’, are increasingly being identified as a ‘typical’ 
symptom of MDD (Privitera et al., 2013). Additionally, a large epidemiological survey 
indicated that the prevalence of MDD with atypical features was almost 40% higher 
than that of MDD without atypical features (Blanco et al., 2012). This apparent rise in 
MDD with weight gain may be associated with the increase of comfort foods in the 
environment (those high in fat and sugar), which people in emotional distress may seek 
out (Privitera et al., 2013).  
Problematic eating behaviours have also been noted in MDD, which are 
commonly measured using the Dutch Eating Behaviours Questionnaire (DEBQ; van 
Strien et al., 1986). These include Emotional eating, or increasing food intake in 
response to negative emotions as a form of coping mechanism; External eating, or 
increased food intake in response to external food cues, including the sight and smell of 
food; and Restrained eating, or deliberately restricting food intake to lose weight or 
prevent weight gain (van Strien et al., 2016). More severe depressive symptoms are 
associated with higher emotional eating (van Strien et al., 2016), increased carbohydrate 
cravings (Christensen & Pettijohn, 2001), increased consumption of energy-dense foods 
in response to emotional distress (Konttinen et al., 2010) and increased food intake in 
response to internal and external food cues (Sevincer et al., 2017). Restrictive eating 




behaviours, and reduced food intake, have also been linked to depressive symptoms in 
previous studies (Polivy et al., 1978; Sevincer et al., 2017).  
Another approach to understanding overeating is the concept of food addiction, 
which can be measured using the Yale Food Addiction Scale (YFAS; Gearhardt et al., 
2009). It has been proposed that food addiction forms part of a continuum consisting of 
varying degrees of overeating behaviours that range from normal eating patterns to 
obesity (Piccinni et al., 2015). Food addiction is also associated with depressed mood, 
with one study reporting that obese individuals who met the YFAS criteria for food 
addiction displayed more severe depressive symptoms (Gearhardt et al., 2012). The 
prevalence of food addiction ranges from 5-10% in the general population, and 15-25% 
in obese individuals (Meule & Gearhardt, 2014). The preference for palatable foods, 
including those high in sugar, fat or carbohydrates during periods of emotional distress 
(Lutter & Nestler, 2009; Hoch et al., 2015) has been attributed to their ability to reduce 
the psychological and physiological impact of stress (Dallman et al., 2003; Ulrich-Lai, 
2016) and activate dopamine-based neural reward pathways (Gearhardt et al., 2011; 
Volkow et al., 2012), which can result in addiction-like behaviours; similar to alcohol or 
other psychoactive substances (Gearhardt et al., 2009; Piccinni et al., 2015). Food 
addiction is not yet recognised as a formal diagnosable disorder and is currently defined 
as a substance-use disorder in the DSM-5 (American Psychiatric Association, 2013); 
however, little is known about the relationships between addictive eating behaviours, 
leptin and MDD. 
 Leptin is a peptide hormone encoded by the ob gene secreted by adipocyte cells, 
with a critical role in regulating adipose tissue mass and energy balance as part of 
homeostasis (Lu, 2007). It has a fundamental role as an appetite suppressant during 
times of excess food consumption (Elmquist et al., 1998; Trayhurn et al., 1999), and is 




involved in weight regulation, where plasma leptin levels are released in proportion to 
adipose tissue mass (Maffei et al., 1995). However, although subcutaneous injection of 
leptin in lean and obese individuals may lead to decreased food intake and moderate 
weight loss (Heymsfield et al., 1999), the use of leptin as a long-term weight loss 
strategy has been unsuccessful (Halaas et al., 1997; Widdowson et al., 1997; 
Heymsfield et al., 1999; Levin & Dunn-Meynell, 2002). A possible explanation for this 
is leptin resistance, which is characterised by high leptin levels but decreased leptin 
sensitivity (Pan et al., 2014). Leptin resistance has been proposed as a mechanism in the 
pathogenesis of obesity (Zigman & Elmquist, 2003; Ozsoy et al., 2014), with obese 
animals and humans being noted to have naturally elevated levels of leptin in the 
absence of food intake (Maffei et al., 1995).  
Leptin also moderates stress responses induced by the hypothalamic-pituitary-
adrenal (HPA) axis. Leptin secretion has been demonstrated to inhibit corticosteroid 
production, and thereby suppressing stress adaptation responses (Bornstein et al., 1997; 
Roubos et al., 2012). Failure of the HPA axis to execute appropriate stress responses 
may lead to the development of mental disorders such as MDD and anxiety (Blackburn-
Munro & Blackburn-Munro, 2001). In animal studies, chronic stress decreases plasma 
leptin levels (Lu et al., 2006) and insufficient circulating leptin is associated with MDD-
like behaviours (Ge et al., 2013; Liu et al., 2017). Administration of leptin to rats after 
laboratory stressors reversed MDD-like behaviour; suggesting that leptin may also have 
antidepressant like efficacy (Kim et al., 2006; Hirano et al., 2007). The relationship 
between leptin and stress, including symptom severity, remains relatively unexplored, 
particularly in the context of MDD where increased stress is a key feature of the 
condition (American Psychiatric Association, 2013).  




Human studies comparing leptin levels in MDD have found inconsistent results, 
with either lower (Kraus et al., 2001; Westling et al., 2004; Atmaca et al., 2003) or 
elevated (Antonijevic et al., 1998; Jiménez et al., 2009; Morris et al., 2012) leptin levels 
overall between depressed and non-depressed individuals. In contrast, several studies 
(Häfner et al., 2012; Ozsoy et al., 2014) have identified no difference in leptin levels 
between depressed and non-depressed individuals; in some cases, even in the presence 
of appetite loss (Deuschle et al., 1996). No overall difference in leptin levels in 
individuals with MDD compared to controls was further supported by a recent large-
scale meta-analysis by Carvalho et al. (2014), however there were inconsistent results 
across the studies included. Studies comparing leptin levels across subtypes of MDD 
have also demonstrated inconsistent results. Individuals with typical/melancholic MDD 
often demonstrate lower leptin levels compared to controls and individuals with atypical 
MDD, with the latter demonstrating consistently higher leptin levels overall (Gecici et 
al., 2005; Lamers et al., 2016a, Milaneschi et al. 2017a). The variability of these results 
may be due to heterogeneity in appetite and weight change symptoms in MDD, and 
subsequent alterations in leptin levels. Further, differences in leptin levels between 
subtypes of MDD with increased or decreased appetite/weight may have been masked 
in previous research, as symptom subtypes are frequently combined in previous studies. 
Further, the methods of classifying atypical MDD symptoms have differed 
between studies. Some studies have used solely DSM based criteria (Gecici et al., 2005; 
Lassere et al., 2014), and others have used latent class analysis based on a combination 
of questionnaire and diagnostic interview responses. The questionnaires and interviews 
used to measure depressive symptoms for latent class analysis vary, with measures such 
as the Inventory of Depressive Symptoms (IDS-SR; Rush et al., 1996), Hamilton 
Depression Rating Scale (HDRS; Hamilton, 1960) and the Composite International 




Diagnostic Interview (CIDI; World Health Organisation, 1997) being used (Lamers et 
al., 2016a, 2016b; Milaneschi et al., 2017a). However, it has been noted that latent class 
analysis classifications of MDD symptoms do not align completely with DSM-based 
criteria (Lamers et al., 2016a; 2016b). Therefore, the inconsistent methods may be a 
potential confounding factor in these studies. Further, not all atypical symptoms have 
been found to correlate with leptin levels; of the atypical symptoms, changes in weight 
gain and appetite are most strongly correlated with leptin levels (Lamers et al., 2016a; 
Milaneschi et al., 2017a). This suggests that changes in appetite/weight may provide a 
clearer means of subtype classification for the purposes of examining connections 
between leptin, MDD, appetite and weight gain than the broader criteria of atypical 
MDD. 
Some studies have indicated a sexual dimorphism in leptin levels, with females 
having higher leptin levels than males (Antonijevic et al., 1998; Rubin et al., 2002). 
However, other studies have indicated no difference in leptin levels between sexes 
(Hillemacher et al., 2006; Atmaca et al., 2003). However, there may be interactions 
between sex and depression status in terms of leptin (Milaneschi et al., 2012; Haleem et 
al., 2017). Depressed women are more prone to weight gain and obesity than males 
(Sutin & Zonderman, 2012; Grundy et al., 2014). It is therefore pertinent to investigate 
leptin levels by sex and MDD status. Further, examining appetite and weight symptom 
presentations by sex is also important in order to elucidate specific relationships 
between leptin and MDD symptom profiles. 
Due to its role in adiposity, leptin has consistently been correlated with body 
mass index (BMI) and waist circumference (Jow et al., 2006; Morris et al., 2012; Chen 
et al., 2016). Leptin has also been related to risk factors for cardiovascular disease, with 
elevated leptin levels associated with higher systolic and diastolic blood pressure 




(Beltowski, 2006; Ma et al., 2009) and heart rate (Brydon, 2011). This is particularly 
relevant to MDD because of its associations with obesity, cardiovascular disease and 
metabolic syndrome (Cassano & Fava, 2002; Penninx et al., 2013). 
In summary, further research is needed to better understand relationships 
between leptin levels, eating behaviours and changes in appetite and weight in MDD, 
and whether these differ by sex. Previous leptin studies have also not measured stress 
severity, which is relevant considering the role of leptin in moderating activity of the 
HPA axis. While relationships between leptin, BMI and waist circumference have been 
previously noted, relationships between leptin and cardiovascular disease risk factors 
such as blood pressure and heart rate have not yet been sufficiently explored in MDD. 
Further, while leptin has been linked to depressed mood (Westling et al., 2004; Ozsoy et 
al., 2014), and depressed mood has been linked to problematic eating behaviours (van 
Strien et al., 2016; Sevincer et al., 2017), there is no direct research examining the 
relationships between food addiction and problematic eating behaviours in MDD, 
particularly in relation to leptin levels. An understanding of these unexplored 
relationships may elucidate relationships between MDD and other chronic health 
conditions. 
 In the current study, plasma leptin levels, biometrics, and psychometric 
measures of depression, anxiety and stress were compared between individuals with 
MDD and healthy controls. Depressed participants were sub-categorised to compare 
those with increased, reduced or unchanged appetite and weight, by sex. Further, 
relationships between leptin, problematic eating behaviours and food addiction were 
examined in a subset of depressed participants. In line with previous literature, it was 
predicted that: 




1. Leptin levels would not differ significantly between depressed and non-
depressed participants overall. 
2. Depressed participants with increased appetite/weight would demonstrate higher 
leptin levels than depressed participants with decreased or unchanged 
appetite/weight, with effects being greater in females; 
3. Psychometric indices of depression severity, anxiety and stress would positively 
correlate with leptin levels; 
4. Biometric indices of obesity and cardiovascular disease risk factors (including 
BMI and blood pressure), would positively correlate with plasma leptin levels; 





One hundred and twenty-three (123) adults aged between 18 and 69 years (M = 
31.87 ± 12.88 years; 70 female, 53 male) participated in the study. 63 participants met 
the diagnostic criteria for MDD, as confirmed by the Mini International 
Neuropsychiatric Interview; a valid semi-structured interview based on the DSM-5 
designed to assess for psychiatric conditions (MINI; Sheehan et al., 1998; Lecrubier et 
al., 1997). Participants were recruited by media advertisements, notices and newsletters 
at the university.  
Depressed participants were required to not be receiving any current or recent 
psychological or medication-based treatment for MDD. The 60 control participants had 
no history of diagnosed psychiatric disorders. Exclusion criteria across both groups 
were use of corticosteroids, neurological illness and substance use disorders. 
Participants were asked to provide details of all medical conditions, medications and 




substance use. Eight participants reported a diagnosis of an insulin dysregulation 
disorder, including diabetes and polycystic ovarian syndrome. No participants had 
diagnosed eating disorders. No participants were current smokers. The study was 





Data collection occurred at the University Clinical Research Trials Unit. All 
appointments were scheduled between 9:00am and 11:00am to control for diurnal 
variations in hormones. On arrival at the clinical trials unit, depressed participants were 
interviewed using the Mini Neuropsychiatric Interview, version 7.0.2 for DSM 5 
(Sheehan, 2015) to confirm MDD diagnoses and symptoms, including weight and 
appetite changes. Control participants were also asked whether they had experienced 
recent changes in weight or appetite. 
After provision of informed consent, height, weight, blood pressure and heart 
rate were taken. Waist circumference was measured in the depressed participants only. 
Following the provision of a non-fasting 10ml blood sample obtained by an experienced 
phlebotomist, participants then completed the Depression, Anxiety and Stress Scale; a 
21 item self-report questionnaire assessing depression, anxiety and stress severity 
(DASS-21; Lovibond & Lovibond, 1995). The DASS-21 total score has high internal 
consistency (Cronbach’s a = .94; Gloster et al., 2008) The three subscales of the DASS-
21 have demonstrated high internal consistency (Cronbach’s a = .96 for depression, .89 
for anxiety, .93 for stress; Brown et al., 1997). 
During the study, when asked about appetite and weight changes, depressed 
participants frequently volunteered that they experienced loss of control around food 




cues and increased emotional eating. Therefore, we obtained ethical approval to 
administer additional questionnaire measures to the remaining participants, to 
investigate eating behaviours in more detail, as an exploratory study. The Dutch Eating 
Behaviours Questionnaire (DEBQ; van Strien et al., 1986) and the Yale Food Addiction 
Scale (YFAS; Gearhardt et al., 2009) were administered to a subset of 33 depressed 
participants (20 female, 13 male) in order to investigate eating behaviours in the context 
of appetite and weight dysregulation in MDD. The DEBQ measures problematic eating 
styles, including restrained, emotional and external eating behaviours; with each of the 
three subscales demonstrating high internal consistency (Cronbach’s a = .93 for 
restrained, .93 for emotional, .80 for external eating; van Strien et al., 1986). The YFAS 
measures food addiction related behaviours, including withdrawal symptoms and loss of 
control around food cues; with the total YFAS score also demonstrating high internal 
consistency (Cronbach’s a = .86; Gearhardt et al., 2009). 
 
2.4.3 Data and Statistical Analysis 
 
Immediately following blood collection, blood samples were spun in a 
centrifuge at 4°C, at 2800rpm for 10 minutes. Plasma was immediately stored in a -
80°C freezer until analysis. Plasma leptin levels were measured using a standard ELISA 
(Abcam, Cambridge, United Kingdom) testing kit. The intra- and inter-assay 
coefficients of the ELISA were <10% and <12% respectively. 
Statistical analysis was conducted using ‘Statistical Package for the Social 
Sciences’ (SPSS, Version 23). A two-way factorial analysis of variance (ANOVA) was 
used to test for differences in the leptin levels, with the between subjects factors being 
Diagnosis (control, depressed) and Sex (male, female), and Age and BMI as covariates. 
A second two-way factorial ANOVA was used to test for differences in leptin levels as 




a function of appetite and weight changes, with the between subjects factors being 
Appetite and Weight Categories (increased, decreased, no change) and Sex (male, 
female), with Age and BMI as covariates. Pearson’s correlation coefficients and 
Spearman’s rank correlations were used to determine relationships between the 
variables as appropriate. Post-hoc analyses were conducted using Bonferroni tests. For 
all statistical tests, a < .05 was considered statistically significant. 
2.5. Results 
2.5.1 Biometric and Psychometric Data 
 
Biometric and psychometric data are displayed in Table 2.1. Diagnostic groups 
did not differ significantly in age. In terms of sex distributions, there were 35 females in 
both the MDD and control groups, 25 males in the control group and 28 males in the 
MDD group. The sex distributions between groups were not significant (c2 (2, N = 123) 
= .097, p = .076).  
Systolic blood pressure was higher in males (M = 135.38, SD = 12.92) than 
females (M = 117.04, SD = 11.64; F(1, 119) = 68.69, p < .001, partial η2 =.366). 
Diastolic blood pressure was also higher in males (M = 80.11, SD = 11.43) than females 
(M = 75.63, SD = 9.24; F(1, 119) = 5.52, p = .020, partial η2 = .044). No significant 
effects for Diagnosis or interaction effects were identified for other biometric data. 
Depressed participants scored significantly higher on each of the Depression, 
Anxiety and Stress subscales of the DASS compared to controls (Depression: M = 
23.21, SD = 9.38 versus M = 6.17, SD = 7.43, F(1, 119) = 117.59, p < .001, partial η2 = 
.497; Anxiety: M = 13.59, SD = 10.65 versus M = 4.60, SD = 5.56, F(1, 119) = 30.70, p 
< .001, partial η2 = .205;  Stress: M = 21.90, SD = 9.60 versus M = 10.30, SD = 7.97; 
F(1, 119) = 49.99, p < .001, partial η2 = .296). No significant effects for Sex or 
interaction effects were identified for DASS scores. 
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Table 2.1:  
Means and standard deviations for biometric and psychometric data, by Diagnosis and Sex (total N = 123; MDD and control participants).  
 
Note: DASS = Depression, Anxiety and Stress Scale.  
    a * a < .05, ** a < .01. 
 
  Sex Diagnosis 
Variable  Male Female Effect Control Depressed Effect 
  M (SD) M (SD) p M (SD) M (SD) p 
 Sample Size (n) 53 70 - 60 63 - 
Biometrics Age (years) 33.94 (14.23) 30.30 (11.61) .134 31.83 (10.98) 31.90 (14.55) .764 
 Weight (kg) 84.18 (14.60) 70.15 (17.32) < .001** 74.53 (16.95) 77.78 (18.16) .476 
 BMI (kg/m2) 26.52 (4.56) 25.57 (5.85) .323 25.13 (4.49) 26.77 (5.95) .147 
 Systolic Blood Pressure (mmHg) 135.38 (12.92) 117.04 (11.64) < .001** 126.40 (14.27) 123.56 (16.01) .153 
 Diastolic Blood Pressure (mmHg) 80.11 (11.43) 75.63 (9.24) .020* 76.83 (9.86) 78.25 (10.99) .422 
 Heart Rate (bpm) 72.68 (13.68) 73.59 (10.40) .693 73.29 (12.31) 73.13 (11.53) .946 
Psychometrics DASS Depression 14.98 (11.55) 14.83 (12.45) .856 6.17 (7.43) 23.21 (9.38) < .001** 
 DASS Anxiety 8.79 (8.50) 9.51 (10.47) .580 4.60 (5.56) 13.59 (10.65) < .001** 
 DASS Stress 15.77 (9.81) 16.60 (11.14) .495 10.30 (7.97) 21.90 (9.60) < .001** 





2.5.2 Leptin Results 
 
Four participants (2 MDD, 2 controls) did not provide a blood sample, so data 
from a total of 119 participants were included in the leptin analysis. There were eight 
univariate outliers in the leptin data detected using boxplot diagrams, with their plasma 
leptin concentration being greater than two standard deviations above the mean (M = 
142.97, SD = 204.48). All outlier values belonged to depressed participants who 
reported insulin dysregulation disorders. Preliminary statistical analyses were conducted 
with and without the outliers. These initial results were similar, however when the 
outliers were removed a higher effect of leptin in MDD overall compared to healthy 
controls was no longer present. In order to eliminate the possibility of a potential 
confounding effect of insulin dysregulation on the leptin data, these outliers were 
excluded from subsequent analyses and results without outliers are henceforth reported. 
Preliminary inspection of the distribution of the raw leptin data from the 
remaining 111 participants indicated a positively skewed distribution (skewness = 3.19, 
SE = .22). In line with previous human studies (Häfner et al., 2012; Milaneschi et al., 
2012) the raw leptin data were natural-log transformed. Means and standard deviations 
for raw leptin and log-leptin values are displayed in Table 2.2 according to Diagnosis 
and Sex. 
After accounting for age and BMI as potential covariates, log-leptin values did 
not differ significantly overall between participants with MDD compared to controls 
(F(1, 111) = 1.99, p = .161, partial η2 = .019). Females (M = 4.70, SD = 1.16) had 
significantly higher log leptin values than males (M = 3.15, SD = 1.54 F(1, 111) = 
81.47, p < .001, partial η2 = .438). Age was identified as a significant covariate (F(1, 
111) = 4.43, p = .038, partial η2 = .040), as was BMI (F(1, 111) = 73.86, p < .001, 
partial η2 = .413). 





The interaction between Diagnosis and Sex was significant (F(1, 111) = 4.99, p 
= .028, partial η2 = .045), with depressed males (M = 3.43, SD = 1.40) having higher 
log-leptin levels than control males (M = 2.82, SD = 1.66). Leptin levels did not differ 
significantly between depressed (M = 4.86, SD = 1.21) and control females (M = 4.56, 
SD = 1.12) overall. 
 
Table 2.2:  
Means and standard deviations for raw and log-transformed leptin data, by Diagnosis 
and Sex (total N = 111; MDD and control participants). 
 
Note: significance noted for log-transformed data only.  
a * a < .05, ** a < .001. 
 
 
2.5.3 Analysis by Appetite and Weight Change Groups 
 
The 111 participants were classified according to whether they reported 
increased (n = 19, all depressed), reduced (n = 20, all depressed) or unchanged 
appetite/weight (n = 72, 12 depressed, 60 controls) from the clinical interview. No 
controls reported significant changes in their appetite/weight, whereas participants with 
MDD reported either increased, decreased or unchanged appetite/weight. One-way 
ANOVAs indicated no significant differences in biometric variables between 
appetite/weight presentations (Table 2.3). 
 






  n M (SD) M (SD) p p 
Diagnosis 
Control 58 106.31 (104.96) 3.85 (1.61) 
.161 
 
Depressed 53 149.42 (226.30) 4.14 (1.48) 
.028* 
Sex 
Males 51 54.36 (63.95) 3.15 (1.54) 
< .001** 
Females 60 188.54 (211.59) 4.70 (1.16)  
Covariates 
Age (years) - - - .038* - 
BMI (kg/m2) - - - < .001** - 






Means and standard deviations for biometric data, by Appetite/Weight Categories (total 
N = 111; MDD and control participants). 
 
 
  Increases Decreases Unchanged p 
  Mean (SD) Mean (SD) Mean (SD)  
 Sample Size (n) 19 20 72 - 
Biometrics Age 34.95 (17.21) 29.60 (11.53) 32.15 (11.91) .425 
 Weight 79.01 (19.67) 76.00 (15.82) 74.91 (15.88) .618 
 BMI 27.52 (5.75) 25.56 (4.64) 25.30 (4.41) .174 
 Systole 121.95 (15.01) 122.00 (15.41) 126.53 (13.88) .303 
 Diastole 78.35 (9.04) 76.60 (13.69) 77.28 (9.50) .861 
 Heart Rate 73.65 (11.84) 70.15 (9.33) 73.21 (12.19) .544 
 
a Indicates significant differences compared to the ‘Increased’ group. 
* a < .05, ** a < .01. 
 
The two-way ANOVA with Appetite/Weight categories (increased, decreased, 
no change) and Sex (male, female) as between group factors, with Age and BMI as 
covariates (Table 2.4), indicated that leptin values did not differ significantly across 
appetite/weight presentations (F(2, 111) = .11, p = .900). However, the interaction 
between Appetite/Weight categories and Sex was significant (F(2, 111) = 3.53, p = 
.033, partial η2 = .064). Females with increased (M = 5.20, SD = .87) or unchanged (M 
= 4.64, SD = 1.12) appetite/weight had higher log-leptin values compared to females 
with decreased appetite/weight (M = 4.16, SD = 1.53). This pattern was the opposite in 
males, as those with decreased appetite/weight (M = 3.65, SD = 1.69) had higher log-
leptin values than males with increased (M = 3.31, SD = 0.99) or unchanged (M = 2.94, 
SD = 1.56) appetite/weight.  
Leptin values were again significantly higher for females (M = 4.70, SD = 1.16) 
compared to males (M = 3.15, SD = 1.54 F(1, 111) = 36.90, p < .001, partial η2 = .264). 
BMI was a significant covariate (F(1, 111) = 69.55, p < .001, partial η2 = .578), 
however age as a covariate was non-significant.  





Table 2.4:  
Means and standard deviations for raw and log-transformed leptin data, by 
Appetite/Weight Categories and Sex (total N = 111; MDD and control participants). 
 
Note: significance noted for log-transformed data only.  
a * a < .05, ** a < .001. 
 
 
Weight correlated positively with systolic (r(111) = .461, p < .001) and diastolic 
(r(111) = .383, p < .001) blood pressure. BMI also correlated positively with systolic 
(r(111) = .257, p = .006) and diastolic (r(111) = .390, p < .001) blood pressure. Further, 
BMI was positively correlated with weight (r(111) = .877, p = < .001). Log-leptin 
values correlated positively with BMI (r(111) = .449, p < .001), but were negatively 
correlated with systolic blood pressure, (r(111) = -.240, p = .011). No significant 
correlations were identified between log-leptin values, the remaining biometric 
measurements and DASS subscales. 
 
2.5.4 Subset Analysis of Eating Addiction and Eating Behaviours in MDD 
 
As a further exploratory analysis, waist circumference was measured, and the 
Dutch Eating Behaviours Questionnaire (DEBQ) and the Yale Food Addiction Scale 
(YFAS) were administered to 33 participants recruited to the MDD group (n = 33). Of 
these 33 participants, 15 reported increased, 11 decreased and 7 unchanged 





AW x S 
Interaction 




Increases 19 192.72 (240.58) 4.60 (1.26) 
.900 
.033* 
Decreases 20 106.31 (156.71) 3.85 (1.60) 
Unchanged 72 113.16 (156.30) 3.86 (1.58) 
Sex 
Males 51 54.36 (63.95) 3.15 (1.54) 
< .001** 
Females 60 188.54 (211.59) 4.70 (1.16) 
Covariates 
Age (years) - - - .133 - 
BMI 
(kg/m2) - - - < .001** - 





appetite/weight. Between-groups analyses based on appetite/weight presentations were 
not performed due to small cell sizes.   
Independent samples t tests were performed to investigate Sex differences for 
the additional measures (Table 2.5). Waist circumference did not differ significantly 
between sexes (t(31) = -.64, p = .528, partial η2 = .013). Females reported more 
Restrained eating behaviours (M = 2.83, SD = 1.03) than males on the DEBQ (M = 
1.72, SD = .64; t(31) = 3.45, p = .002, partial η2 = .278). Females also reported more 
frequent instances of Emotional eating (M = 2.93, SD = 1.11) than males (M = 2.02, SD 
= .93; t(31) = 2.43, p = .021, partial η2 = .160). However, Sensitivity to external food 
cues was similar between sexes. 
Eight (24%; all female) of the 33 depressed participants in the sub-analysis met 
the YFAS criteria for food addiction. The Loss of control subscale was higher in 
females (M = .25, SD = .444) than males (M = .00, SD = .000; t(31) = 2.52, p = .021, 
partial η2 = .116). The Large amounts of time spent acquiring food subscale was also 
higher in females (M = .40, SD = .50) than males (M = .08, SD = .28; t(31) = 2.37, p = 
.024, partial η2 = .126). Females reported higher scores than males for Giving up 
important activities for the sake of acquiring food (M = .45, SD = .51, versus M = .08, 
SD = .28; t(31) = 2.71, p = .011, partial η2 = .157) and Withdrawal symptoms (M = .45, 
SD = .51 versus M = .08, SD = .28; t(31) = 2.71, p = .011, partial η2 = .157). Females 
had a higher total number of symptoms on the Food addiction symptom count (M = 
3.50, SD = 1.82) than males (M = 1.92, SD = 1.26; t(31) = 2.94, p = .006, partial η2 = 









Table 2.5:  
Means, standard deviations and symptom endorsement rates for the eating measures and 
biometrics in a subset of depressed participants, by Sex (total N = 33; MDD only). 
 
 
Note: DEBQ = Dutch Eating Behaviours Questionnaire, YFAS = Yale Food Addiction 
Scale. YFAS subscales are scored dichotomously and occur between 0.00 and 1.00.  
* a < .05. 
 
Waist circumference was positively correlated with weight (r(27) = .900, p < 
.001), BMI (r(27) = .874, p < .001) and diastolic blood pressure (r(27) = .413, p = .032). 
Log-leptin values correlated positively with waist circumference (r(25) = .510, p = 
.009) and BMI (r(25) = .549, p = .004), and correlated negatively with heart rate (r(25) 
= -.404, p = < .001). Log-leptin values were also positively correlated with DEBQ 
Restrained eating (r(25) = .403, p = .046), and Emotional eating (r(25) = .438, p = 
.029). No further results were significant. 
2.6. Discussion 
 
This is one of the first studies to examine leptin in relation to increased weight 
and appetite in MDD. A significant interaction effect between appetite/weight 
Scale  Male Female p Endorsement 
  Mean (SD) Mean (SD)  % 
 Sample Size (n) 13 20 - - 
Biometrics Waist Circumference (cm) 92.54 (13.70) 88.36 (18.89) .528 - 
DEBQ Restrained 1.72 (.64) 2.83 (1.03) .002* - 
 Emotional 2.02 (.93) 2.93 (1.11) .021* - 
 External Cues 3.03 (.82) 3.34 (.72) .257 - 
YFAS Loss of Control .00 (.00) .25 (.44) .021* 15.2% 
 Inability to Cut Down 1.00 (.00) .85 (.37) .083 91% 
 Large amounts of Time .08 (.28) .40 (.50) .024* 27.3% 
 Giving up Activities .08 (.28) .45 (.51) .011* 30.3% 
 Continued Use  .38 (.51) .50 (.51) .530 45.5% 
 Tolerance  .31 (.48) .60 (.50) .107 48.5% 
 Withdrawal Symptoms .08 (.28) .45 (.51) .011* 30.3% 
 Symptom Count 1.92 (1.26) 3.50 (1.82) .006* - 





categories and sex was observed with respect to plasma leptin levels. Females with 
increased or stable appetite/weight had higher leptin levels than those with reduced 
appetite/weight; however the opposite effect occurred for males, whereby males with 
decreased appetite/weight had higher leptin than those with increased or stable 
appetite/weight. These effects were present with correction for age and BMI. Since 
leptin has a fundamental role as an appetite suppressant (Elmquist et al., 1998), the 
higher leptin levels in males with decreased appetite/weight is consistent with normal 
leptin regulation. However, higher leptin levels in females with increased 
appetite/weight may be consistent with an interpretation of leptin resistance, a condition 
which is characterised by chronically elevated leptin levels and decreased leptin 
sensitivity (Pan et al., 2014). It is possible that the female participants who reported 
appetite/weight increases have become desensitised to endogenous signals regarding 
stores of body fat. As such, they continue to experience high levels of hunger despite 
higher levels of circulating leptin. This may be coupled with continuing to eat as a 
coping strategy for any physiological and psychological stress they are experiencing, 
with certain foods dampening HPA activity (Dallman et al., 2003; Ulrich-Lai, 2016).  
Leptin levels did not differ significantly between depressed and non-depressed 
participants in the current study. Further, no significant relationships between leptin 
levels and depression, anxiety or stress scores were present. Previous research has 
identified inconsistent results regarding leptin levels in MDD; some studies report 
increased leptin levels in depressed mood (Antonijevic et al., 1998; Morris et al., 2012), 
whereas others report lower or equivalent leptin levels in depressed participants versus 
controls (Carvalho et al., 2014; Westling et al., 2004; Atmaca et al., 2003; Häfner et al., 
2012; Ozsoy et al., 2014). Symptom profiles present heterogeneously in MDD, and 
previous studies did not specifically analyse leptin levels as a function of increased or 





decrease weight and appetite. Also, despite previous literature linking leptin to 
depressed mood (Westling et al., 2004; Morris et al., 2012), the current results, in 
combination with previous studies, indicate that leptin may be linked to sex-specific 
symptoms and pathophysiology of MDD (Lu, 2007), as opposed to the disorder as a 
whole. 
A clear overall sex difference in terms of plasma leptin levels was observed in 
all analyses, with female participants having higher plasma leptin levels than males, 
irrespective of MDD or appetite/weight change status. This is consistent with previous 
findings of a sexual dimorphism in leptin studies (Antonijevic et al., 1998; Rubin et al., 
2002). Females tend to store more body fat for reproductive purposes (Blaak, 2001) and 
given a certain BMI, females are likely to have a higher percentage of body fat than 
males. As leptin secretion is proportional to adipose tissue mass (Maffei et al., 1995), 
females may have higher circulating leptin levels. Higher leptin levels and body fat 
percentages may act as a risk factor for weight gain in depressed females, and may 
perhaps explain why females are more prone to weight gain in MDD (Sutin & 
Zonderman, 2012; Grundy et al., 2014). Increased weight gain further represents a risk 
factor for other associated health risks in MDD, including cardiovascular disease and 
metabolic syndrome (Cassano & Fava, 2002; Penninx et al., 2013). As such, higher 
leptin levels may also represent a risk factor for these conditions, particularly in 
depressed females; however further longitudinal research is needed to explore the time 
course of these factors. 
Exploratory analysis of problematic eating behaviours and food addiction in a 
subset of depressed participants provided promising evidence. To our knowledge, 
relationships between leptin, MDD, problematic eating behaviours and eating addiction 
have not been previously reported. In the current study, instances of these problematic 





eating behaviours, including emotional and restrained eating, were consistently higher 
in depressed females compared to depressed males. These results indicate that these 
behaviours may represent sex-specific coping mechanisms for depressed mood, which 
are also linked to hormone levels. Further, while depressed mood has previously been 
associated with increased emotional eating and food intake in response to food cues 
(van Strien et al., 2016; Sevincer et al., 2017), the current study is the first to identify a 
direct link between MDD, leptin levels and problematic eating behaviours, including 
eating addiction. Despite the small sample size for the subset analysis, which limited the 
power to detect effects, plasma leptin was positively correlated with restrained and 
emotional eating. This may provide further evidence of leptin resistance in MDD, given 
that there were higher instances of food consumption and related behaviours despite the 
presence of equivalent leptin levels. In addition, approximately one quarter of depressed 
participants in the sub-analysis, all females, met the YFAS criteria for food addition, 
double the prevalence rates reported in non-clinical samples, and equivalent to that 
reported in obese samples (Meule & Gearhardt, 2014). This effect relating to food 
addiction has not, to our knowledge, been previously examined in a depressed sample. 
This suggests that food addiction may be a more common problem in MDD than 
previously realised. However, further research is needed to determine whether the role 
of leptin is causal or is a result of other mechanisms. 
Overall, the results of the current study suggest that leptin is related to sex-
specific weight changes and problematic eating behaviours in MDD, even after 
controlling for BMI. Leptin levels were higher in female participants with increased 
appetite or weight gain, however this pattern was the opposite in males, who showed 
higher leptin with decreased appetite or weight loss. Leptin levels were positively 
correlated with measures of comfort eating and loss of control in food consumption. 





These results provide further support for leptin dysregulation in problematic eating 
behaviours in MDD that differs by sex. Leptin resistance may be a factor in appetite and 
weight dysregulation, particularly in females, and problematic eating behaviours in 
MDD. Further elucidation of the pathways between depression, health indicators and 
problematic eating behaviours could assist in the development of early interventions and 
preventative measures for individuals at risk of weight gain and associated chronic 
disease due to MDD. Research aimed at identifying interventions to treat leptin 
resistance is emerging (Pan et al., 2014), which in future may be of value in assisting in 
reducing the risk of weight gain for depressed individuals. 
There are several limitations to the current study. Participants were not required 
to fast prior to blood collection, and diets were not controlled for. Previous leptin 
studies have used fasting and non-fasting protocols, and this should be considered when 
interpreting the results. Additional potential confounding variables, such as physical 
activity, were not controlled for, and should be considered for future studies. Further, 
the sub-investigation of food addiction and eating behaviour in relation to leptin was 
exploratory and conducted for only 33 participants. While these results are promising 
and showed that problematic eating behaviours were linked to leptin levels, larger 
studies with control participants are needed to investigate the predictive value of leptin 
and other hormones in relation to appetite and weight dysregulation. This may further 
serve as potential modifiable risk factors or points for early intervention in depression or 
obesity treatment. 
In conclusion, the current study provides new insights into the relationships 
between leptin, problematic eating behaviours, weight gain and MDD. In particular, the 
results suggest a possible role of leptin resistance in problematic eating behaviours in 
MDD, particularly in females. This highlights the need for further, longitudinal, 





research evaluating the temporal relationships between these variables and the role of 
leptin and leptin resistance as potential risk factors for weight gain and associated 
cardiovascular and metabolic health risks in subsets of individuals with MDD. This may 
lead to opportunities for early interventions aimed at preventing weight gain in at-risk 
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CHAPTER THREE 
 
3.1 Introductory Comments 
 
The results of Study 1 indicated that problematic eating and weight gain in 
MDD are related to leptin. The higher leptin concentrations in females with appetite and 
weight gain, in addition to the positive correlations between leptin and problematic 
eating behaviours, is suggestive of leptin resistance in MDD and in females. These 
results indicate that both psychological and physiological variables are linked to 
problematic eating behaviours, and that integrated approaches may lead to a better 
understanding of problematic eating in the context of MDD. However, in Study 1 the 
relationships between leptin and problematic eating were only examined in a small 
subset of depressed individuals, with no comparisons made to healthy controls. 
Additionally, ghrelin is implicated in the stimulation of appetite and food intake, but has 
not been examined in relation to problematic eating and weight gain in MDD. 
Therefore, the second study of this thesis expanded on the previous pilot study 
to examine the relationships between problematic eating behaviours and appetite 
hormones in a new cohort. Plasma leptin and ghrelin levels, biometrics and 
psychometric indices of mood and eating were compared between 60 individuals with 
MDD and 60 healthy controls. A sub-analysis based on self-reported weight changes in 
the MDD cohort was conducted to assess whether problematic eating and appetite 
hormones differed based on weight symptom profiles. 
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Major Depressive Disorder (MDD) involves changes in appetite and weight, with a 
subset of individuals at an increased risk of weight gain. Pathways to weight gain may 
include appetite disturbances, excess eating, and dysregulation of appetite hormones. 
However, little research has simultaneously examined relationships between hormones, 
eating behaviours and MDD symptoms. Plasma ghrelin and leptin, biometrics, eating 
behaviours and psychopathology were compared between depressed (n = 60) and 
control (n = 60) participants. Depressed participants were subcategorised into those with 
increased or decreased appetite/weight for comparison by subtype. The Dutch Eating 
Behaviours Questionnaire and Yale Food Addiction Scale measured eating behaviours. 
Disordered eating was higher in MDD than controls, in females than males, and in 
depressed individuals with increased, compared to decreased, appetite/weight. Leptin 
levels were higher in females only. Leptin levels correlated positively, and ghrelin 
negatively, with disordered eating. The results provide further evidence for high levels 
of disordered eating in MDD, particularly in females. The correlations suggest that 
excessive eating in MDD is significantly linked to appetite hormones, indicating that it 
involves physiological, rather than purely psychological, factors. Further, longitudinal, 
research is needed to better understand whether hormonal factors play a causal role in 
excessive eating in MDD. 




Research indicates that obesity increases the risk of Major Depressive Disorder 
(MDD) by approximately 18-55%, and in turn, MDD increases the risk of obesity by 
approximately 37-58% (Luppino et al., 2010; Heiskanen et al., 2013; Mannan et al., 




2015). The prevalence rates of both MDD and obesity are increasing annually, with 
these rises attributed to physiological and psychological stress, obesogenic 
environments and changes in modern lifestyles (Hidaka, 2012). Consequently, 
individuals with MDD are at increased risk of developing additional health 
complications, including cardiovascular disease and metabolic syndrome (Cassano & 
Fava, 2002; Penninx et al., 2013). Identifying potential mechanisms for weight gain in 
MDD may help improve interventions aimed at reducing the likelihood of chronic 
disease in these at-risk individuals. 
Changes in appetite and weight are diagnostic criteria for MDD (American 
Psychiatric Association, 2013), with the direction of appetite/weight changes differing 
by MDD subtype. Melancholic MDD is characterised by decreased appetite and weight 
loss. In contrast, atypical MDD features hyperphagia, weight gain (American 
Psychiatric Association, 2013), higher BMI values, increased endocrine dysregulation 
and more frequent instances of cardiovascular disease and metabolic syndrome (Gecici 
et al., 2005; Lamers et al., 2016; Milaneschi et al., 2017a). Epidemiological studies have 
indicated that atypical MDD is now 40% more prevalent than melancholic MDD; 
indicating that ‘atypical’ symptoms, including weight gain, are increasingly becoming 
more ‘typical’ (Blanco et al., 2012; Privitera et al., 2013). Despite clearly established 
risks for chronic disease (Cassano & Fava, 2002; Penninx et al., 2013), there is a lack of 
both specific treatment guidelines for the treatment or prevention of depressogenic 
weight gain, and integrated approaches that address both biological and physiological 
factors. The long-term success of weight loss programs in general is also limited 
(MacLean et al., 2015). Understanding the mechanisms underlying the pathways to 
weight gain in MDD may allow for better preventative strategies in individuals at risk 
due to MDD. 




Pathways to weight gain in MDD may include appetite disturbances linked to 
neuroendocrine changes and associated disordered eating. Disordered eating may act as 
a coping mechanism for psychological distress, as foods, particularly those high in 
carbohydrates, can dampen physiological stress responses produced by the 
hypothalamic-pituitary-adrenal (HPA) axis (Dallman et al., 2003). Disordered eating 
includes emotional eating, increasing food intake in response to emotional distress; 
restrained eating, deliberately restricting food intake to prevent weight gain or 
encourage weight loss; and external eating, increasing food intake in response to 
sensory food cues (van Strien et al., 2016). Depressed mood and MDD symptom 
severity are associated with emotional eating (van Strien et al., 2016; Paans et al., 
2018), increased consumption of food in response to external cues, and with restricting 
food intake (Sevincer et al., 2017).  
Food addiction characterises a subset of disordered eating behaviours, defined 
by a preference for highly palatable foods and addiction-like behaviours such as a loss 
of control and withdrawal (Piccinni et al., 2015). Dopaminergic reward pathways can be 
activated by highly palatable foods, particularly those high in carbohydrates or fat, 
which can result in addiction-like behaviours similar to substance use disorders 
(Gearhardt et al., 2009; Piccinni et al., 2015). Food addiction can be measured using the 
Yale Food Addiction Scale (YFAS; Gearhardt et al., 2009), with a prevalence of 5-10% 
in the general population, and 15-25% in obese individuals (Meule & Gearhardt, 2014; 
Hauck et al., 2017). In a recent pilot, we found that 25% of a sample with MDD met 
Yale criteria for food addiction, considerably higher than general community samples 
(Mills et al., 2018).  
The concept of food addiction is still controversial, since food is necessary for 
survival whereas psychoactive substances that form the basis of other addictions are not 




(Ziauddeen & Fletcher, 2013: Onaolapo & Onaolapo, 2018). The composition of 
modern foods has been altered to increase their palatability and hedonistic qualities 
compared to naturally occurring foods (Leigh & Morris, 2018), to the extent that they 
could be argued to act similarly to addictive substances. There is increasing evidence of 
an overlap between activation of neural reward circuitry in response to food and drugs 
of addiction (Gearhardt et al., 2011; Volkow et al., 2012). Several studies have linked 
the concept of food addiction to MDD (Gearhardt et al., 2012; Eichen et al., 2013; Mills 
et al., 2018). As such, it is possible that obesogenic environments promoting the 
availability of highly palatable foods may be related to the increased prevalence of 
atypical MDD characterised by weight gain, however further research is needed. 
While previous studies indicate that MDD is associated with disordered eating 
(Bailly et al., 2012; van Strien et al., 2016), food addiction (Eichen et al., 2013; Mills et 
al., 2018) and weight gain (Blanco et al., 2012), the mechanisms underlying the 
relationships between these factors are unclear. The hunger and satiety hormones 
ghrelin and leptin are related to HPA axis activity and suppression of stress responses, 
and therefore may be associated with MDD and associated symptomatic appetite/weight 
changes (Roubos et al., 2012; Spencer et al., 2014). However, little research has 
examined direct relationships between these hormones, disordered eating behaviours 
and appetite/weight changes in MDD. 
Leptin is secreted by adipocyte cells in proportion to adipose tissue mass, with 
critical roles in regulating adipose tissue and body weight (Maffei et al., 1995). Leptin 
has important anorexigenic effects, acting as an appetite suppressant during times of 
energy excess (Elmquist et al., 1998; Trayhurn et al., 1999; Lu, 2007). Leptin 
resistance, or having high leptin levels but decreased leptin sensitivity (Pan et al.,, 2014) 
has been implicated in the pathogenesis of obesity (Zigman & Elmquist, 2003; Ozsoy et 




al., 2014). Since leptin is secreted relative to adipose tissue mass, higher levels signal 
the increased availability of fat and in turn lead to a reduction in food intake such that 
stored fat can be utilised for energy. However, in leptin resistance individuals become 
desensitised to endogenous satiety signals, resulting in elevated leptin levels without the 
usual satiety, and subsequently increased food intake and weight gain or obesity (Maffei 
et al., 1995).  
Human research investigating leptin levels in MDD has identified inconsistent 
results, with either lower (Kraus et al., 2001; Atmaca et al., 2003; Westling, et al., 2004) 
or elevated (Antonijevic et al., 1998; Jimenez et al., 2009; Morris et al., 2012) leptin 
levels in MDD versus control populations. In contrast, several studies, including large-
scale meta-analyses, have indicated no difference between diagnostic groups (Hafner et 
al., 2012; Ozsoy et al., 2014; Carvalho et al., 2014). Individuals with atypical MDD 
have higher leptin levels compared to controls, and individuals with melancholic MDD 
(Gecici et al., 2005; Lamers et al., 2016a; Milaneschi et al., 2017a), suggesting that 
leptin may be involved in a subset of individuals with increased appetite/weight. 
Ghrelin is secreted from the stomach and gastrointestinal tract (Kojima et al., 
1999), with important orexigenic roles in promoting increased food intake (Wren et al., 
2000) and increased adiposity (Tschop et al., 2001; Thompson et al., 2004). 
Significantly lower total ghrelin concentrations have been observed in obese humans, 
indicating possible downregulation of ghrelin levels associated with excessive eating 
(Atalayer et al., 2013).  
Studies of ghrelin in MDD are also inconsistent, with elevated (Kurt et al., 2008; 
Atescelik et al., 2017; Ozsoy et al., 2014) lowered (Barim et al., 2009) or no difference 
between MDD and control participants observed (Kluge et al., 2009; Lawson et al., 
2011; Matsuo et al., 2012). Whether ghrelin levels differ by melancholic/atypical 




subtype is currently unclear, however due to its role in stimulating appetite levels (Wren 
et al., 2000) ghrelin levels may possibly be higher in those experiencing appetite/weight 
gain, or possibly lowered due to the downregulation observed in obesity (Atalayer et al., 
2013).  
The inconsistent results for leptin and ghrelin levels may be accounted for by the 
heterogeneity in appetite/weight change symptom profiles in MDD. Previous studies 
have either combined symptom subtypes (Antonijevic et al., 1998; Ozsoy et al., 2014) 
or have classified symptoms based on broader atypical MDD criteria, differing also in 
the classification methods used (Gecici et al., 2005; Lamers et al., 2016; Milaneschi et 
al., 2017a). These inconsistent classification methods may act as potential confounds in 
these studies. In addition, leptin levels are more strongly correlated with appetite and 
weight gain and not other atypical symptoms (Milaneschi et al., 2017a), suggesting that 
comparison by appetite/weight symptom profile may provide a clearer understanding of 
relationships between appetite hormones and weight gain than atypical criteria more 
generally. 
Leptin and ghrelin are noted to vary between sexes, with higher leptin and 
ghrelin levels reported in females than males (Antonijevic et al., 1998; Soriano-Guillen 
et al., 2016); which may be explained by females having different body fat 
compositions than males for reproductive purposes (Blaak, 2001). However, sex 
differences in leptin and ghrelin levels are not always observed (Kluge et al., 2009; 
Tschop et al., 2001). In humans, leptin and ghrelin levels have also previously been 
correlated with body mass index (BMI) and waist circumference (Mills et al., 2018; 
Akamizu et al., 2004), suggesting potential roles for both hormones as risk factors for 
chronic diseases. However, no studies have simultaneously examined associations 
between appetite hormones, disordered eating and BMI in MDD.  




Our previous pilot study (Mills et al., 2018) found that a high proportion of 
participants with MDD reported disordered eating, including emotional and restrained 
eating as measured by the Dutch Eating Behaviours Questionnaire (van Strien et al., 
1986), and food addiction behaviours as measured by the Yale Food Addiction Scale 
(Gearhardt et al., 2009). Disordered eating was higher in females with MDD than males 
with MDD. Further, disordered eating correlated positively with leptin levels, 
suggesting that leptin resistance may be involved in disordered eating in MDD. The 
current study expands on our previous work by investigating eating behaviours in 
relation to neurobiological measures in a new cohort. Leptin and ghrelin levels, 
biometrics and psychometric indices of mood and problematic eating behaviours were 
compared between individuals with MDD and healthy controls. Given the 
heterogeneous nature of MDD, participants with MDD were further subcategorised by 
appetite/weight symptom presentation to compare subtypes. It was predicted that: 
1. Participants with MDD would report greater levels of disordered eating 
compared to controls. By symptom profile, MDD participants with increased 
appetite/weight would demonstrate higher instances of these behaviours than 
MDD participants without increased appetite/weight; with effects being greater 
in females. 
2. Psychometric indices of problematic eating behaviours, food addiction and 
depression severity will correlate with leptin and ghrelin levels.  
3. Leptin and ghrelin levels would not differ significantly between depressed and 
non-depressed participants overall. However, at the subgroup level in MDD, 
these values will be higher in those with increased appetite/weight compared to 
those with reduced or unchanged appetite/weight; with effects being greater in 
females. 







One hundred and twenty (120) adults aged between 18 and 54 years (M = 25.05, 
SD = 6.61 years; 68 female) participated. Participants were recruited by media and 
university advertisements. Depressed participants were pre-screened to confirm that 
they currently met DSM-5 criteria prior to inclusion in the MDD group (N = 60). 
Control participants (N = 60) were age and gender matched to the MDD group. 
Depressed participants were not receiving any current or recent psychological, 
pharmacological or somatic treatment for MDD. All control participants had no history 
of diagnosed mental disorders. Use of corticosteroids, neurological illness and 
substance use were general exclusion criteria. Participants were asked to provide 
information about any medical conditions and medications being taken. The study 
received approval from the local ethics committee. 
 
3.4.2 Measures 
Depressive symptom severity was assessed using the Beck Depression Inventory 
(BDI-II), a 21 item self-report questionnaire (Beck et al., 1996). Disordered eating, 
including Emotional, Restrained and External eating, were measured using the Dutch 
Eating Behaviours Questionnaire (DEBQ; van Strien et al., 1986). Food addiction and 
related behaviours, including Withdrawal symptoms, Cravings and Tolerance to 
increased food intake, were assessed using the Yale Food Addiction Scale (YFAS; 
Gearhardt et al., 2009).  
3.4.3 Procedure 
 
Participants attended one visit at the university clinical trials research unit. All 
participants provided informed written consent. Depressed participants were 




interviewed to confirm that they met criteria for MDD using the Mini Neuropsychiatric 
Interview, version 7.0.2 for DSM-5 (MINI; Sheehan, 2015). Depressed participants 
were asked to indicate whether they had experienced any recent changes to their 
appetite or weight. To meet the criteria for increased or decreased/unchanged 
appetite/weight, MDD participants were required to endorse a 5% (or 3 kilogram) 
increase or decrease to their weight that was not the result of deliberate weight changes, 
such as intentional weight loss, in the previous month (Sheehan, 2015).  
Participants’ height, weight, waist circumference, blood pressure and heart rate 
were measured, then a 10ml blood sample was obtained by a phlebotomist. All blood 
samples were taken between 9:00-11:00am. Participants were not required to fast, 
however details of food consumption in the previous 12h were recorded. Participants 
then completed the psychometric questionnaires. 
 
3.4.4 Data and Statistical Analysis 
 
Blood samples were centrifuged at 4°C, at 2800rpm for 10 min immediately 
following blood collection. Plasma was stored in a -80°C freezer until analysis. Plasma 
leptin and total ghrelin levels were measured using standard ELISA testing kits (Abcam, 
Cambridge, United Kingdom and Thermofisher Scientific, Carlsbad, United States of 
America respectively). The intra- and inter-assay coefficients of the leptin ELISA were 
<10% and <12% respectively, and <6% and <8.5% for the total ghrelin ELISA. 
Statistical analysis was conducted using ‘Statistical Package for the Social 
Sciences’ (SPSS, Version 23). The dependent variables of interest were the 
psychometric measurements (BDI, DEBQ and YFAS scores), plasma leptin and total 
ghrelin levels. Due to the relationship between leptin and adipogenesis (Maffei et al., 




1995), to control for potential confounding effects of visceral fat, plasma leptin was 
normalised to waist circumference (in metres) prior to statistical analysis.  
Two-way factorial analyses of variance (ANOVA) were used to test for 
differences in the dependent variables with the between-subjects factors of Diagnosis 
(MDD, control) and Sex (male, female), with Age and BMI used as covariates. Further 
two-way factorial ANOVAs were used to test for subgroup differences in the variables 
as a function of appetite and weight changes in MDD participants only, with the 
between-subjects factors of Appetite and Weight Categories (increased, decreased/no 
change) and Sex (male, female), with Age and BMI also as covariates. Pearson’s 
correlation coefficients and Spearman’s rank correlations were used to determine 
relationships between the variables. For all statistical tests, a < .05 was considered 
statistically significant. Post-hoc analyses were conducted using Bonferroni corrections. 
 
3.5. Results 
3.5.1 Analyses of MDD (combined subtypes) compared to controls) 
3.5.1.1 Demographic and Biometric Data 
 
Participant characteristics are shown in Table 3.1. There were 34 females and 26 
males in both MDD (N = 60) and control (N = 60) groups. No participants had a 
diagnosed eating disorder, and none were current smokers. Of the 120 participants, 30 
(18 MDD) had not consumed any food or drink other than water for approximately 12h.  
The groups did not differ significantly in age. Males weighed more than females 
(F(1, 116) = 18.159, p < .001). No further differences for Diagnosis, Sex or interaction 





Table 3.1:  
Means and standard deviations for biometric data, by Diagnosis and Sex (total N = 120; MDD and control participants).  
 
Note: MDD = Major Depressive Disorder; BMI = Body Mass Index. * Indicates a significant difference compared to the other diagnostic group 





  Diagnosis Sex 
Variable  Control MDD Effect Effect Size Male Female Effect Effect Size 
  M (SD) M (SD) p partial η2 M (SD) M (SD) p partial η2 
 Sample size (n) 60 60 - - 52 68 - - 
Biometrics Age (years) 25.40 (7.17) 24.70 (6.03) .422 .006 25.31 (5.38) 24.85 (7.44) .709 .001 
 Weight (kg) 73.29 (16.67) 74.65 (16.13) .721 .001 80.79 (13.98)* 68.76 (16.18) < .001 .135 
 BMI (kg/m2) 25.10 (5.35) 25.80 (5.41) .580 .003 25.51 (4.35) 25.40 (6.06) .910 .000 
 Waist Circumference (m) 0.89 (0.14) 0.85 (14.30) .150 .018 0.90 (0.12) 0.82 (0.13) .071 .028 
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3.5.1.2 Psychometric Data 
Participants with MDD had significantly higher Total BDI scores compared to 
controls (F(1, 116) = 354.013, p < .001). Females had higher Total BDI scores than 
males (F(1, 116) = 4.860, p = .029). The interaction between Diagnosis and Sex was not 
significant.  
Depressed participants scored significantly higher on the Emotional (F(1, 116) = 
20.194, p < .001) and Restrained (F (1, 116) = 9.576, p = .002) subscales of the DEBQ 
compared to controls. Females also scored significantly higher on the Emotional (F(1, 
116) = 10.392, p = .002) and Restrained (F (1, 116) = 6.268, p = .014) subscales 
compared to males. External eating did not differ between diagnostic groups or sexes. 
No interaction effect between Diagnosis and Sex was observed for any DEBQ 
subscales. 
Endorsement rates for each YFAS symptom are presented in Table 3.3. 
Seventeen (28%; 13 female) MDD participants met the YFAS criteria for food 
addiction compared to two (3%; both female) of controls. Overall, participants with 
MDD had significantly more food addiction symptoms than controls (F(1, 116) = 
22.139, p < .001), and scored significantly higher than controls on each YFAS subscale, 
with the exception of Continued Use Despite Problems. Withdrawal scores were 
significantly higher in females compared to males (F(1, 116) = 4.208, p = .042), with no 







Table 3.2:  
Means and standard deviations for psychometric data, by Diagnosis and Sex (total N = 120; MDD and control participants). 
 
 
Note: MDD = Major Depressive Disorder; BDI = Beck’s Depression Inventory; DEBQ = Dutch Eating Behaviours Questionnaire; YFAS = Yale Food 
Addiction Scale. YFAS subscales are scored dichotomously and occur between 0.00 and 1.00. * Indicates a significant difference compared to the other 
diagnostic group or sex being compared. 
  Diagnosis Sex 
Psychometric  Control MDD Effect Effect Size Male Female Effect Effect Size 
  M (SD) M (SD) p partial η2 M (SD) M (SD) p partial η2 
 Sample size (n) 60 60 - - 52 68 - - 
BDI Total Score 4.80 (4.75) 30.72 (9.59)* < .001 .753 16.06 (13.82) 19.06 (15.88)* .029 .040 
DEBQ Emotional Eating 1.99 (0.72) 2.75 (1.11)* < .001 .148 2.07 (0.95) 2.60 (.99)* .002 .082 
 Restrained Eating 1.94 (0.83) 2.49 (1.07)* .002 .076 1.97 (0.93) 2.40 (1.01)* .014 .051 
 External Eating 2.98 (0.71) 3.20 (0.67) .117 .021 3.08 (0.72) 3.10 (0.69) .923 .000 
YFAS Increased Intake 0.13 (0.34) 0.33 (0.48)* .012 .053 0.27 (0.45) 0.21 (0.41) .410 .006 
 Failure to Quit 0.10 (0.30) 0.37 (0.49)* .001 .093 0.15 (0.36) 0.29 (0.46) .059 .030 
 Time Taken to Obtain 0.10 (0.30) 0.37 (0.49)* .001 .096 0.27 (0.45) 0.21 (0.41) .400 .006 
 Activities Given Up 0.02 (0.13) 0.28 (0.45)* < .001 .138 0.13 (0.35) 0.16 (0.37) .662 .002 
 Adverse Consequences 0.07 (0.25) 0.30 (0.46)* .001 .090 0.15 (0.36) 0.21 (0.41) .452 .005 
 Tolerance 0.03 (0.18) 0.28 (0.45)* < .001 .111 0.17 (0.38) 0.15 (0.36) .685 .001 
 Withdrawal 0.10 (0.30) 0.42 (0.50)* < .001 .121 0.17 (0.38) 0.32 (0.47)* .042 .035 
 Use Despite Problems 0.08 (0.28) 0.22 (0.41) .061 .030 0.10 (0.30) 0.19 (0.40) .144 .018 
 Failed Role Obligations 0.02 (0.13) 0.17 (0.38)* .006 .063 0.10 (0.30) 0.09 (0.29) .880 .000 
 Physically Hazardous Use 0.08 (0.28) 0.30 (0.46)* .002 .079 0.21 (0.41) 0.18 (0.38) .621 .002 
 Cravings 0.07 (0.25) 0.23 (0.43)* .012 .053 0.12 (0.32) 0.18 (0.38) .348 .008 
 Symptom Count 0.80 (3.35) 3.27 (3.45)* < .001 .160 1.85 (2.89) 2.18 (3.12) .519 .004 
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Table 3.3:  
Endorsement rates for Yale Food Addiction Scale (YFAS) data, by Diagnosis and Sex 
(total N = 120; MDD and control participants). 
 
Note: MDD = Major Depressive Disorder; YFAS = Yale Food Addiction Scale. 
 
 
3.5.1.3 Leptin and Ghrelin 
 
Initial inspection of the distribution of the waist-circumference normalised leptin 
data across all participants indicated a positively skewed distribution (skewness = 
6.448, SE = .231). The normalised leptin data were subsequently natural-log 
transformed (Milaneschi et al., 2012; Mills et al., 2018). Following log-transformation, 
three univariate outliers were detected, two of which were MDD participants with leptin 
levels below the limit of detection. Eleven participants (8 MDD, 3 control; 10 female) 
had reported insulin dysregulation issues (three had diabetes, two had insulin resistance 
and six had polycystic ovarian syndrome). In order to eliminate potential confounding 
effects, the univariate outliers and leptin data from all participants with insulin 
dysregulation disorders were excluded from subsequent leptin analyses (Mills et al., 
2018). Means and standard deviations for the log-transformed leptin values are 
  Sex Diagnosis 
  Male Female Control MDD 
  % % % % 
 Sample size (n) 52 68 60 60 
YFAS Increased Intake 26.92 20.59 13.33 33.33 
 Inability to Quit 15.38 29.41 10 36.67 
 Time Taken to Obtain 26.92 20.59 10 36.67 
 Activities Given Up 13.46 16.18 1.67 28.33 
 Adverse Consequences 15.38 20.59 6.67 30 
 Tolerance 17.30 14.71 3.33 28.33 
 Withdrawal 17.30 32.35 10 41.67 
 Use Despite Problems 9.61 19.12 8.33 21.67 
 Failed Role Obligations 9.61 8.82 1.67 16.67 
 Physically Hazardous Use 21.15 17.65 8.33 30 
 Cravings 11.54 17.65 6.67 23.33 
Chapter 3 – Leptin and Ghrelin 
 
67 
displayed in Table 3.4. Log-normalised leptin values did not differ between participants 
who elected to fast and those who did not (F(1, 102) = .103, p = .749). 
Accounting for age and BMI, log-normalised leptin values were not significantly 
different between MDD and control participants. Females had significantly higher log-
normalised leptin values than males (F(1, 100) = 110.391, p < .001). BMI was a 
significant covariate (F(1, 100) =77.460, p < .001), however Age as a covariate, and the 
interaction between Diagnosis and Sex, were non-significant. 
Means and standard deviations for the ghrelin data are also displayed in Table 4. 
Inspection of the ghrelin data indicated a normal distribution (skewness = .135, SE = 
.231), and no outliers in boxplot diagrams were detected. Participants reporting insulin 
dysregulation issues (n = 11) were also excluded from ghrelin analyses. Ghrelin values 
did not differ between fasting and non-fasting participants (F(1, 105) = .164, p = .686). 
Ghrelin values did not differ significantly between MDD and control 
participants, or by Sex, after accounting for age and BMI as potential covariates. BMI 
was identified as a significant covariate (F(1, 103) = 8.007, p = .006), however Age as a 







Table 3.4:  
Means and standard deviations for raw and log-transformed leptin (N = 106) and ghrelin (N = 109) data (ng/ml), by Diagnosis and Sex (MDD 
and control participants). 
 
Note: MDD = Major Depressive Disorder; BMI = Body Mass Index.  Leptin values normalised to waist circumference. Significance noted for 
log-transformed data.




D x S 
Interaction 




D x S 
Interaction 
  n M (SD) M (SD) p partial η2 p n M (SD) p partial η2 p 
Diagnosis Control 56 8.51 (13.44) 1.11 (1.58) 
.173 .018 
.814 
57 2.77 (1.22) 
.994 .000 
.668 
MDD 55 16.94 (38.80) 1.42 (1.90) 52 2.70 (1.25) 
Sex Male 48 3.10 (5.17) 0.13 (1.49) 
< .001 .525 
51 2.54 (1.10) 
.150 .020 Female 58 20.26 (36.66) 2.19 (1.32) 58 2.90 (1.31) 
Covariates Age  - - - .104 .026 - - - .241 .013 - 
BMI  - - - < .001 .436 - - - .006 .072 - 
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3.5.2 Analysis by Appetite/Weight Change Sub-Groups in MDD 
 
All 60 MDD participants were categorised based on self-reported increases (n = 
28), decreases (n = 25) or no changes (n = 7) to their appetite/weight from the clinical 
interview. Data from participants with increased appetite/weight were compared to 
those with decreased or unchanged appetite/weight (n = 32) combined. Further analyses 
were performed removing the seven participants with unchanged appetite/weight due to 
potential differences from participants experiencing appetite/weight dysregulation, 
however the results were equivalent in terms of significant effects and interactions. 
Hence, the results from the total sample are reported. There were 17 females and 11 
males in the increased group, and 17 females and 15 males in the decreased/unchanged 
group. The Appetite/Weight Categories did not differ in sex distributions (c2 (1, N = 60) 
= .350, p = .554) or age. 
 Weight (F(1, 56) = 4.041, p = .049) and BMI (F(1, 56) = 7.480, p = .008) was 
significantly higher in participants reporting increased appetite/weight than those with 
decreased/unchanged appetite/weight. Participants with increased appetite/weight also 
scored significantly higher on the Emotional eating subscale of the DEBQ (F(1, 56) = 
37.388, p < .001) and reported a greater number of YFAS food addiction symptoms 
(F(1, 56) = 13.650, p = .001) They also scored significantly higher on each of the YFAS 
subscales (data not shown). Sex differences for the biometric and psychometric data 
were as reported previously in sections 3.1.1 and 3.1.2.  
Following the exclusion of 10 MDD participants for insulin dysregulation issues 
as previously described (section 3.3), log-normalised leptin and ghrelin values did not 
differ between participants who elected to fast and those who did not, and they were not 
significantly different between those with increased or decreased/unchanged 
appetite/weight. BMI was a significant covariate in both analyses. Sex effects reflected 
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those reported previously for the larger comparison (section 3.1.3). No further 
differences or interaction effects based on Appetite/Weight Categories or Sex were 
identified. Means and standard deviations for the biometric, psychometric and 





Table 3.5:  
Means and standard deviations for biometric, psychometric (N = 60), leptin (N = 50; ng/ml) and ghrelin (N = 52; ng/ml) data by Appetite/Weight 
Categories (increased compared to decreased/unchanged) and Sex (MDD participants only). 
 
 
Note: MDD = Major Depressive Disorder; BMI = Body Mass Index; BDI = Beck’s Depression Inventory; DEBQ = Dutch Eating Behaviours 
Questionnaire; YFAS = Yale Food Addiction Scale. # N = 50; normalised to waist circumference. ## N = 52. * Indicates a significant difference 
compared to the other appetite/weight group or sex being compared. 
  Appetite/Weight Categories Sex 
Variables  Increased Decreased or 
Unchanged 
Effect Size Male Female Effect Size 
  M (SD) M (SD) p partial η2 M (SD) M (SD) p partial η2 
 Sample Size (n) 28 32 - - 26 34 - - 
Biometrics Weight (kg) 78.37 (16.6)* 71.4 (15.23) .049 .067 79.98 (16.48)* 70.58 (14.82) .014 .104 
 BMI (kg/m2) 27.81 (4.99)* 24.04 (5.20) .008 .118 25.21 (4.77) 26.25 (5.87) .580 .006 
 Waist Circumference (m) 0.93 (0.14) 0.86 (0.14) .072 .056 0.90 (0.13) 0.90 (0.15) .839 .001 
BDI Total Score 31.96 (10.21) 29.62 (9.02) .444 .011 27.73 (9.44) 33.00 (9.18)* .041 .072 
DEBQ Emotional Eating 3.49 (0.98)* 2.10 (0.75) < .001 .400 2.41 (1.12) 3.01 (1.03)* .024 .087 
 Restrained Eating 2.52 (0.97) 2.47 (1.17) .964 .000 2.17 (1.01) 2.73 (1.07) .051 .066 
 External Eating 3.35 (0.63) 3.08 (0.69) .087 .051 3.10 (0.73) 3.30 (0.63) .447 .010 
YFAS Symptom Count 4.96 (3.74)* 1.78 (2.37)  .001 .196 2.81 (3.31) 3.62 (3.57) .415 .012 
Hormones Leptin (ng/ml)# 1.88 (2.00) 1.03 (1.74) .536 .009 0.24 (1.66) 2.51 (1.40)* < .001 .506 
 Ghrelin (ng/ml)## 2.68 (1.39) 2.71 (1.14) .594 .006 2.48 (1.16) 2.92 (1.31) .260 .027 
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3.5.3 Correlation Analyses 
 
BMI correlated positively with Restrained (r(120) = .200, p = .028) and 
Emotional (r(120) = .274, p = .002) eating. Waist circumference also correlated 
positively with Emotional eating (r(120) = .248, p = .006). YFAS Symptom Count 
scores correlated positively with participant weight (r(120) = .217, p = .017), BMI 
(r(120) = .285, p = .002) and waist circumference (r(120) = .310, p = .001). Total BDI 
scores positively correlated with the Restrained (r(120) = .335, p < .001) and Emotional 
(r(120) = .462, p < .001) subscales of the DEBQ, and with the YFAS Symptom Count 
score (r(120) = .501, p < .001). YFAS Symptom Count scores further correlated with 
Restrained (r(120) = .216, p = .018), Emotional (r(120) = .548, p < .001) and External 
(r(120) = .211, p = .020) eating. 
Log-normalised leptin values correlated positively with weight (r(106) = .203, p 
= .037), BMI (r(106) = .490, p < .001) and waist circumference (r(106) = .378, p = < 
.001). Log-normalised leptin values correlated positively with Emotional (r(106) = .334, 
p < .001) and Restrained (r(106) = .366, p = < .001) eating, and the Failure to Quit 
(r(106) = .289, p = .003), Adverse Consequences (r(106) = .198, p = .042) and 
Continued Use Despite Problems (r(106) = .218, p = .025) subscales of the YFAS. 
Ghrelin values correlated negatively with weight (r(109) = -.239, p = .012), BMI 
(r(109) = -.247, p = .010) and waist circumference (r(109) = -.253, p = .008) and 




The current study examined relationships between disordered eating, the 
hunger/satiety hormones ghrelin and leptin and symptomatic weight changes in MDD. 
It was found that disordered eating was higher in MDD than controls, in females than 
males, and in a subset of depressed individuals with appetite/weight gain compared to 
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decreased/unchanged appetite/weight. Leptin levels correlated positively, and ghrelin 
negatively, with disordered eating. 
Emotional and restrained eating behaviours were higher in MDD than controls. 
Food addiction symptoms were also higher in MDD, with 28% of MDD participants 
compared to 3% of control participants meeting the Yale criteria for food addiction; 
double that reported in general community samples (Meule & Gearhardt, 2014) and 
replicating our earlier findings (Mills et al., 2018). These findings align with previous 
studies indicating that MDD is associated with increased emotional (van Strien et al., 
2016; Paans et al., 2018), restrained (Sevincer et al., 2017) and food addiction eating 
behaviours (Eichen et al., 2013; Gearhardt et al., 2012). Consistent with our previous 
study, emotional eating and food addiction were also higher in females compared to 
males (Mills et al., 2018). In addition, they were higher in participants in the MDD 
subgroup who had increased compared to reduced or unchanged appetite/weight, 
consistent with previous research identifying a higher prevalence of these behaviours in 
overweight and obese populations compared to normal weight controls (Bailly et al., 
2012). These findings provide evidence in support of dysregulated appetite and food 
intake patterns in MDD, particularly in females. Increased intake of highly palatable 
foods and related behaviours may be used to minimise psychological distress or dampen 
physiological stress responses produced by the HPA axis (Dallman et al., 2003; Leow et 
al., 2018), therefore acting as a potential coping mechanism for stress or low mood. 
This is supported by the positive associations between MDD symptom severity, 
emotional eating and food addiction. Given that increased food intake and emotional 
eating have been linked to weight fluctuations (Keller & Siegrist, 2015), these findings 
provide support for such behaviours acting as potential risk factors for weight gain in 
those with increased appetite/weight in MDD, particularly females.  
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Leptin levels were positively correlated with emotional and restrained eating, 
and food addiction symptoms including loss of control in food consumption and 
continuing to eat despite negative consequences. Leptin was also positively associated 
with BMI and weight. The associations between problematic eating behaviours and 
leptin are consistent with our previous study (Mills et al., 2018), which identified that 
disordered eating was correlated with leptin levels. Higher leptin levels correlating 
positively with measures of emotional eating and food addiction relating to increased 
food intake lead to the suggestion of possible leptin resistance, because higher leptin 
levels would normally be expected to be associated with satiety rather than behaviours 
related to increased food intake. In the current study we provide new information about 
the relationships between ghrelin and some eating behaviours, with ghrelin levels 
negatively correlating with restrained eating. This suggests that individuals with higher 
ghrelin levels may be more likely to experience hunger and increased food intake, with 
a lower degree of control over these behaviours. Comfort eating in MDD is often 
viewed as having psychological underpinnings (Leow et al., 2018), however the 
associations between leptin, ghrelin and disordered eating in MDD suggest that 
excessive eating behaviours are also related to physiological pathways, which is 
relevant to intervention approaches. Further research is required to assess the temporal 
nature and causal relationships between these variables. 
Leptin and ghrelin levels did not differ significantly by diagnosis, consistent 
with some previous studies investigating leptin (Carvalho et al., 2014; Mills et al., 
2018) and ghrelin (Kluge et al., 2009; Matsuo et al., 2012) levels in MDD, but are in 
contrast to other studies reporting either elevated or lowered levels (Antonijevic et al., 
1998; Ozsoy et al., 2014). The inconsistencies in findings may be due to the 
heterogeneous nature of symptom profiles in MDD, which has not been a notable factor 
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in previous research. However, in the current study, neither leptin nor ghrelin levels 
differed significantly by appetite/weight symptom profile. These findings, in 
combination with the aforementioned correlations, suggest that leptin and ghrelin may 
be specifically linked to disordered eating behaviours in MDD as opposed to the 
disorder more generally, and differences may not be clearly discernible in between-
groups analyses. 
Clear sex differences were observed in relation to leptin levels, with females 
having higher waist-normalised leptin levels than males. These results are consistent 
with previous findings (Antonijevic et al., 1998; Mills et al., 2018). Because females 
store more body fat for reproductive purposes (Blaak, 2001), and leptin secretion is 
proportional to adipose tissue mass (Maffei et al., 1995), females may have naturally 
higher leptin levels. No sex difference was observed in ghrelin levels, consistent with 
some previous studies (Tschop et al., 2001) but in contrast to others (Soriano-Guillen et 
al., 2016), indicating that further research is required to examine ghrelin levels in 
relation to depressogenic weight gain in females also. 
These findings help to better understand potential biological, psychological and 
behavioural pathways associated with depressogenic weight gain, which have 
previously not been studied in unison. While we did not find an influence of MDD or 
depression subtypes in leptin levels, their significant correlation with problematic eating 
behaviours warrants further investigation. Collectively, the identified variables 
represent promising targets for research into potentially modifiable risk factors for 
disordered eating behaviours, which may act as risk factors for weight gain in MDD. If 
increased leptin occurs in the absence of satiety behaviours, but rather in association 
with depressogenic increased eating corresponding to leptin resistance, this may be a 
potential therapeutic target to address problematic eating and weight gain risk in a large 
Chapter 3 – Leptin and Ghrelin 
 
76 
subset of individuals with MDD, particularly females. The potential of leptin as a 
therapeutic target for other symptoms in MDD is currently being considered (Ge et al., 
2018), however its potential role in weight gain associated with MDD has received little 
consideration to date. 
 There are some limitations of the study which need to be considered. 
Participants were not required to fast prior to blood sampling; previous leptin and 
ghrelin studies have used both fasting and non-fasting protocols (Milaneschi et al., 
2017a; Mills et al., 2018). Previous research has found that non-fasting leptin levels are 
not significantly different from fasting leptin levels (Hancox & Landhuis, 2011). 
Additionally, ghrelin levels maintain characteristic meal-related changes at mealtimes 
even when fasting (Natalucci et al., 2005). We did compare subgroups of participants 
who had not consumed food or drink for 12h with those who had and did not find 
significant hormonal differences, however, use of differing protocols should be 
considered when interpreting hormone results. Potential confounding variables, such as 
participants’ dietary nutrient intake, physical activity levels and menstrual phase in 
female participants were also not controlled for. Much previous leptin research does not 
include information on physical activity or menstrual phase (Ozsoy et al., 2014; 
Milaneschi et al., 2017a), however these factors should be considered in future studies. 
This study is also limited by its cross-sectional design. Longitudinal research is 
necessary to examine temporal relationships, if any, between disordered eating, appetite 
hormones and weight gain in MDD. 
In conclusion, the current study provides new information regarding problematic 
eating behaviours in MDD and their relationships to hormones and other symptoms. 
While comfort eating in MDD is often viewed as an emotional issue, the results suggest 
that self-reported excessive eating in MDD correlates with appetite hormones, implying 
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that these behaviours may have a greater physiological basis than previously 
understood, related to appetite and core depressive symptoms. The results also suggest 
that leptin dysregulation may be important to depressogenic excessive eating and weight 
gain, representing a potential treatment target for weight gain and associated chronic 
disease in individuals affected by MDD, particularly females. Future longitudinal 
















4.1 Introductory Comments 
 
The results of the second study suggested that excessive eating and weight gain 
in MDD are significantly related to hunger and satiety hormones. These findings 
suggest that problematic eating behaviours in MDD involve both psychological and 
physiological processes, further supporting the notion that integrated approaches may be 
associated with a greater understanding of problematic eating in MDD.  
Serotonin has long been implicated in the pathogenesis of MDD, however the 
role of peripheral serotonin in MDD has not been well investigated. Elevated plasma 
serotonin has been linked to highly palatable food intake, obesity and energy balance, 
and may therefore be implicated in depressogenic problematic eating behaviours and 
appetite/weight changes. However, potential relationships between plasma serotonin, 
overeating and weight gain have not yet been investigated. 
 In Study 3, plasma serotonin levels were compared between 60 individuals with 
MDD and 60 healthy controls, in the same cohort as Study 2. A sub-analysis by appetite 
and weight changes in MDD was also conducted to determine differences in plasma 
serotonin levels by this symptom profile. The relationships between plasma serotonin 
levels, problematic eating behaviours and depressive symptoms related to weight gain, 
including low mood, depressogenic thinking and sleep disturbances, were also assessed. 
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Aims: Individuals with Major Depressive Disorder (MDD) are at an increased risk of 
chronic disease, partly through appetite and weight gain associated with low mood. 
Peripheral serotonin has been linked to appetite disturbances and obesity in non-
depressed individuals. However, little is known about relationships between plasma 
serotonin concentrations, specific depressive symptoms, eating behaviours and physical 
health indicators in MDD. 
Methods: Plasma serotonin concentrations and psychopathology were compared 
between participants with MDD (n = 60) and controls (n = 60) by sex, as well as by 
symptom-specific subgroups in MDD (increased or decreased/unchanged appetite and 
weight). Problematic eating behaviours and depressive symptoms were assessed using 
semi-structured interviews and psychometric questionnaires. Biometric data collected 
included body mass index and waist circumference. 
Results: Plasma serotonin concentrations were significantly higher in participants with 
MDD than controls, and in males than females. In the total sample, plasma serotonin 
was associated with depressive symptom severity and insomnia. In males, plasma 
serotonin was positively correlated with indices of depressed mood, depressogenic 
thinking and anxiety, whereas in females serotonin was associated with agitation only. 
Plasma serotonin did not differ by appetite and weight symptom profile in MDD, and 
was not related to indices of problematic eating behaviours or weight. 
Conclusions: Despite no significant links to appetite, weight or physical health 
indicators, these results provide new evidence to indicate that plasma serotonin levels 
are meaningfully linked to other symptoms of MDD, including disturbances to mood, 
cognitions and sleep, particularly in males. These findings suggest that further research 
into plasma serotonin and its relationships to the symptoms of MDD is warranted. 
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Individuals with Major Depressive Disorder (MDD) are at an elevated risk of 
weight gain (Luppino et al., 2010; Mannan et al., 2015). Appetite and weight changes 
are a core symptom of MDD and present dichotomously by MDD subtype (American 
Psychiatric Association, 2013). Hypophagia and weight loss are features of melancholic 
MDD, whereas hyperphagia and weight gain characterise atypical MDD (American 
Psychiatric Association, 2013). Importantly, the prevalence of depressogenic weight 
gain as part of atypical MDD is increasing in concordance with the increasing 
prominence of obesogenic environments (Blanco et al., 2012; Privitera et al., 2013). 
Consistent weight gain is associated with a greater risk of chronic conditions such as 
cardiovascular disease and metabolic syndrome, suggesting that those with MDD who 
experience weight gain are at a greater risk of these conditions (Kearns et al., 2014; 
Zhao et al., 2009). However, the pathways between MDD and weight gain are unclear, 
which is reflected in the lack of effective treatment approaches (Clarke & Currie, 2009). 
Improved strategies to reduce chronic disease risk in MDD may be developed if the 
mechanisms underlying depressogenic weight gain are elucidated.  
Problematic eating behaviours represent a potential pathway to weight gain in 
MDD. Emotional eating is increasing food intake in response to negative emotions. 
Restrained eating is deliberately restricting food intake to promote weight loss. External 
eating is increasing food intake in response to sensory food cues (van Strien et al., 
2016). A fourth type of problematic eating is food addiction, that is the development 
addiction-like behaviours in association with consistent highly palatable food intake 
(Gearhardt et al., 2016). We previously identified a high prevalence of these behaviours 
in MDD, particularly in females and in those with appetite and weight gain compared to 
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loss. Problematic eating behaviours were associated with more severe depressive 
symptoms, as well as higher BMI and waist circumference values (Mills et al., 2019; 
Mills et al., 2020). We also identified that these behaviours were related to the satiety 
hormone leptin (Mills et al., 2018), hunger hormone ghrelin (Mills et al., 2019) and the 
peripheral sympathetic stress hormone dopamine (Mills et al., 2020), which suggests 
that depressed individuals may be at a greater risk of weight gain linked to both 
problematic eating behaviours and biological factors (Mills et al., 2020). In addition to 
the aforementioned hormones, the peripheral hormone serotonin may also be relevant to 
problematic eating, weight gain and depressive symptoms in MDD.  
Only 5-10% of serotonin originates in the central nervous system (Berger et al., 
2009), with the majority of serotonin synthesised peripherally in the gastrointestinal 
(GI) tract (Wu et al., 2019). Central and peripheral pools of serotonin are separated by 
the blood brain barrier, and are independently regulated (Andrews et al., 2015). 
However, it has been suggested that MDD may be associated with greater blood brain 
permeability (Steiner et al., 2011) that is potentially linked to higher concentrations of 
serotonin in the periphery, which may lead to crosstalk between the two pools (Maurer-
Spurej, 2005). Peripheral serotonin, indexed by plasma or platelet concentrations in 
blood, is implicated in the regulation of gastric motility, digestion (Amireault et al., 
2013), cardiovascular function, inflammation (Wu et al., 2019), energy balance (El-
Merahbi et al., 2015) and mood (Jenkins et al., 2016). In addition, plasma serotonin has 
been linked to food intake and weight gain, with increased carbohydrate intake (Blum et 
al., 1992) and higher BMI values (Young et al., 2018) associated with higher plasma 
serotonin. Higher plasma serotonin has also been reported in obese individuals 
compared to controls (Young et al., 2018), and in chronic health conditions featuring 
exhaustion and inflammation (Andrews et al., 2015; Shajib & Khan, 2015).  
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Previous studies investigating plasma serotonin in MDD have identified this to 
be lower (Messaoud et al., 2018; Paul-Savoie et al., 2011; Sarrias et al., 1987), elevated 
(Tyano et al., 2006) or not different (Holck et al., 2019; Ortiz et al., 1993; Pan et al., 
2018) in MDD compared to controls. Relationships between plasma serotonin and 
psychopathology, such as depressive symptom severity, are equally inconsistent, with 
negative (Paul-Savoie et al., 2011; Tyano et al., 2006), positive (Gauthier et al., 2014) 
or no relationships identified (Messaoud et al., 2018). The inconsistencies between 
these findings may be a function of differing methodologies and small samples in 
previous studies, which may limit statistical power and the reliability of the results 
(Button et al., 2013) or the inclusion of only a composite score of MDD symptoms 
instead of a symptom level analysis, which may mask effects (Fried & Nesse, 2015b). 
Plasma serotonin reportedly does not differ by sex (Demerdash et al., 2018), however 
sex comparisons have not been consistently included in previous studies (Holck et al., 
2019; Pan et al., 2018). The mechanisms underlying plasma serotonergic dysregulation 
in MDD are unclear, however low plasma serotonin may indicate reduced peripheral 
serotonergic synthesis in MDD (Sarrias et al., 1987). In contrast, due to its links to 
energy balance and exhaustion, upregulation may reflect a compensatory response for 
increased physical and emotional energy expenditure as a result of MDD (Andrews et 
al., 2015). Elevated plasma serotonin prior to antidepressant treatment is also associated 
with greater antidepressant responsivity, suggesting that higher basal concentrations 
may have clinical relevance to MDD treatment (Holck et al., 2019). 
Given the links to food intake, weight and energy balance, plasma serotonin may 
be relevant to depressogenic overeating and weight gain, however this is yet to be 
assessed. Further, to our knowledge, other depressive symptoms, which have the 
capacity to influence appetite and weight changes in MDD, have not yet been studied in 
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relation to plasma serotonin. An increased frequency of depressogenic thoughts related 
to guilt or worthlessness have been linked to greater instances of problematic eating 
behaviours, which may be used to help cope with such negative thoughts (Conradt et al., 
2008). Similarly, sleep disturbances such as insomnia have been linked to appetite 
increases to compensate for excess energy expenditure (Knutson, 2007). As such, 
plasma serotonin may indirectly contribute to weight gain risk via psychological effects. 
Assessing plasma serotonin with respect to appetite and weight and associated 
symptoms of MDD, with a comparison by symptom profile and sex, may provide a 
greater understanding of the pathways between MDD and weight gain, which in turn 
may allow for better preventative measures.  
This study aimed to examine plasma serotonin in relation to specific 
depressogenic symptoms, problematic eating behaviours and weight gain. Plasma 
serotonin levels were compared between individuals with MDD and healthy controls, 
by sex. MDD participants were subcategorised into those reporting appetite and weight 
increases versus decreases, for a comparison of serotonin levels by appetite/weight 
symptom profile. The relationships between plasma serotonin and low mood, 





This study was part of a larger investigation examining relationships between 
mental and physical health in MDD, with the study protocol published elsewhere (Mills 
et al., 2019). One hundred and twenty (120) adults (52 male) participated in the study, 
with participants recruited by university and media advertisements. Individuals who 
were experiencing depressive symptoms (n = 60) were initially screened prior to 
participation using the MINI Neuropsychiatric Interview (Sheehan, 2015) to confirm 
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they currently met DSM-5 criteria for MDD. Participants in the MDD group were 
required to not be receiving any current or recent treatment for MDD in the 2 months 
prior to participation. Comorbid psychiatric diagnoses were excluded with the exception 
of generalised anxiety disorder (GAD) due to high comorbidity rates. Sixty (60) control 
participants were age and sex matched to the MDD group, and had no significant mental 
health history or diagnosed mental disorders. Exclusion criteria across both groups were 
use of corticosteroids, neurological illness and substance use disorders. All participants 
were asked to provide information regarding any medical conditions and any 
medications being taken. The study was approved by the local joint university and 
health district ethics committee. 
 
4.4.2 Assessment Instruments 
 
Depressive symptoms were measured using the Beck Depression Inventory 
(BDI-II; Beck et al., 1996), a 21-item self-report questionnaire that measures symptom 
severity with cognitive-affective and somatic symptom sub-classifications (Viljoen et 
al., 2003). The 21-item Depression, Anxiety and Stress Scale (DASS-21; Lovibond & 
Lovibond, 1995) was used as an index of self-reported psychological distress, and 
measures depressive, anxiety and stress-related symptomology. Overeating behaviours 
were assessed using the Dutch Eating Behaviours Questionnaire (DEBQ), a 33-item 
questionnaire that measures emotional, restrained and external eating behaviours (van 
Strien et al., 1986). Total food addiction symptoms were measured using the 35-item 
Yale Food Addiction Scale, version 2 (YFAS; Gearhardt et al., 2016). Additional 
depressive symptoms, such as depressogenic thinking and insomnia-related sleep 
disturbances, were respectively assessed using the 30-item Automatic Thoughts 
Questionnaire (ATQ; Hollon & Kendall, 1980) and the summed score of the first three 
items of the Insomnia Severity Index (ISI; Morin et al., 2011). 





 Participants attended one visit at the university Clinical Research and Trials 
Unit. All participants provided written informed consent. Participants with MDD were 
interviewed with the Mini Neuropsychiatric Interview, version 7.0.2 for DSM-5 (MINI; 
Sheehan, 2015) to confirm that at the time of their visit they met the criteria for a 
current depressive episode. Participants’ height and weight were measured to calculate 
body mass index (BMI) values, and waist circumference measurements were also taken. 
A 10ml blood sample was then collected in an EDTA coated tube by a phlebotomist, 
with all blood samples collected between 9:00-11:00am to control for diurnal variations 
in hormones. Participants were not required to fast, however details of food intake in the 
12 hours preceding the blood sample were recorded. Participants then completed the 
psychometric questionnaires. 
 
4.4.4 Data and Statistical Analysis 
4.4.4.1 Blood and Serotonin Analyses 
 
Immediately following collection, 20µl per millilitre of aprotinin inhibitor was 
added to each blood sample to prevent blood coagulation. Blood samples were then 
centrifuged at 4°C, at 2800rpm for 10 minutes. Aliquoted plasma was stored at -80°C 
until analysis. Plasma serotonin concentrations were quantified measured using standard 
ELISA kits (Abcam, Cambridge, United Kingdom). The ELISA inter- and intra-assay 
coefficients were <16% and <5% respectively. 
 
4.4.4.2 Statistical Analyses 
Statistical analyses were conducted using ‘Statistical Package for the Social 
Sciences’ (SPSS, Version 25). The dependent variables of interest were plasma 
serotonin concentrations, the biometric measurements (BMI, waist circumference) and 
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the psychometric measurements (BDI-II, DASS, DEBQ, YFAS, ATQ and ISI). The 
questionnaire values were log-transformed to correct for skewed distributions, however 
the results for transformed and untransformed data were equivalent in terms of 
significant effects and interactions; hence, the results from untransformed analyses only 
are reported. 
Two-way factorial analyses of variance (ANOVA) were used to compare groups 
on the psychometric and biological measures, with between-subjects factors of 
Diagnosis (MDD, control) and Sex (female, male), and Age entered as a covariate. 
Two-way ANOVAs were also used to determine subgroup differences in the dependent 
variables as a function of appetite and weight changes in MDD participants only, with 
the between-subjects factors of Appetite and Weight Change (increased appetite/weight, 
decreased/unchanged appetite/weight) and Sex (female, male), and Age as a covariate. 
An a < .05 was considered statistically significant.  
Pearson’s correlation coefficients were used to determine relationships between 
the study variables. To reduce the probability of Type I errors in the correlational 
analyses, the false discovery rate (FDR) control procedure (Benjamini & Hochberg, 




4.5.1 Comparisons between MDD and controls 
4.5.1.1 Biometric and Psychometric Data 
 
Demographic and biometric data for the total sample are presented in Table 4.1. 
Participants were aged between 18 and 54 years (M = 25.05, SD = 6.61 years), with 34 
females and 26 males in both MDD (n = 60) and control (n = 60) groups. No 
participants had a diagnosed eating disorder, and none were smokers. The diagnostic 
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groups (MDD versus control) did not differ significantly in age. As previously reported, 
males weighed more than females, with no further differences by Diagnosis, Sex or 
interaction effects identified for biometric data (Mills et al., 2019). 
Means and standard deviations for psychometric data are also presented in Table 
4.1. Participants with MDD had significantly higher BDI Cognitive and Somatic, DASS 
Depression, Anxiety and Stress, ATQ and ISI Insomnia scores compared to controls. 
Females scored higher than males on the Somatic subscale of the BDI and the Anxiety 
subscale of the DASS. As reported previously, participants with MDD had significantly 
higher BDI Total scores, as well as DEBQ Emotional and Restrained eating behaviours 
compared to controls, and females scored higher on each of these scales compared to 
males. Participants with MDD also had significantly higher total food addiction 
symptoms compared to controls as indicated by the YFAS. No further effects were 
identified (Mills et al., 2019). 
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Table 4.1:  









Note: MDD = Major Depressive Disorder; BMI = Body Mass Index; BDI = Beck’s Depression Inventory; DASS = Depression, Anxiety and Stress Scale; 
DEBQ = Dutch Eating Behaviours Questionnaire; YFAS = Yale Food Addiction Scale; ATQ = Automatic Thoughts Questionnaire; ISI = Insomnia Severity 
Index. *Indicates a significant difference compared to the other diagnostic group or sex being compared. 
  Diagnosis Sex 
Variable  MDD Control Effect Effect Size Female Male Effect Effect Size 
  M (SD) M (SD) p partial η2 M (SD) M (SD) p partial η2 
 Sample size (n) 60 60 - - 68 52 - - 
 Age (years) 24.70 (6.03) 25.40 (7.17) .422 .006 24.85 (7.44) 25.31 (5.38) .709 .001 
Biometric Weight (kg) 74.65 (16.13) 73.29 (16.67) .721 .001 68.76 (16.18) 80.79 (13.98)* < .001 .135 
 BMI (kg/m2) 25.80 (5.41) 25.10 (5.35) .580 .003 25.40 (6.06) 25.51 (4.35) .910 .000 
 Waist Circumference (cm) 89.47 (14.30) 85.36 (12.65) .149 .018 85.48 (14.74) 89.94 (11.58) .070 .028 
BDI Total Score 30.72 (9.59)* 4.80 (4.75) < .001 .753 19.06 (15.88)* 16.06 (13.82) .029 .040 
 Cognitive 18.92 (6.81)* 2.42 (2.95) < .001 .716 11.38 (10.19) 9.73 (9.28) .086 .025 
 Somatic 11.80 (3.72)* 2.38 (2.50) < .001 .697 7.68 (6.06)* 6.33 (5.11) .019 .046 
DASS Depression 24.47 (9.00)* 2.80 (3.45) < .001 .715 13.71 (13.19) 13.54 (12.46) .895 .000 
 Anxiety 14.77 (8.85)* 2.43 (3.81) < .001 .456 9.85 (9.50)* 6.96 (8.57) .020 .045 
 Stress 22.37 (9.28)* 5.37 (4.86) < .001 .573 14.97 (11.43) 12.42 (11.03) .062 .030 
DEBQ Emotional 2.75 (1.11)* 1.99 (0.72) < .001 .148 2.60 (.99)* 2.07 (0.95) .002 .082 
 Restrained 2.49 (1.07)* 1.94 (0.83) .002 .076 2.40 (1.01)* 1.97 (0.93) .014 .051 
 External 3.20 (0.67) 2.98 (0.71) .117 .021 3.10 (0.69) 3.08 (0.72) .923 .000 
YFAS Symptom Count 3.27 (3.45)* 0.80 (1.83) < .001 .160 2.18 (3.12) 1.85 (2.89) .519 .004 
ATQ Frequency of Thoughts 96.30 (27.5)* 41.55 (13.62) < .001 .619 72.04 (36.79) 64.85 (32.33) .069 .028 
ISI Insomnia Score 5.45 (2.30)* 1.88 (1.51) < .001 .458 3.66 (2.59) 3.67 (2.72) .975 .000 





Four (4; 3 MDD, 1 female) univariate outliers were detected in the serotonin 
data using boxplot diagrams. Further, eleven participants (8 MDD; 10 female) reported 
insulin dysregulation issues (six with polycystic ovarian syndrome, two with insulin 
resistance, three with diabetes). The results including all participants (n = 120) and 
excluding the outliers and those with insulin dysregulation (n = 106) were equivalent in 
terms of effects and interactions; as such, results from the 120 participants are reported. 
Plasma serotonin was significantly higher in participants with MDD than 
controls (F(1, 115) = 9.981, p = .002, partial h2 = .080), and in males compared to 
females (F(1, 115) = 4.323, p = .040, partial h2 = .036). Age as a covariate, and the 
interaction between Diagnosis and Sex, was not significant (Table 4.2). 
 
Table 4.2:  
Means and standard deviations for serotonin concentrations (total N = 120; ng/ml), by 
Diagnosis and Sex (MDD and control participants). 
 
Note: MDD = Major Depressive Disorder.  
 
 
4.5.2 Analysis by Appetite/Weight Change Sub-Groups in MDD 
 
Following the approach in one of our previous studies (Mills et al., 2019), the 60 
MDD participants were sub-classified according to self-reported increases (n = 28) or 
decreases/no changes (n = 32) to their appetite and weight, based on the DSM-5 criteria 
ascertained during the MINI clinical interview. The increased group consisted of 11 
Variable   Serotonin Main Effect Effect Size Interaction 
  n M (SD) p partial η2 p 
Diagnosis 
MDD 60 464.17 (269.20) 
.002 .080 
.772 
Control 60 315.21 (241.55) 
Sex 
Female 68 349.01 (240.90) 
.040 .036 
Male 52 441.90 (288.20) 
Covariates Age  - - .117 .021 - 
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males and 17 females, whereas the decreased/unchanged group consisted of 15 males 
and 17 females. Sex distributions did not differ significantly across Appetite/Weight 
Change groups (c2 (1, N = 60) = .350, p = .554), nor did Appetite/Weight Change 
groups differ significantly in age.  
Weight, BMI, DEBQ Emotional and Restrained eating behaviours and YFAS 
Food Addiction symptoms were significantly higher in participants reporting increased 
appetite/weight compared to those with decreased/unchanged appetite/weight (Mills et 
al., 2019). Sex effects for biometric and psychometric data were as reported in section 
4.5.1.1. No further effects were identified. 
Plasma serotonin levels did not differ significantly between MDD participants 
reporting increased or decreased/unchanged appetite/weight, nor did values differ 
significantly by sex in this sub-group analysis. Age was not a significant covariate, and 
no interaction effect was identified. Means and standard deviations for the biometric, 



















Means and standard deviations for biometric, psychometric and serotonin data (total N = 60), by Appetite/Weight Categories (increased 
compared to decreased/unchanged) and Sex (MDD participants only). 
 
 
Note: MDD = Major Depressive Disorder; BMI = Body Mass Index; BDI = Beck’s Depression Inventory; DASS = Depression, Anxiety and Stress Scale; 
DEBQ = Dutch Eating Behaviours Questionnaire; YFAS = Yale Food Addiction Scale; ATQ = Automatic Thoughts Questionnaire; ISI = Insomnia Severity 
Index. * Indicates a significant difference compared to the other appetite/weight group or sex being compared.
  Appetite/Weight Categories Sex 
Variables  Increased Decreased  Effect Size Female Male Effect Size 
  M (SD) M (SD) p partial η2 M (SD) M (SD) p partial η2 
 Sample Size (n) 28 32 - - 34 26 - - 
Biometrics Weight (kg) 78.37 (16.6)* 71.40 (15.23) .049 0.67 70.58 (14.82) 79.98 (16.48)* .014 0.104 
 BMI (kg/m2) 27.81 (4.99)* 24.04 (5.20) .008 .118 26.25 (5.87) 25.21 (4.77) .580 .006 
 Waist Circumference (cm) 93.11 (14.23) 86.28 (13.79) .072 .056 89.35 (15.39) 89.62 (13.03) .839 .001 
BDI Total Score 31.96 (10.21) 29.62 (9.02) .444 .011 33.00 (9.18)* 27.73 (9.44) .041 .072 
 Cognitive  19.50 (7.26) 18.41 (6.47) .580 .005 20.21 (6.32) 17.23 (7.18) .117 .043 
 Somatic 12.46 (3.85) 11.22 (3.56) .331 .017 12.79 (3.66)* 10.50 (3.46) .016 .099 
DASS Depression 25.43 (9.09) 23.62 (8.98) .561 .006 24.71 (9.72) 24.15 (8.14) .788 .001 
 Anxiety 15.00 (9.47) 14.56 (8.43) .913 .000 16.65 (8.26) 12.31 (9.15) .052 .066 
 Stress 23.29 (9.51) 21.56 (9.14) .492 .008 23.94 (8.58) 20.31 (9.91) .170 .033 
DEBQ Emotional 3.49 (0.98)* 2.10 (0.75) < .001 .400 3.01 (1.03)* 2.41 (1.12) .024 .087 
 Restrained 2.52 (0.97) 2.47 (1.17) .964 .000 2.73 (1.07) 2.17 (1.01) .051 .066 
 External 3.35 (0.63) 3.08 (0.69) .087 .051 3.30 (0.63) 3.10 (0.73) .447 .010 
YFAS Symptom Count 4.96 (3.74)* 1.78 (2.37) < .001 .196 3.62 (3.57) 2.81 (3.31) .415 .012 
ATQ Frequency of Thoughts 103.14 (28.17) 90.31 (25.15) .101 .047 102.50 (25.06) 88.19 (28.91) .058 .063 
ISI Insomnia Score 5.54 (2.65) 5.38 (1.99) .996 .000 5.41 (2.19) 5.50 (2.49) .996 .000 
Serotonin Serotonin (ng/ml) 457.60 (207.32) 469.93 (316.89) .837 .001 412.50 (238.06) 531.74 (296.38) .143 .039 




4.5.3 Correlation Analyses 
4.5.3.1 Serotonin Correlations in the Total Sample 
Plasma serotonin correlated positively with depressive symptom severity (BDI 
Total score), as well as the cognitive-affective and somatic symptoms (BDI) of MDD. 
Further, plasma serotonin was positively associated with anxiety-related psychological 
distress (DASS) and insomnia-related sleep disturbances (ISI). Plasma serotonin was 
not significantly associated with BMI, depression or stress-related psychological 
distress (DASS), problematic eating behaviours (DEBQ, YFAS) or depressogenic 
thinking (ATQ; Table 4.4). Depressive symptom severity (BDI), psychological distress 
(DASS), negative cognitions (ATQ), sleep disturbances (ISI) and problematic eating 
(DEBQ, YFAS) were all positively correlated with one another. BMI correlated 
positively with the DEBQ Emotional and Restrained, and YFAS, scores (Table 4.4). 
FDR-corrected correlations were conducted between plasma serotonin levels 
and the individual items of the BDI-II to provide a clearer understanding of the 
relationships between plasma serotonin and depressive symptoms. This analysis found 
positive associations with eleven items relating to low mood such as pessimism and 
agitation, negative cognitions such as self-criticism and self-dislike, anhedonia-related 
symptoms and somatic symptoms such as loss of libido, fatigue and loss of energy 
(Table 4.5). No further correlations were significant. 
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Table 4.4:  
Pearson’s correlation coefficients for the study variables (total N = 120; MDD and control participants). 
 
 
Note: MDD = Major Depressive Disorder; BDI = Beck’s Depression Inventory; DASS = Depression, Anxiety and Stress Scale; DEBQ = Dutch 
Eating Behaviours Questionnaire; YFAS = Yale Food Addiction Scale; ATQ = Automatic Thoughts Questionnaire; ISI = Insomnia Severity 
Index. Effects reported are Benjimani-Hochberg adjusted p values (False Discovery Rate corrected); * a < .05. 
Variables 1 2 3 4 5 6 7 8 9 10 11 12 13 
1. Serotonin -             
2. BMI .003 -            
3. BDI Total Score .259* .024 -           
4. BDI Cognitive .246* .037 .983* -          
5. BDI Somatic .259* -.001 .950* .878* -         
6. DASS Depression .194 .040 .928* .929* .853* -        
7. DASS Anxiety .244* -.050 .816* .799* .781* .755* -       
8. DASS Stress .152 .017 .837* .817* .806* .798* .812* -      
9. DEBQ Emotional .017 .274* .462* .435* .473* .424* .397* .465* -     
10. DEBQ Restrained -.081 .200* .335* .320* .335* .343* .250* .340* .375* -    
11. DEBQ External .062 -.070 .161 .166 .141 .153 .134 .194 .294* -.039 -   
12. YFAS Symptoms .068 .285* .501* .471* .514* .423* .372* .415* .548* .216* .211* -  
13. ATQ Frequency .195 .029 .912* .925* .817* .883* .789* .793* .434* .308* 255* .480* - 
14. ISI Insomnia .240* .078 .712* .669* .729* .660* .642* .649* .322* .262* -.016 .394* .610* 




Table 4.5:  
Pearson’s correlation coefficients for the exploratory analysis of BDI-II items and 
plasma serotonin (total N = 120; MDD and control participants). 
 
Note: MDD = Major Depressive Disorder; BDI = Beck’s Depression Inventory. Effects 
reported are Benjimani-Hochberg adjusted p values (False Discovery Rate corrected); * 
a < .05. 
 
4.5.3.2 Serotonin Correlations by Diagnosis and Sex 
The relationships between serotonin levels and the dependent variables were 
further separately examined in those with MDD and controls, as well as in males and 
females, to investigate whether serotonin showed diagnostic or sex-based relationships 
to depressive psychopathology. No significant associations between serotonin and the 
variables of interest were observed in the MDD or control groups. With respect to sex, 
in females plasma serotonin levels were significantly associated with the Agitation item 
of the BDI only (r(68) = .388, p = .021). In contrast, in males serotonin positively 
correlated with depressive symptom severity (BDI; r(52) = .380, p = .018), cognitive-
affective depressive symptoms (r(52) = .402, p = .033) and anxiety related 
psychopathology (DASS; r(52) = .408, p = .017). Further, in males plasma serotonin 
levels were also correlated with the Punishment (r(52) = .462, p = .007), Self-Dislike 
(r(52) = .442, p = .011), Suicidal Ideation (r(52) = .403, p = .013), Indecisiveness (r(52) 
= .342, p = .046), Worthlessness (r(52) = .426, p = .011) and Loss of Libido (r(52) = 
.468, p < .001) items of the BDI. No further correlations were significant. 
BDI-II Item Pearson’s Effect BDI-II Item Pearson’s Effect 
 r p  r p 
1. Sadness .212 .047* 12. Social Withdrawal .149 .121 
2. Pessimism .245 .029* 13. Indecisiveness .177 .081 
3. Sense of Failure .163 .105 14. Sense of Worthlessness .192 .036 
4. Loss of Pleasure .215 .049* 15. Loss of Energy .261 .021* 
5. Guilt Feelings .244 .025* 16. Sleep Disturbances .181 .078 
6. Sense of Punishment .208 .046* 17. Irritability .161 .105 
7. Self-Dislike .274 .042* 18. Changes in Appetite .094 .323 
8. Self-Criticism .221 .045* 19. Concentration Difficulties .140 .139 
9. Suicidal Ideation .160 .100 20. Fatigue .268 .032* 
10. Crying .073 .427 21. Loss of Libido .266 .021* 
11. Agitation .203 .049*    





This study adds important information to the current understanding of peripheral 
serotonin concentrations in relation to depressogenic symptoms. Plasma serotonin was 
significantly higher in individuals with MDD compared to healthy controls, and was 
also higher in males compared to females. Across the total sample, plasma serotonin 
correlated positively with depressive symptom severity and insomnia. Serotonin 
correlated with depressed mood, negative thinking and anxiety in males, but not in 
females. Plasma serotonin did not differ by appetite and weight symptom presentation 
in MDD, and was not associated with problematic eating behaviours or physical health 
indices. These findings support a possible dysregulation of peripheral serotonin in 
MDD, which is related to select depressive symptoms, particularly in males. 
Higher plasma serotonin was observed in individuals with MDD compared to 
controls, which is consistent with some previous studies reporting elevated plasma 
serotonin in MDD (Tyano et al., 2006). However, this contrasts with other studies 
reporting lower or similar plasma serotonin between MDD and control groups, which 
may be a product of different methodologies and smaller samples used in previous 
studies (Holck et al., 2019; Pan et al., 2018). Elevated plasma serotonin in MDD is 
consistent with the hypothesis of upregulation in the peripheral serotonergic system, 
suggesting differences in serotonergic regulation in individuals with MDD compared to 
controls (Andrews et al., 2015). The mechanisms underlying plasma serotonergic 
upregulation remain to be identified, though given the links between plasma serotonin 
and physical and mental exhaustion, upregulation may reflect compensatory responses 
to physical and emotional expenditure linked to depressive symptoms in energy balance 
pathways (Andrews et al., 2015). In addition, elevated peripheral serotonin levels prior 
to treatment with antidepressant medications has been linked to greater treatment 




responsivity (Holck et al., 2019) suggesting that it may be a clinically relevant marker. 
However, plasma serotonin in MDD remains an under-researched area. Given the 
inconsistent results in existing literature (Pan et al., 2018; Tyano et al., 2006), 
longitudinal research is warranted to determine whether upregulation of plasma 
serotonin is an antecedent or consequence of MDD and its role in treatment outcomes. 
A clear sex difference in plasma serotonin concentrations was also observed, 
with this being higher in males than females. This is inconsistent with limited previous 
research that identified no difference in plasma serotonin between sexes (Demerdash et 
al., 2018), however analyses by sex have not been consistently included in previous 
plasma serotonin studies (Holck et al., 2019; Pan et al., 2018). Higher plasma serotonin 
in males suggests that plasma serotonin synthesis and regulation may be sexually 
dimorphic. There was further sexual dimorphism in the correlations between plasma 
serotonin and depressive symptoms. In males, plasma serotonin was positively 
correlated with depressive symptom severity, anxiety, cognitive symptoms such as self-
dislike, suicidal ideation and feelings of worthlessness and somatic symptoms such as 
loss of libido, but in females plasma serotonin correlated with agitation only. These 
associations, in combination with the higher plasma serotonin in males, suggest that 
serotonin may be relevant to a broader range of depressive symptoms in males 
compared to females. The sexual dimorphisms identified warrant further research, as 
plasma serotonin may be important to understanding the aetiology of select 
depressogenic symptoms, particularly in males, and treatment outcomes, given the links 
between higher serotonin and antidepressant treatment responsivity (Holck et al., 2019). 
Plasma serotonin did not differ significantly between depressed individuals 
reporting appetite and weight gain compared to loss, nor did plasma serotonin correlate 
with psychometric indices of problematic eating behaviours or BMI. To our knowledge, 




this is the first study to examine these variables in participants with MDD. This is 
inconsistent with previous research identifying positive associations between plasma 
serotonin, weight gain and BMI values (Young et al., 2018); however, Young et al. 
(2018) used a non-depressed and clinically obese sample with a higher average BMI 
than the current study. The absence of significant relationships between plasma 
serotonin and problematic eating behaviours in MDD in the current study may be due to 
greater regulation of the latter by other neuropeptides or hormones such as leptin, 
ghrelin and peripheral dopamine. Our previous research indicates that these hormones, 
particularly leptin, were closely related to problematic eating behaviours and weight 
changes in atypical MDD and in females; however, these hormones were not linked to 
depressive symptom severity (Mills et al., 2018; Mills et al., 2019; Mills et al., 2020). 
Despite plasma serotonin not correlating with problematic eating behaviours, plasma 
serotonin was positively associated with depressive symptom severity and insomnia, as 
well as with depressogenic thinking in males, which were in turn associated with 
problematic eating behaviours. Greater depressive symptom severity, sleep disturbances 
and depressive thinking have previously been linked to a greater risk of problematic 
eating behaviours (Conradt et al., 2008; Knutson, 2007; Mills et al., 2020), which 
themselves are risk factors for weight gain and chronic health conditions in MDD (Mills 
et al., 2019; Mills et al., 2020). These associations, in combination with the sexual 
dimorphism in plasma serotonin observed in the current study, add to a growing body of 
research indicating greater neuroendocrine involvement in MDD than previously 
considered, with peripheral hormones correlating with specific symptom types and sex 
differences (Mills et al., 2018; Mills et al., 2019; Mills et al., 2020; Thomas & Larkin, 
2018; Thomas & Larkin, 2020). The current study suggests that plasma serotonin may 
be more relevant to males and non-atypical symptom presentations in MDD, as 




serotonin was more closely related to cognitive, affective and behavioural depressive 
symptoms in males, as opposed to being directly connected to an atypical symptom 
profile featuring depressogenic overeating, weight gain and leptin dysregulation in 
females (Mills et al., 2019).  
Overall, the results from the current study provide new evidence that plasma 
serotonin is related to select affective, cognitive and behavioural depressive symptoms. 
These findings also highlight that unlike other peripheral hormones such as leptin, 
plasma serotonin does not appear to be directly implicated in depressogenic overeating, 
weight gain and chronic health condition risk as part of atypical MDD. Instead, plasma 
serotonin may be important to other depressive symptoms including depressive 
symptom severity, sleep and cognitive disturbances, particularly in males. These 
findings suggest that upregulation in plasma serotonin may potentially be an important 
factor in MDD symptoms, particularly in males, and also suggest that hormonal 
differences between sexes have an important role in symptom presentations in MDD. 
Further research is needed in order to determine the time course of the identified 
relationships to further elucidate the role of plasma serotonin in the onset of depressive 
symptoms and to establish whether plasma serotonin represents an additional or 
alternative target for MDD treatment. Since peripheral serotonin is more easily 
measured than CNS serotonin (Andrews et al., 2015), it may have utility as a more 
accessible biomarker of MDD symptoms and treatment in research and clinical 
contexts. Given that elevated peripheral serotonin is associated with greater 
antidepressant responsivity (Holck et al., 2019), if plasma serotonin is higher in males 
than females with MDD, males in particular may be more responsive to antidepressant 
medications, which in turn may lead to more tailored interventions by MDD subtype 
and sex. Further research is warranted to examine this possibility. 




Some limitations of the study need to be considered when interpreting the 
results. The study was limited by its cross-sectional design; longitudinal research is 
required to further elucidate the pathways between MDD and the onset of depressive 
symptoms related to plasma serotonin. As central and peripheral serotonin are 
considered separate pools in the body (Andrews et al., 2015), peripheral serotonin may 
not be indicative of central serotonergic pathways and functioning; however, evidence 
in support of permeability of the blood brain barrier, and potential crosstalk between the 
two pools is emerging (Maurer-Spurej, 2005). Further, given the links between 
peripheral serotonin and obesity, further research in depressed individuals with higher 
BMIs may be of interest in order to understand the potential links between MDD and 
chronic health problems. 
To conclude, this study provides new evidence suggesting that plasma serotonin 
is meaningfully associated with several symptoms of MDD including mood and 
cognition, but not problematic eating behaviours and weight changes. Longitudinal 
research is warranted in order to understand the nature of peripheral serotonergic 
upregulation in MDD, its relationships to the onset of depressive symptoms and to 
treatment outcomes. This may lead to a greater understanding of the pathophysiology of 
MDD and to potential alternative treatment targets which may lead to improved 
outcomes for those affected by MDD. 
 





5.1 Introductory Comments 
 
Despite not being directly associated with problematic eating behaviours and 
physical health indices, Study 3 identified that plasma serotonin was significantly 
associated with depressive symptoms related to mood, cognition and sleep disturbances, 
particularly in males. These results provide a preliminary indication that, in contrast to 
leptin, serotonin may be more relevant to males and a non-atypical presentation of 
MDD. Further research is needed to examine biological correlates of MDD subtypes, 
with the findings thus far implying that interventions for MDD and associated chronic 
health conditions may need to be tailored by MDD symptom presentation and sex. 
As observed in Studies 1 and 2, a high proportion of individuals with MDD met 
the YFAS criteria for food addiction. Dopamine has been implicated in the pathogenesis 
of addictions, however the role of peripheral dopamine in problematic eating behaviours 
and food addiction is unknown. Peripheral dopamine is synthesised in the adrenal 
medulla and is associated with the sympathetic stress response, and may therefore be 
relevant to food addiction and stress-related overeating behaviours observed in MDD. 
However, there has been little research conducted to evaluate this hypothesis. 
In Study 4, plasma dopamine levels, biometrics and psychometric indices of 
problematic eating behaviours and low mood were compared between 80 individuals 
with MDD and 60 healthy controls, in an extended cohort to the previous two studies. A 
sub-analysis of food addiction group was conducted to investigate whether mood and 
appetite-related psychopathology and peripheral dopamine levels were related to 
specific symptoms. 
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Published in Appetite: Mills, J.G., Thomas, S.J., Larkin, T.A. & Deng, C. (2020). 
Overeating and food addiction in Major Depressive Disorder: Links to peripheral 
dopamine. Appetite, 148, 104586. https://doi.org/10.1016/j.appet.2020.104586.  
5.2 Abstract 
 
The concept of food addiction refers to addiction-like behaviours that develop in 
association with the intake of highly palatable foods. Previous research indicates that a 
high proportion of individuals with Major Depressive Disorder (MDD) meet the criteria 
for food addiction, and are also at an increased risk of weight gain and chronic disease. 
In the central nervous system, dopamine is a neurotransmitter associated with reward 
salience and food intake, whereas peripheral dopamine is involved in sympathetic stress 
regulation, digestion and gastrointestinal motility. However, little research has 
examined relationships between peripheral dopamine, depressive symptoms and 
problematic eating behaviours in MDD. Biometrics, psychopathology and plasma 
dopamine levels were compared between participants with MDD (n = 80) and controls 
(n = 60). Participants were sub-categorised into those meeting or not meeting Yale Food 
Addiction Scale (YFAS) criteria. Psychometric measures of mood and appetite were 
used to assess MDD symptoms, problematic eating behaviours and food-addiction 
related symptoms. Twenty-three (23; 29%) MDD participants met the Yale criteria for 
food addiction. Depressed individuals meeting YFAS criteria had significantly greater 
psychopathology scores for both mood and eating compared to depressed individuals 
not meeting YFAS criteria and controls. A significant interaction between food 
addiction status and sex was also observed for plasma dopamine levels. Plasma 
dopamine levels correlated positively with disordered eating behaviours in females, and 
negatively in males. The results provide evidence that depressogenic excess eating and 
weight gain are associated with peripheral dopamine levels. Longitudinal research is 
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warranted investigating endocrine dysregulation and excess eating in MDD, which may 
inform interventions and reduce chronic disease risk in affected individuals. 




A growing body of evidence indicates that individuals with Major Depressive 
Disorder (MDD) are at an increased risk of weight gain (Luppino et al., 2010; Mannan 
et al., 2015). Changes in appetite and weight are symptomatic of MDD, with the 
direction of such changes varying as a function of MDD subtype (American Psychiatric 
Association, 2013). Melancholic MDD is associated with appetite and weight loss, 
whereas atypical MDD is characterised by hyperphagia, weight gain, higher BMI values 
and a higher prevalence of chronic disease (Cassano & Fava, 2002; American 
Psychiatric Association, 2013; Lassere et al., 2014). Perhaps due to the increasing 
prominence of obesogenic environments, depressogenic weight gain as part of atypical 
MDD is now more prevalent than weight loss and melancholia (Blanco et al., 2012; 
Privitera et al., 2013). Further, depressogenic weight gain has been observed to occur 
more frequently in females than in males (Sutin & Zonderman, 2012). Consistent 
weight gain and carriage of excess weight has been linked to insulin dysregulation, 
hypertension, sleep apnoea and high cholesterol, which in turn increase the risk of 
chronic diseases such as cardiovascular disease and metabolic syndrome (Kearns et al., 
2014). Consequently, depressed individuals who experience weight gain are at a greater 
risk of developing these conditions (Zhao et al., 2009; Kearns et al., 2014). Despite the 
associated increased risk of chronic disease development, the pathways between 
depressogenic weight gain factors remain unclear, and this is reflected in the lack of 
integrated treatment approaches that address biological and psychological aspects of 
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weight gain. An understanding of the mechanisms underlying depressogenic weight 
gain may lead to improved interventions and treatment outcomes. 
A proposed pathway to depressogenic weight gain in atypical MDD is 
problematic eating associated with changes in complex biopsychosocial pathways. 
Problematic eating behaviours can be conceptualised into several subtypes. Emotional 
eating is an increase in food intake in response to negative emotions. Restrained eating 
is the deliberate restriction of food intake to encourage weight loss or prevent weight 
gain, and can be followed by compensatory binge eating behaviours. External eating is 
an increase in food intake in response to sensory food cues, such as the sight and smell 
of food (van Strien et al., 2016). Depressive symptom severity is associated with greater 
emotional eating (van Strien et al., 2016; Mills et al., 2019), food restriction (Mills et 
al., 2019) and food intake in response to external food cues (Sevincer et al., 2017). We 
previously identified that problematic eating behaviours are more prevalent in MDD 
than healthy controls, in females than males, and in a subset of depressed individuals 
experiencing weight gain compared to weight loss. Problematic eating behaviours are 
also associated with higher BMI and waist circumference values, and related to the 
hormones leptin and ghrelin (Mills et al., 2019). This evidence suggests that depressed 
individuals, particularly females, may be at a greater risk of weight gain and chronic 
disease due to problematic eating behaviours, which are linked to biological factors and 
may not be purely psychologically driven (Mills et al., 2019). 
Food addiction, that is addiction-like behaviours that develop in association with 
the consistent intake of highly palatable foods high in sugar or fat, is a relatively new 
approach to understanding problematic eating behaviours (Piccinni et al., 2015). 
Increased consumption of highly palatable foods has been observed to occur frequently 
during periods of emotional distress, possibly due to the ability of sugar and fat to 
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dampen the hypothalamic-pituitary-adrenal (HPA) axis stress response by reducing 
glucocorticoid sensitivity, thereby reducing arousal and irritability (Dallman et al., 
2003) and therefore possibly acting as a coping mechanism for depressed mood (Finch 
& Tomiyama, 2015). Food addiction has been linked to the catecholamine 
neurotransmitter dopamine, which is released by both central (CNS) and peripheral 
(PNS) nervous systems. CNS-dopamine has a core role in the regulation of movement 
and mood, in addition to the modulation of brain reward and motivation pathways 
(Drozak & Bryla, 2005; Opmeer et al., 2010). Dopaminergic dysregulation is associated 
with the formation and maintenance of addictions to psychoactive substances (Volkow 
et al., 2012), as well as highly palatable foods. With respect to the latter, this can lead to 
addiction-like behaviours similar to general substance use disorders including a loss of 
control around particular foods and withdrawal effects when these foods are not 
consumed (Gearhardt et al., 2009; Gearhardt et al., 2011; Meule & Gearhardt, 2014).  
Food addiction is currently not recognised as a formally diagnosable disorder in 
the Diagnostics and Statistical Manual for Mental Disorders (DSM-5; American 
Psychiatric Association, 2013), however criteria have been developed to systematically 
assess it based on the DSM-5 criteria for substance use disorders, including tolerance 
and withdrawal (Meule & Gearhardt, 2014). Food addiction is currently measured using 
the Yale Food Addiction Scale (YFAS; Gearhardt et al., 2016), with the prevalence of 
food addiction as indicated by the YFAS ranging from 5-10% in the general population, 
and between 15-25% in people with obesity (Meule & Gearhardt, 2014; Hauck et al., 
2017).  
The concept of food addiction is still controversial since food is considered 
necessary for survival whereas the targets of other addictions, such as psychoactive 
substances, are not (Ziauddeen & Fletcher, 2013; Onaolapo & Onaolapo, 2018). It has 
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been argued that food addiction may be more appropriately defined as ‘compulsive 
overeating’, however unlike Binge Eating Disorder (BED) where similar food intake 
patterns similar to food addiction occur there is no preoccupation with weight, 
suggesting that they are different syndromes (Burrows et al., 2017). Similarly, food 
addiction may be more appropriately characterised as ‘additive addiction’ as the 
addictive nature of the behaviour is in response to the sugar or fat content of the food, as 
opposed to the food as a whole (Onaolapo & Onaolapo, 2018). Many modern foods 
have been altered to increase their palatability compared to natural foods to the extent 
that they arguably act in similar ways to addictive substances (Leigh & Morris, 2018), 
which increases the likelihood of consuming these foods in excess (Johnson & Wardle, 
2014). As such, food addiction may be a useful approach to understanding 
depressogenic weight gain in obesogenic environments. 
Food addiction has been linked to MDD, with the prevalence rates of meeting 
YFAS criteria in MDD ranging from 25-28% in some studies (Mills et al., 2018; Mills 
et al., 2019), which is higher than rates reported in general community samples and 
among people with obesity (Hauck et al., 2017). Depressive symptom severity has also 
been linked to higher food addiction symptomology, such as tolerance and cravings 
(Gearhardt et al., 2012; Mills et al., 2019). Food addiction symptoms are also more 
common in females overall than in males (Mills et al., 2019). However, beyond its 
higher prevalence in MDD and its links to depressive symptom severity, depressogenic 
food addiction remains poorly understood. Due to the relationships between atypical 
MDD and appetite increases, it is possible that depressogenic overeating may be closely 
aligned with food addiction, however at present no research has examined this 
relationship. 
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The mechanisms underlying depressogenic overeating, including food addiction, 
also remain unclear; however, dopamine may be related to these behaviours. Activation 
of CNS-dopamine pathways in response to food is associated with reward and addiction 
(Gearhardt et al., 2011). Emotional and restrained eating behaviours have been 
associated with hypoactivity in CNS-dopamine pathways (Volkow et al., 2003; Alsio et 
al., 2010), and therefore overeating may compensatory to promote dopamine release to 
enhance reward and improve mood (Avena et al., 2009). CNS-dopamine pathways have 
also been linked to the pathogenesis of MDD, however findings are inconsistent. 
Neuroimaging studies indicate lower dopamine receptor binding in individuals with 
MDD compared to controls, which is linked to the depressogenic symptoms of 
anhedonia and low motivation (Der-Avakian & Markou, 2012). In contrast, 
cerebrospinal fluid levels of dopamine have been reported to be higher in MDD 
compared to controls (Gjerris et al., 1987), whereas a post-mortem study comparing 
brain concentrations of dopamine following suicides found no difference compared to 
controls (Bowden et al., 1997). 
Peripheral dopamine is more easily measurable in blood, and may be implicated 
in the context of MDD and overeating; however, there is limited research in this area. In 
the periphery, dopamine is linked to the homeostatic regulation of blood pressure, 
respiration, gastrointestinal motility, insulin production, circadian rhythms and the 
immune response (Rubi & Maechler, 2010). Peripheral dopamine is also closely linked 
to the HPA axis and stress response, and is positively associated with sympathetic 
nervous system activity, with higher levels of stress linked to elevated dopamine release 
(Rubi & Maechler, 2010). Given that HPA axis hyperactivity is a central physiological 
feature of MDD (Dallman et al., 2003), peripheral dopamine levels may therefore be 
elevated in MDD. Plasma dopamine levels have been reported to be higher in MDD 
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compared to controls (Pan et al., 2018), and are also elevated in psychotic MDD 
compared to non-psychotic MDD (Rothschild et al., 1986). Positive correlations 
between plasma dopamine levels and psychopathology, including depression, anxiety 
and stress related symptom severity, have also been reported (Hamner & Diamond, 
1996; LeBlanc & Ducharme, 2007; Tomei et al., 2007). However, other studies have 
reported no difference in plasma dopamine levels between those with MDD and healthy 
controls (Hamner & Diamond, 1996; Fajardo et al., 2003). 
Interestingly, in previous peripheral dopamine studies sex comparisons were not 
conducted (Fajardo et al., 2003; Pan et al., 2018). Comparing peripheral dopamine 
levels between males and females would be of interest, particularly due to the higher 
incidence of food addiction in females (Mills et al., 2019). Peripheral dopamine has also 
not been examined in relation to food addiction. Further, the role of peripheral 
dopamine signalling in relation to depressogenic appetite and weight changes has yet to 
be explored. An understanding of these relationships may provide new information 
about the nature of depressogenic overeating and weight gain, which may lead to the 
development of preventative measures to reduce chronic disease risk in those affected 
by MDD.  
The current study aimed to examine the extent of symptoms of overeating, food 
addiction and plasma dopamine levels in participants with MDD overall compared to 
controls by sex, in addition to an examination of these symptoms by food addiction 
status. The current study also aimed to assess the relationships between plasma 











This study is an extension of previous MDD research (Mills et al., 2019). 
Participants were recruited by media and university advertisements, with one hundred 
and forty (140) adults (80 female) included in the study. Individuals reporting 
depressive symptoms (n = 80) were pre-screened using the Mini International 
Neuropsychiatric Interview, version 7.0.2 (MINI; Sheehan, 2015) to confirm a current 
major depressive episode based on DSM-5 criteria. Depressed participants were 
required to not be receiving any current or recent treatment for MDD. Sixty (60) 
individuals with no significant mental health history or current diagnosed mental 
disorders were included in the control group. General exclusion criteria were 
corticosteroid use, neurological illness and substance use disorders. Participants were 
asked to provide information about any current medical conditions and medications. 
The study received approval from the local ethics committee. 
 
5.4.2 Psychometric Measures 
 
Depressive symptom severity was assessed using the 21-item Beck Depression 
Inventory (BDI-II; Beck et al., 1996). Problematic eating behaviours, including 
emotional, restrained and external eating, were measured using the 33-item Dutch 
Eating Behaviours Questionnaire (DEBQ; van Strien et al., 1986). Food addiction 
symptoms, including withdrawal symptoms and tolerance to increased food intake, were 





Participants attended one visit at the local Clinical Research and Trials Unit, 
with appointments scheduled between 9:00 and 11:00am. On arrival, all participants 
Chapter 5 – Plasma Dopamine 
 
109 
provided written informed consent. Participants with MDD were interviewed using the 
MINI (Sheehan, 2015) to confirm a current depressive episode at the time of their visit. 
Participant height and weight were measured to determine body mass index (BMI) 
values. Waist circumference, blood pressure and heart rate were also measured. A 10ml 
blood sample was then obtained by a phlebotomist. Participants were not required to 
fast, however details of any food intake in the preceding 12 hours were recorded. 
Participants then completed the psychometric questionnaires. Participants were seated 
in stable conditions for the duration of the interview and blood sampling in order to 
reduce possible confounding effects of movement on peripheral dopamine levels. 
 
5.4.4 Data and Statistical Analysis: 
 
Blood samples were centrifuged 4°C, at 3000rpm for 10 minutes immediately 
following collection, with aliquoted plasma stored at -80°C until analysis. Plasma 
dopamine analyses were completed using a standard competitive-inhibition ELISA 
testing kit (Cusabio Technology LLC, Texas, United States of America). The inter- and 
intra-assay coefficients of the ELISA were 6.8% and 6.4% respectively. 
Statistical analyses were conducted using ‘Statistical Package for the Social 
Sciences’ (SPSS, Version 25). The dependent variables were plasma dopamine levels, 
biometrics and the psychometric measurement scores (BDI-II, DEBQ and YFAS). Raw 
dopamine values were natural-log transformed prior to analyses to better approximate a 
normal distribution. BDI-II, DEBQ and YFAS scores were also natural-log transformed 
to correct for skewed distributions, however analyses on transformed and untransformed 
questionnaire data were equivalent in terms of effects and interactions. As such, results 
based on untransformed questionnaire data are reported. 
Two-way factorial analyses of variance (ANOVA) were used to test for 
differences in the dependent variables, with the between-subjects factors of Diagnosis 
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(MDD, control) and Sex (female, male), and Age included as a covariate for dopamine 
analyses. Two-way ANOVAs were also used to test for subgroup differences in the 
dependent variables as a function of food addiction status (MDD meeting YFAS 
criteria, MDD not meeting YFAS criteria, control) and Sex (female, male), with Age 
also used as a covariate for dopamine analyses. Confirmatory Welch’s ANOVAs were 
conducted when between-group violations in homogeneity of variance were detected in 
ANOVA analyses, and are reported where appropriate. Pearson’s correlation 
coefficients and Spearman’s rank correlations were used to determine relationships 
between the study variables. An a < .05 was considered statistically significant for all 
analyses. Bonferroni corrected pairwise comparisons are indicated where appropriate.  
Using the G*Power statistical tool, version 3.1.9.4, to achieve a statistical power 
of 80% with significance at p < .05, for a factorial ANCOVA with two or three groups, 
with a medium effect size (.03), a total of 90 participants are required, and for a 
bivariate correlation with a medium effect size (.03), a total of 84 participants are 




5.5.1 Analyses of MDD compared to Controls 
5.5.1.1 Demographic and Biometric Data 
 
Participant demographic and biometric data are presented in Table 5.1. 
Participants were aged between 18 and 63 years (M = 25.45, SD = 7.16 years), with 46 
females and 34 males in the MDD group (n = 80) and 34 females and 26 males in the 
control group (n = 60). Sex distributions did not differ significantly between diagnostic 
groups (χ2 (1, N = 140) = 0.10, p = .921). No participants had a diagnosed eating 
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disorder, and none were smokers. The diagnostic groups (MDD versus control) did not 
differ significantly in age.  
Participants with MDD had higher waist circumference values than controls 
(Welch’s F(1, 136.76) = 7.120, p = .009, w2 = .042). Males weighed more (F(1, 136) = 
13.183, p < .001, partial η2 = .088) and had higher systolic blood pressure (Welch’s F(1, 
103.19) = 64.706, p < .001, w2 = .313) than females. No further differences based on 
Diagnosis, Sex or interaction effects were identified for biometric data (Table 5.1). 
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Table 5.1:  
Means and standard deviations for demographic and biometric data, by Diagnosis and Sex (total N = 140; MDD and control participants).  
 
 
Note: MDD = Major Depressive Disorder; BMI = Body Mass Index. * Indicates a significant difference compared to the other condition(s). a 





  Diagnosis Sex 
Variable  MDD Control Effect Effect Size Female Male Effect Effect Size 
  M (SD) M (SD) p ηp2 /w2 M (SD) M (SD) p ηp2 /w2 
 Sample size (n) 80 60 - - 80 60 - - 
Biometric Age (years) 25 (7) 25 (7) .880 .000 25 (8) 26 (5) .595 .002 
 Weight (kg) 77.1 (18.1) 73.3 (16.7) .177 .013 71.6 (18.5) 81.5 (14.6)* <.001 .088 
 BMI (kg/m2) 26.7 (5.9) 25.1 (5.4) .173a .014b 26.2 (6.6) 25.7 (4.3) .556a .000b 
 Waist Measurement (cm) 92 (16)* 85 (13) .009a .042b 88 (13) 91 (12) .157a .001b 
 Systolic BP (mmHg) 119 (13) 121 (15) .581a .000b 113 (10) 129 (13)* <.001a .313b 
 Diastolic BP (mmHg) 75 (10) 72 (10) .206 .012 73 (9) 74 (9) .287 .008 




5.5.1.2 Psychometric Data 
 
Means and standard deviations for psychometric data are presented in Table 5.2. 
Participants with MDD had significantly greater depressive symptom severity (BDI-II 
Total score; Welch’s F(1, 119.81) = 418.058, p < .001, w2 = .749) compared to controls. 
The difference between sexes, in addition to the interaction between Diagnosis and Sex, 
were not significant for the BDI. 
Individuals with MDD reported greater DEBQ Emotional (Welch’s F(1, 134.06) 
= 38.807, p <.001, w2 = .213), and Restrained (F(1, 136) = 12.766, p < .001, partial η2 = 
.086) eating behaviours than controls. Females had higher Emotional (Welch’s F(1, 
133.85) = 14.552, p <.001, w2 = .088), and Restrained (F(1, 136) = 6.656, p = .011, 
partial η2 = .047) eating scores than males. External eating did not differ between 
diagnostic groups or sexes. No interaction effects were identified for any DEBQ 
subscales. 
Endorsement rates for each YFAS symptom are presented in Table 5.3. Twenty-
three (29%, 17 female) MDD participants met the YFAS criteria for food addiction, 
compared to two (3%, both female) controls. Depressed participants reported higher 
total YFAS scores (Welch’s F(1, 124.16) = 35.546, p < .001, w2  = .198), and also 
scored higher on each YFAS subscale compared to controls. Females had higher scores 
on the Failure to Quit (Welch’s F(1, 137.06) = 5.127, p = .025, w2  = .031) and 
Withdrawal (Welch’s F(1, 136.60) = 5.393, p = .022, w2  = .031) subscales compared to 
males, with no further differences by Sex or interaction effects identified (Table 5.2).
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Table 5.2:  
Means and standard deviations for psychometric data, by Diagnosis and Sex (total N = 140; MDD and control participants). 
 
 
Note: MDD = Major Depressive Disorder; BDI = Beck’s Depression Inventory; DEBQ = Dutch Eating Behaviours Questionnaire; YFAS = Yale Food 
Addiction Scale. DEBQ scores occur between 0 and 5. YFAS subscale scores are dichotomous and occur between 0.0 and 1.0. *Indicates a significant 
difference compared to the other diagnostic group or sex being compared. a Indicates significance for Welch’s ANOVA. b Indicates w2 values. Significance 
values for DEBQ and YFAS scores have been corrected for multiplicity.
  Diagnosis Sex 
Psychometrics  MDD Control Effect Effect Size Female Male Effect Effect Size 
  M (SD) M (SD) p ηp2 /w2 M (SD) M (SD) p ηp2 /w2 
 Sample size (n) 80 60 - - 80 60 - - 
BDI Total Score 31 (10)* 5 (5) < .001a .749b 21 (16) 18 (14) .255a .023b 
DEBQ Emotional 3 (1)* 2 (1) < .001a .213b 3 (1)* 2 (1) < .001a .088b 
 Restrained 3 (1)* 2 (1) < .001 .086 3 (1)* 2 (1) .011 .047 
 External 3 (1) 3 (1) .080 .022 3 (1) 3 (1) .729 .001 
YFAS Symptom Count 4 (4)* 1 (2) < .001a .198b 3 (4) 2 (3) .152a .008b 
 Increased Intake 0.4 (0.5)* 0.1 (0.3) .001a .072b 0.3 (0.4) 0.3 (0.5) .787a .000b 
 Failure to Quit 0.4 (0.5)* 0.1 (0.3) < .001a .126b 0.4 (0.5)* 0.2 (0.4) .025a .029b 
 Time Taken to Obtain 0.4 (0.5)* 0.1 (0.3) < .001a .086b 0.3 (0.4) 0.2 (0.4) .821a .000b 
 Activities Given Up 0.3 (0.5)* 0.0 (0.1) < .001a .168b 0.2 (0.4) 0.1 (0.3) .158a .007b 
 Adverse Consequences 0.3 (0.5)* 0.1 (0.3) < .001a .081b 0.2 (0.4) 0.2 (0.4) .258a .002b 
 Tolerance 0.3 (0.5)* 0.0 (0.2) < .001a .140b 0.2 (0.4) 0.2 (0.4) .855a .000b 
 Withdrawal 0.5 (0.5)* 0.1 (0.3) < .001a .153b 0.4 (0.5)* 0.2 (0.4) .022a .030b 
 Use Despite Problems 0.3 (0.5)* 0.1 (0.3) .001a .072b 0.2 (0.4) 0.2 (0.4) .301a .000b 
 Failed Role Obligations 0.2 (0.4)* 0.0 (0.1) < .001a .097b 0.2 (.4) 0.1 (0.3) .152a .007b 
 Physically Hazardous Use 0.3 (0.5)* 0.1 (0.3) < .001a .065b 0.2 (0.4) 0.1 (0.4) .670a .000b 
 Cravings 0.3 (0.4)* 0.1 (0.3) .002a .055b 0.2 (0.4) 0.1 (0.3) .125a .009b 




Table 5.3:  
Percentage of endorsement rates for Yale Food Addiction Scale (YFAS) data, by 
Diagnosis and Sex (total N = 140; MDD and control participants). 
 
 





Means and standard deviations for the raw and log-transformed dopamine values 
are displayed in Table 5.4. Following log-transformation, no univariate outliers in the 
dopamine data were detected in boxplot diagrams. Eleven (11) participants (8 MDD, 3 
control; 10 female) reported insulin dysregulation issues (six polycystic ovarian 
syndrome, two insulin resistance, three diabetes). Log-dopamine values did not differ 
significantly between those with insulin dysregulation and those without (F(1, 138) = 
.950, p = .331), and results for including and excluding these participants are equivalent 
in terms of effects and interactions. Consequently, dopamine data from the whole 
sample (n = 140) are reported.  
Log-dopamine values were marginally higher in MDD compared to controls 
(F(1, 135) = 3.820, p = .053, partial η2 = .028). Males had significantly higher log-
  Diagnosis Sex 
  MDD Control Female Male 
  % % % % 
 Sample Size (n) 80 60 80 60 
YFAS Increased Intake 38 13 26 28 
 Inability to Quit 41 10 35 18 
 Time Taken to Obtain 35 10 25 23 
 Activities Given Up 31 2 23 13 
 Adverse Consequences 29 7 23 15 
 Tolerance 31 3 19 20 
 Withdrawal 45 10 38 20 
 Use Despite Problems 30 8 24 17 
 Failed Role Obligations 21 2 16 8 
 Physically Hazardous Use 29 8 21 18 
 Cravings 25 7 21 12 




dopamine values than females (F(1, 135) = 265.740, p < .001, partial η2 = .663). Age 
was a significant covariate (F(1, 135) = 7.488, p = .007, partial η2 = .053). The 
interaction between Diagnosis and Sex was not significant. 
Table 5.4:  
Means and standard deviations for raw and log-transformed dopamine (total N = 140; 
ng/ml), by Diagnosis and Sex (MDD and control participants). 
 
 
Note: MDD = Major Depressive Disorder. Significance noted for log-transformed data. 
 
 
5.5.2 Analysis by Food Addiction Group in MDD 
 
To further investigate depressed individuals with food addiction, all 140 
participants were sub-categorised into those with MDD who met the YFAS criteria for 
food addiction (n = 23), those with MDD who did not meet YFAS criteria (n = 57) and 
healthy controls (n = 58). Two control participants who met YFAS criteria were 
removed from these analyses due to the small number in the group. Welch’s ANOVAs 
are reported where violations in homogeneity of variance occurred in conjunction with 
uneven subgroup sizes. There were 17 females and 6 males in the MDD meeting YFAS 
criteria group, 29 females and 28 males in the MDD not meeting YFAS criteria group, 
and 32 females and 26 males in the control group. The sex distributions for the Food 
Addiction groups were not significantly different (χ2 (1, N = 138) = 3.613, p = .164).  
Depressed individuals meeting YFAS criteria had significantly higher weight 
(F(2, 132) = 6.102, p = .003, partial η2 = .085), BMI (Welch’s F(2, 60.26) = 8.060, p = 







  n M (SD) M (SD) p partial η2 p 
Diagnosis MDD 80 29 (35) 3 (1) .053 .028 
.436 
Control 60 23 (22) 3 (1) 
Sex Female 80 10 (8) 2 (1) < .001 .663 
Male 60 48 (35) 4 (1) 
Covariate Age  - - - .007 .053 - 




.001, w2 = .093) and waist circumference (Welch’s F(2, 58.25) = 9.575, p < .001, w2 = 
.111) than depressed individuals not meeting YFAS criteria and controls. Sex effects for 
biometric data are as reported previously (section 3.1.1). No further differences or 
interaction effects were identified (Table 5.5). 
Depressed individuals meeting YFAS criteria reported significantly higher 
depressive symptom severity (BDI-II Total; Welch’s F(2, 51.20) = 266.354, p < .001, 
w2 = .794), emotional (DEBQ Emotional; Welch’s F(2, 56.99) = 31.869, p < .001, w2 = 
.309) and restrained (DEBQ Restrained; F(2, 132) = 9.848, p < .001, partial η2 =  .131) 
eating behaviours compared to depressed individuals who did not meet YFAS criteria 
and controls. Depressed individuals meeting YFAS criteria also demonstrated 
significantly greater total food addiction symptomology (Welch’s F(2, 55.480) = 
64.029, p < .001, w2 = .477), in addition to scoring significantly higher on each YFAS 
subscale. Sex differences for psychometric data are as reported previously (section 
3.1.2). External eating did not differ between Food Addiction groups, and no interaction 
effects were identified (Table 5.6). Percentage of endorsement rates for each YFAS 
symptom by Food Addiction group are presented in Table 5.7. 
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Table 5.5:  
Means and standard deviations for biometric data, by Food Addiction Group and Sex (total N = 138, MDD and control participants).  
 
 
Note: MDD = Major Depressive Disorder; FA = Food Addiction; BMI = Body Mass Index; BP = blood pressure. * Indicates a significant 
difference compared to the other condition(s).
Variable  MDD-FA MDD Non-FA Control Effect Effect 
Size 
Female Male Effect Effect 
Size 
  M (SD) M (SD) M (SD) p ηp2 /w2 M (SD) M (SD) p ηp2 /w2 
 Sample size (n) 23 57 58 - - 78 60 - - 
Biometrics Age (years) 27 (10) 25 (6) 25 (7) .872 .002 25 (8) 26 (5) .813 .000 
 Weight (kg) 85.4 (18.9)* 74.6 (16.9) 73.6 (16.8) .003 .085 71.7 (18.5) 81.5 (14.6)* < .001 .094 
 BMI (kg/m2) 30.3 (5.7)* 25.2 (5.4) 25.1 (5.4) .001a .093b 26.3 (6.7) 25.7 (4.3) .556a .000b 
 Waist Circumference (cm) 101 (15)* 88 (14) 85 (13) < .001a .111b 88 (16) 91 (12) .158a .007b 
 Systolic BP (mmHg) 118 (13) 120 (13) 121 (15) .496 .011 113 (10) 129 (13)* <. 001 .270 
 Diastolic BP (mmHg) 78 (10) 73 (9) 72 (10) .139 .029 73 (9) 74 (9) .431 .005 
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Table 5.6:  
Means and standard deviations for psychometric data, by Food Addiction Group and Sex (total N = 138, MDD and control participants). 
 
 
Note: MDD = Major Depressive Disorder; BDI = Beck’s Depression Inventory; DEBQ = Dutch Eating Behaviours Questionnaire; YFAS = Yale Food Addiction Scale. 
DEBQ scores occur between 0 and 5. YFAS subscale scores are dichotomous and occur between 0.0 and 1.0. *Indicates a significant difference compared to the other FA 
group or sex being compared.  a Indicates significance for Welch’s ANOVA. b Indicates w2 values. Significance values for DEBQ and YFAS scores have been corrected for 
multiplicity.
  Food Addiction Diagnosis Sex 
Psychometric  MDD-FA MDD Non-FA Control Effect Effect Size Female Male Effect Effect Size 
  M (SD) M (SD) M (SD) p ηp2 /w2 M (SD) M (SD) p ηp2 /w2 
 Sample size (n) 23 57 58 - - 78 60 - - 
BDI Total Score 37 (8)* 28 (9) 4 (4) < .001a .794b 21 (16) 18 (14) .255a .002b 
DEBQ Emotional 4 (1)* 3 (1) 2 (1) < .001a .309b 3 (1)* 2 (1) < .001a .089b 
 Restrained 3 (1)* 2 (1) 2 (1) < .001 .130 2 (1) 2 (1) .103 .020 
 External 3 (1) 3 (1) 3 (1) .198 .024 3 (1) 3 (1) .628 .002 
YFAS Symptom Count 7 (3)* 2 (3) 1 (2) < .001a .477b 3 (4) 2 (3) .152a .008b 
 Increased Intake 0.6 (0.5)* 0.3 (0.5) 0.1 (0.4) < .001a .103b 0.3 (0.5) 0.3 (0.5) .787a .000b 
 Failure to Quit 0.9 (0.3)* 0.2 (0.4) 0.1 (0.3) < .001a .397b 0.4 (0.5)* 0.2 (0.4) .025a .029b 
 Time Taken to Obtain 0.7 (0.5)* 0.2 (0.4) 0.1 (0.3) < .001a .160b 0.2 (0.4) 0.2 (0.4) .821a .000b 
 Activities Given Up 0.7 (0.5)* 0.2 (0.4) 0.0 (0.1) < .001a .262b 0.2 (0.4) 0.1 (0.3) .158a .007b 
 Adverse Consequences 0.8 (0.4)* 0.1 (0.3) 0.1 (0.2) < .001a .303b 0.2 (0.4) 0.2 (0.4) .258a .002b 
 Tolerance 0.7 (0.5)* 0.1 (0.4) 0.0 (0.2) < .001a .273b 0.2 (0.4) 0.2 (0.4) .855a .000b 
 Withdrawal 0.8 (0.4)* 0.3 (0.5) 0.1 (0.3) < .001a .329b 0.4 (0.5) 0.2 (0.4) .022a .031b 
 Use Despite Problems 0.6 (0.5)* 0.2 (0.4) 0.1 (0.3) < .001a .142b 0.2 (0.4) 0.2 (0.4) .301a .000b 
 Failed Role Obligations 0.6 (0.5)* 0.1 (0.3) 0.0 (0.1) < .001a .153b 0.2 (0.4) 0.1 (0.3) .152a .008b 
 Physically Hazardous Use 0.6 (0.5)* 0.2 (0.4) 0.1 (0.3) < .001a .120b 0.2 (0.4) 0.2 (0.4) .670a .000b 
 Cravings 0.6 (0.5)* 0.1 (0.4) 0.0 (0.2) < .001a .127b 0.2 (0.4) 0.1 (0.3) .125a .010b 
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Table 5.7:  
Percentage of endorsement rates for Yale Food Addiction Scale (YFAS) data, by Food 
Addiction Group (total N = 138; MDD and control participants). 
 
 
Note: MDD = Major Depressive Disorder; FA = Food Addiction; YFAS = Yale Food 
Addiction Scale. 
 
For peripheral dopamine levels (ng/ml), there was a significant interaction 
between Food Addiction group and Sex (F(2, 131) = 4.815, p = .010, partial η2 = .068). 
Bonferroni-corrected simple effects, with an adjusted alpha of .025, indicated that 
depressed males meeting YFAS criteria (M = 3, SD = 1) had significantly lower log-
dopamine values than depressed males not meeting YFAS criteria (M = 4, SD = 1) and 
control males (M = 4, SD = 1; F(2, 57) = 4.742, p = .012, partial η2 = .173). However, 
there was no difference in plasma dopamine levels between depressed females meeting 
YFAS criteria (M = 2, SD = 1), depressed females not meeting YFAS criteria (M = 2, 
SD = 1) and control females (M = 2, SD = 1; F(2, 57) = 2.059, p = .146, partial η2 = 
.046). Similarly to previous analyses, log-dopamine values were higher in males than in 
females (F(1, 131) = 157.463, p < .001, partial η2 = .546), and Age was a significant 
covariate (F(1, 131) = 8.790, p = .004, partial η2 = .063; Table 8). Log-dopamine levels 
did not differ significantly across food addiction diagnoses.  
  Food Addiction Categories 
  MDD-FA MDD Non-FA Controls 
  % % % 
 Sample Size (n) 23 57 58 
YFAS Increased Intake 23 57 58 
 Inability to Quit 61 28 14 
 Time Taken to Obtain 87 23 9 
 Activities Given Up 65 23 9 
 Adverse Consequences 70 16 2 
 Tolerance 78 9 5 
 Withdrawal 74 14 3 
 Use Despite Problems 83 30 9 
 Failed Role Obligations 61 18 7 
 Physically Hazardous Use 57 7 2 
 Cravings 57 18 7 




Means and standard deviations for log-transformed dopamine data (total N = 138; 
ng/ml), by Food Addiction Group and Sex (MDD and control participants). 
 
 
Note: MDD = Major Depressive Disorder; FA = Food Addiction; G = Group; S = Sex. 
* Indicates a significant difference compared to the other condition(s).  
 
 
5.5.3 Correlation Analyses 
 
Log-dopamine values correlated positively with weight and systolic blood 
pressure, and negatively with Restrained eating. Weight, BMI and waist circumference 
each positively correlated with Emotional eating and YFAS Symptom Count scores, 
and BMI also with Restrained eating. Waist circumference positively correlated with 
Emotional eating and YFAS Symptom Count. Systolic blood pressure was negatively 
correlated with BDI Total scores, Restrained and Emotional eating. Depressive 
symptom severity (BDI-II), disordered eating (DEBQ) and food addiction (YFAS) 
correlated positively with one another (Table 9). 
Due to the large sex difference observed in previous analyses, relationships 
between log-dopamine levels, biometric and psychometric data were further examined 
in males and females separately to assess whether dopamine showed sex-specific 
relationships to psychopathology. In females, log-dopamine values correlated 
negatively with age (r(80) = -.282, p = .011), however were positively correlated with 
Variable   Log-Dopamine Main Effect G x S Interaction 




MDD-FA 23 3 (1) 
.124 
.010 
MDD-No FA 57 3 (1) 
Controls 58 3 (1) 
Sex 
Female 78 2 (1) 
< .001 
Male 60 4 (1)* 
Covariate Age  - - .004 - 
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Emotional (r(80) = .284, p = .011) and Restrained (r(80) = .289, p = .009) eating. Log-
dopamine values were also correlated with the Failure to Quit (Spearman’s r(80) = 
.249, p = .026), Adverse Consequences (Spearman’s r(80) = .328, p = .003), Withdrawal  
(Spearman’s r(80) = .366, p < .001), Continued Use Despite Problems (Spearman’s 
r(80) = .399, p < .001) and Failed Role Obligations (Spearman’s r(80) = .252, p = .024) 
subscales of the YFAS. In contrast, in males log-dopamine values correlated negatively 




Table 5.9:  
















Note: MDD = Major Depressive Disorder; BMI = Body Mass Index; BDI = Beck’s Depression Inventory; DEBQ = Dutch Eating Behaviours 
Questionnaire; YFAS = Yale Food Addiction Scale. *a < .05, ** a < .01. 
 
Variables 1 2 3 4 5 6 7 8 9 10 11 
1. Dopamine -           
2. Age -.109 -          
3. Weight .298** .262** -         
4. BMI .024 .319** .874** -        
5. Waist Circumference .124 .413** .887** .896** -       
6. Systolic BP .503** .096 .524** .276** .347** -      
7. Diastolic BP .103 .235** .515** .474** .504** .580** -     
8. BDI Total Score .014 -.034 .042 .067 .160 -.169* .055 -    
9. DEBQ Emotional -.098 .060 .188* .312** .277** -.210* .017 .493** -   
10. DEBQ Restrained -.166* -.039 .065 .197* .158 -.190* -.009 .276** .350** -  
11. DEBQ External .070 .082 -.001 -.016 .005 -.013 -.028 .170* .325** -.024 - 
12. YFAS Symptoms  .010 .069 .285** .350** .367** -.014 .051 .513** .567** .176* .226** 





The current study aimed to provide a greater understanding of depressogenic 
eating dysregulation and food addiction, and associations with peripheral dopamine 
levels. It was found that depressed individuals meeting YFAS criteria for food addiction 
displayed significantly greater mood and eating related psychopathology compared to 
depressed individuals who did not meet YFAS criteria and controls. Depressogenic food 
addiction was also associated with a sexual dimorphism in plasma dopamine levels; 
depressed males meeting YFAS criteria had significantly lower plasma dopamine levels 
than depressed males not meeting YFAS criteria and male controls, whereas there was 
no effect of YFAS status on dopamine levels in depressed or control females. Plasma 
dopamine levels correlated positively with emotional eating and food addiction related 
behaviours in females, and negatively in males. Plasma dopamine levels were not 
correlated with mood or other depressive symptoms. 
The findings of the current study provide evidence that a high proportion of 
participants with MDD experience overeating which overlaps closely with the concept 
of food addiction as measured by the YFAS, characterised by loss of control, tolerance 
and withdrawal symptoms in relation to food. Problematic eating behaviours were 
higher in those with MDD overall compared to controls. The proportion of participants 
with MDD meeting criteria for food addiction in this study was 29%; which is nearly 
three times higher than food addiction prevalence rates reported in general community 
samples (Meule & Gearhardt, 2014). This is also similar to our previous findings in 
MDD in both a separate cohort (Mills et al., 2018) and a smaller, overlapping cohort 
(Mills et al., 2019) which has been extended for the current study. Across sexes, 
depressed individuals meeting YFAS criteria demonstrated significantly greater mood 
psychopathology and problematic eating (emotional and restrained), in addition to 
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higher health risk indices (BMI and waist circumference), compared to depressed 
individuals not meeting YFAS criteria and controls. The endorsement of food addiction 
criteria in a significantly higher proportion of participants with MDD suggests that food 
addiction, in addition to emotional and restrained eating behaviours, is an important 
concept which may contribute to risk of weight gain and health problems in MDD. 
Additionally, the positive correlations between depressive symptom severity, overeating 
and BMI in the current study suggest that depressogenic overeating may be related to 
the ability of some types of food to dampen the physiological stress response produced 
by the HPA axis in order to improve mood (Dallman et al., 2003; Finch & Tomiyama, 
2015), which in turn is associated with greater BMI (Mills et al., 2019). Collectively, 
these findings indicate that food addiction is associated with greater psychopathology 
and risk for chronic health conditions in MDD.  
A significant interaction effect was observed between food addiction group and 
sex for plasma dopamine levels in individuals with MDD. Depressed males meeting 
YFAS criteria had significantly lower plasma dopamine levels compared to depressed 
males not meeting YFAS criteria and control males, whereas plasma dopamine levels 
did not differ between females by food addiction group. This suggests that plasma 
dopamine levels are differentially related to depressogenic symptom profiles in males 
compared to females. This was also reflected in the relationships observed between 
plasma dopamine levels and problematic eating behaviours. In females, plasma 
dopamine levels were positively correlated with emotional eating, restrained eating, and 
select YFAS subscales such as a failure to quit food intake and withdrawal when certain 
foods are not consumed. In males however, dopamine levels correlated negatively with 
restrained eating only. These relationships suggest that females with higher dopamine 
levels, and males with lower dopamine levels, may be more likely to eat excessively in 
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association with problematic eating behaviours, and also exert a lower degree of control 
over these behaviours as well. Consistent intake of highly palatable foods in depressed 
individuals who meet YFAS criteria may increase the risk for weight gain in both sexes 
(Paans et al., 2018), which is likely related to peripheral dopamine levels. Further 
research is required to better understand these effects and their significance. 
Peripheral dopamine levels were also positively correlated with weight and 
systolic blood pressure, which is consistent with the role of peripheral dopamine in the 
regulation of body weight and blood pressure (Rubi & Maechler, 2010). Higher body 
weight and systolic blood pressure are risk factors for obesity and cardiovascular 
disease respectively (Kannel, 2000; Kearns et al., 2014). Higher plasma dopamine 
levels may therefore be related to increased health risks, however further longitudinal 
research is required to understand whether this is the case. 
Dopamine levels were marginally higher in the MDD than control groups. 
Previous studies are inconsistent, with some previous studies reporting no differences 
between groups (Hamner & Diamond, 1996; Fajardo et al., 2003), and others reporting 
elevated dopamine levels in MDD (Rothschild et al., 1986; Pan et al., 2018). Further, in 
the current study dopamine levels did not correlate significantly with indices of low 
mood. This is also inconsistent with some previous studies (Hamner & Diamond, 1996; 
LeBlanc & Ducharme, 2007). These findings suggest that peripheral dopamine may be 
related to specific symptom subtypes in MDD such as eating patterns, rather than all 
depressive symptoms; however further research is needed due to the paucity of research. 
Collectively, the findings from the current study provide a greater understanding 
of potential pathways to depressogenic weight gain and chronic disease. Depressed 
individuals meeting YFAS criteria may be at greater risk of chronic disease linked to 
greater depressive symptoms, appetite disturbances and altered sympathetic stress 
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which is related to peripheral dopamine. These results provide further evidence that 
problematic eating behaviours are common in MDD and are more closely associated 
with physiological factors than recognised previously (Mills et al., 2019). The role of 
peripheral dopamine in depressogenic problematic eating and weight gain has at present 
not been studied extensively. Further research is necessary in order to understand these 
relationships, which may assist in the development of interventions to reduce chronic 
disease risk in affected individuals. 
 Some limitations of the study need to be considered. The current study was 
cross-sectional in design. Longitudinal research is required to understand the temporal 
relationships between peripheral dopamine, food addiction and MDD, in order to 
determine whether these factors may act as potential points of early interventions. The 
analyses examining food addiction subgroups in MDD should be further investigated in 
larger samples. Potential covariates such as diet and physical activity levels were also 
not controlled for. Due to the role of increased consumption of highly palatable food in 
depressogenic food addiction and weight gain, and the potential moderation effect of 
exercise and specific dietary habits, such covariates should be considered.  
 In conclusion, the current study provides novel evidence highlighting the nature 
of depressogenic food addiction, and its relationships to peripheral dopamine levels. 
The results indicate that depressogenic overeating, particularly food addiction, may 
have a greater physiological basis than considered previously and be related to health 
risk indices associated with greater chronic disease risk. These findings necessitate 
future longitudinal research to examine the roles of both psychological and 
physiological factors in depressogenic weight gain, which may lead to improved and 
integrated interventions.   








6.1 Introductory Comments 
 
The results from Study 4 emphasised the prevalent nature of problematic eating 
behaviours in MDD, particularly food addiction, with the prevalence of individuals with 
MDD meeting YFAS criteria identified as 29%. Study 4 also provided the first reported 
evidence that peripheral dopamine is associated with depressogenic overeating 
behaviours and biometric indices of obesity. These findings provide additional support 
that problematic eating in MDD is related to physiological factors, however as this was 
the first study examining peripheral dopamine in depressogenic overeating, further 
research is necessary to understand these relationships in more depth. 
This thesis has identified that leptin, ghrelin and dopamine are related to 
depressogenic overeating behaviours and BMI, and that serotonin is related to 
depressive symptom severity. However, the unique contribution of each hormone to 
variance in depressive symptoms and health indices has not yet been explored. As such, 
the unique and collective contributions of leptin, ghrelin, serotonin and dopamine to 
problematic eating behaviours, depressive symptom severity and biometric indices of 
health in MDD was investigated. Due to the sex differences identified in the proportion 
of problematic eating behaviours and hormones levels in all thesis studies, regression 
analyses with Sex as a moderating variable were performed. 
 
6.2 Data and Statistical Analysis 
The data for the integrated analyses were derived from MDD and control 
participants in Studies 2, 3 and 4 in whose plasma all four biomarkers had been 
analysed (n = 140; 80 female). The variables of interest with respect to hormones were 
leptin (normalised to waist circumference), ghrelin, serotonin and dopamine levels. BMI 




was included as an index of physical health. The psychometric variables were 
depressive symptom severity (BDI total score), problematic eating behaviours (DEBQ 
Emotional eating score) and food addiction (YFAS symptom count). 
Pearson’s and Spearman’s rank correlation coefficients were used to assess 
interrelationships between Sex, peripheral hormones, health indices and 
psychopathology. The false discovery rate (FDR) procedure (Benjamini & Hochberg, 
1995) was applied to control for Type I errors. Four hierarchical multiple regressions 
were conducted to investigate the potential moderating effects of Sex on the relationship 
between hormones and BMI, depressive symptom severity, emotional eating and food 
addiction respectively. For all four regressions, Sex was entered in the first step, and 
values for all four hormones (leptin normalised to waist circumference, ghrelin, 
serotonin and dopamine) entered in the second step. Interaction effects between Sex and 
each hormone were entered as the third step. Interaction terms were calculated by 
standardising hormone values to prevent multicollinearity and multiplying these values 
by Sex (female = 0, male = 1). The visual inspection of plots, tolerance values greater 
than 0.10 and variance inflation factor values below 2 indicated that the assumptions of 
normality, linearity, multicollinearity and homoscedasticity were satisfied. 
 
6.3 Correlation Analyses 
The correlation results for the variables of interest are reported in Table 6.1. 
Leptin positively correlated with BMI, problematic eating behaviours (DEBQ, YFAS) 
and Sex, and negatively correlated with dopamine. Ghrelin negatively correlated with 
BMI only. Serotonin correlated positively with dopamine and depressive symptom 
severity (BDI), and negatively with Sex. Dopamine also negatively correlated with Sex. 
Sex positively correlated with Emotional eating. Further, depressive symptom severity, 
emotional eating, food addiction and BMI were positively correlated with one another. 




Table 6.1:  
Correlation coefficients for the study variables (total N = 140). 
 
 
Note: BMI = Body Mass Index; BDI = Beck’s Depression Inventory; DEBQ = Dutch Eating 
Behaviours Questionnaire, YFAS = Yale Food Addiction Scale. Effects reported are False 
Discovery Rate corrected p values. * p < .05. a Spearman’s correlation coefficients. 
  
6.4 Hierarchical Multiple Regression Analyses 
The results of the four hierarchical regressions are reported in Table 6.2. In the 
first analysis investigating the influence of Sex and peripheral hormones on BMI, in 
Step 1, Sex accounted for a non-significant 0.2% of unique variance in BMI (F(1, 138) 
= .309, p = .579, R2 = .002). In Step 2, the addition of the hormone values accounted for 
an additional 38.9% of unique variance in BMI (F(5, 134) = 17.248, p < .001, R2 = 
.389). At this step, higher leptin and lower ghrelin were related to significantly higher 
BMI values. At Step 3, the interaction between Sex and hormones accounted for a 
further 15% of unique variance in BMI (F(9, 130) = 17.052, p < .001, R2 = .150). Only 
the relationship between leptin levels and BMI was significantly moderated by Sex. 
Post-hoc analyses using the procedure outlined in Holmbeck (2002) were conducted to 
determine the nature of the interaction. Male centred (male = 0, female = 1) and female 
centred (female = 0, male = -1) Sex variables were multiplied by standardised leptin 
values to create new interaction terms. Two regression analyses including the main 
effect for leptin, one of the Sex variables and the interaction term were then conducted. 
The results of these analyses indicated that higher leptin levels were associated with 
Variables 1 2 3 4 5 6 7 8 
1. Leptin -        
2. Ghrelin -.136 -       
3. Serotonin -.094 -.021 -      
4. Dopamine -.436* -.107 .178* -     
5. BMI .493* -.330* -.084 .033 -    
6. BDI Total .136 -.094 .207* -.009 .067 -   
7. DEBQ Emotional .408* -.153 -.064 -.104 .312* .493* -  
8. YFAS Symptoms .191* -.151 -.007 .003 .350* .513* .567*  
9. Sexa .611* .060 -.209* -.788* -.042 .088 .316 .069 




greater BMI values across sexes, however this effect was more pronounced in females 
(b = 1.327, p < .001) than males (b = .352, p < .001). 
In the second analysis relating to depressive symptom severity, at Step 1 Sex 
explained a non-significant 0.9% of unique variance in BDI Total scores (F(1, 138) = 
1.262, p = .263, R2 = .009). At Step 2, the four hormone values significantly explained 
an additional 7.5% of unique variance (F(5, 134) = 2.468, p = .036, R2 = .075), where 
higher plasma serotonin values were the only predictor of higher BDI Total scores. At 
Step 3, the interactions between Sex and hormones were not associated with depressive 
symptom severity, explaining a non-significant 1.5% of unique variance in BDI Total 
scores (F(9, 130) = 1.578, p = .126, R2 = .015). 
In the third analysis pertaining to emotional eating, Sex at Step 1 accounted for a 
significant 9.3% of unique variance in DEBQ Emotional eating scores (F(1, 138) = 
14.083, p < .001, R2 = .093). The four hormones at Step 2 explained a further 13.3% of 
unique variance (F(5, 134) = 7.795, p < .001, R2 = .133), with higher levels of leptin and 
dopamine associated with higher Emotional eating scores. At Step 3, the overall 
regression model including interaction effects was significant and accounted for an 
additional 3% of unique variance in Emotional eating scores (F(9, 130) = 4.946, p < 
.001, R2 = .030), however only main effects for Sex and leptin levels were observed, and 
no interaction terms between Sex and the hormones were significant. 
In the final analysis assessing food addiction symptoms, in Step 1 Sex explained 
a non-significant 1.4% of variance (F(1, 138) = 1.947, p = .165, R2 = .014), and in Step 
2, the four hormones explained an additional non-significant 5.8% of variance (F(5, 
134) = 2.088, p = .071, R2 = .058). Further, at Step 3 the interaction terms between Sex 
and hormone values explained a non-significant 3% of variance in YFAS Symptom 





Table 6.2:  
Standardised and unstandardised regression coefficients for the hierarchical regression models (total N = 140). 
 
  BMI BDI Total DEBQ Emotional YFAS Symptom Count 
  B b p B b p B b p B b p 
Step 1 Sex .544 .047 .579 2.908 .095 .263 .676 .304 <.001* .767 .118 .165 
Step 2 Leptin 1.806 .651 <.001* .649 .088 .403 .165 .309 .002* 224 .143 .179 
 Ghrelin -.953 -.214 .003* -.917 -.077 .365 -.090 -.105 .182 -.310 -.123 .154 
 Serotonin -.002 -.095 .168 .013 .227 .008* .000 -.023 .772 .000 .007 .939 
 Dopamine .658 .117 .290 2.115 .141 .297 .350 .321 .011* .715 .224 .101 
Step 3 Leptin x Sex 5.235 .506 <.001* 2.572 .094 .442 .186 .093 .401 .221 .038 .755 
 Ghrelin x Sex -.385 -.054 .600 -2.289 -.121 .404 -.337 -.246 .064 -1.074 -.267 .067 
 Serotonin x Sex -1.205 -.146 .084 -.904 -.041 .726 .040 .025 .815 -.285 -.061 .604 
 Dopamine x Sex 1.518 .161 .199 -2.866 -.115 .514 -.077 -.042 .792 .331 .062 .722 
 












The results from the integrated analyses provide further evidence that 
problematic eating behaviours, depressive symptoms and indices of adiposity in MDD 
are associated with peripheral hormones. Higher leptin and lower ghrelin concentrations 
were significant predictors of BMI, with a stronger effect between leptin and BMI 
identified for females compared to males. Across sexes, higher leptin and dopamine 
levels were significant predictors of Emotional eating, and higher serotonin 
concentrations predicted more severe depressive symptoms. In contrast, when including 
all hormones in the regression analyses, no hormone accounted for unique variance in 
the number of food addiction symptoms. These findings suggest that individuals with 
higher leptin and dopamine levels may experience greater instances of overeating 
behaviours and weight gain, and that individuals with higher serotonin levels may 
experience more severe depressive symptoms.   
In combination, these findings provide evidence that hormones related to satiety 
and energy balance account for unique variance in depressive symptoms, which 
supports a potential and specific role of peripheral hormones in depressogenic 
symptomology. Broadly, leptin and dopamine levels may act as risk factors for 
overeating, and serotonin levels may act as risk factors for more severe depressive 
symptoms. Consistent with the sexual dimorphisms observed in leptin, serotonin and 
dopamine levels in Studies 2, 3 and 4, females may be at greater risk of overeating 
behaviours linked to leptin and dopamine levels, whereas males with higher serotonin 
levels may be at greater risk of more severe depressive symptoms. Further, the 
relationship between peripheral hormones and adiposity indices differed by sex, with 
higher leptin levels acting as a potential risk factor for greater weight gain in females 
compared to males. These differences highlight that sex differences in MDD symptom 




presentation and hormone levels are an important consideration with respect to 
depressogenic weight gain. Taken together, these findings support that the assessment 
of these peripheral hormones may assist in providing important information about 
depressive symptom risk, particularly weight gain. 
However, these findings are preliminary in nature and should be interpreted 
tentatively. While these results are promising, larger longitudinal studies are needed in 
order to provide more detailed information regarding these findings. 
 
 








The aims of this doctoral thesis were to systematically assess the nature of 
depressogenic problematic eating behaviours, and to examine their relationship to 
peripheral hormones, health risk indices and depressive symptom profiles in order to 
better understand the associations between MDD, obesity and cardiometabolic disease. 
Concerning these aims, four empirical investigations were conducted utilising an 
integrated biopsychosocial approach. Problematic eating behaviours, peripheral 
hormones implicated in the regulation of satiety, hunger, weight, energy balance and the 
sympathetic stress response, biometric health indices and depressive symptoms were 
compared between those with MDD and unaffected controls, between females and 
males, and by symptom profile of depressogenic appetite and weight changes. The 
interrelationships between these variables were also assessed. The results of this thesis 
indicate that there is a high prevalence of problematic eating behaviours in MDD, and 
that these are associated with greater BMI and waist circumference values, as well as 
the peripheral hormones leptin, ghrelin and dopamine, particularly in females. Serotonin 
was associated with depressive symptom severity, particularly in males. This thesis 
highlights possible pathways to weight gain, obesity and cardiometabolic disease risk in 
individuals affected by MDD, particularly in females. 
6.1 Summary of Findings 
The first study of this thesis assessed whether depressive appetite/weight 
symptom profiles, problematic eating behaviours and physical health indices were 
related to leptin. Leptin concentrations were associated with sex-specific 
appetite/weight change patterns and problematic eating behaviours in MDD. Leptin was 
higher in females with appetite/weight gain and in males with appetite/weight loss. 




Problematic eating behaviours, including emotional eating and food addiction, were 
more prevalent in females than males with MDD, and correlated positively with leptin 
concentrations. Leptin also correlated with greater physical health indices, such as BMI. 
The findings from Study 1 suggest that higher concentrations of plasma leptin may have 
an important role in appetite/weight changes and overeating behaviours in MDD, 
particularly an atypical MDD symptom profile and in females, providing a preliminary 
indication that problematic eating and risk factors for chronic health conditions in MDD 
are related to hormonal factors. 
Study 2 expanded on the previous study by evaluating whether problematic 
eating behaviours differed between those with MDD and healthy controls by sex, as 
well as by appetite/weight symptom profile. Associations between problematic eating in 
MDD and leptin, the hunger hormone ghrelin, and physical health indicators such as 
BMI were also assessed. It was identified that problematic eating behaviours occur 
frequently in MDD and vary by sex and symptom profile. Emotional eating and food 
addiction were higher in MDD than in controls, particularly in those with self-reported 
appetite/weight gain, and more prevalent among females. Leptin was positively, and 
ghrelin was negatively, associated with emotional and restrained eating and food 
addiction, as well as BMI. These findings from Study 2 highlight the high prevalence of 
overeating in MDD, and provide additional evidence that these behaviours and physical 
health indicators are associated with hunger and satiety hormones. 
Having established links between problematic eating and hunger and satiety 
hormones, Study 3 investigated peripheral serotonin, an energy balance hormone, in 
MDD compared to controls, by sex and appetite/weight symptom profile. The 
relationships between serotonin, problematic eating and other depressive symptoms 
were also assessed. Upregulation in serotonin was identified as a potentially important 




factor in depressive symptomology, with varying effects across sexes. Serotonin levels 
were elevated in MDD and in males. Serotonin correlated positively with depressive 
symptom severity, negative thinking and anxiety in the total sample and in males, but 
linked to agitation only in females. Serotonin was not associated with problematic 
eating or weight changes. Study 3 highlights that, unlike the associations observed with 
leptin and atypical MDD profiles in females, plasma serotonin may be more relevant to 
non-atypical MDD symptom profiles and males with MDD, further indicating that sex 
differences in peripheral hormones may be important to depressive symptom 
presentations. 
Following the high prevalence of problematic eating behaviours in MDD 
identified in the previous studies, Study 4 investigated the role of peripheral dopamine 
in depressogenic overeating and food addiction in greater detail. It was identified that 
depressed individuals who met YFAS criteria for food addiction may be at greater risk 
of obesity and cardiometabolic disease linked to depressive symptoms and altered 
sympathetic stress responses. Measures of psychopathology, overeating behaviours and 
indices of health risk including BMI and waist circumference were greater in 
individuals with MDD who met YFAS food addiction criteria than those with MDD 
who did not meet YFAS criteria and controls. Plasma dopamine correlated positively 
with overeating in females and negatively in males, providing additional support that 
problematic eating in MDD is related to hormonal factors, and that sex differences are 
an important factor in these relationships. 
The final study of this thesis investigated the individual and combined 
contributions of leptin, ghrelin, serotonin and dopamine to variance in problematic 
eating behaviours, depressive symptom severity and BMI, and the potential moderating 
effect of Sex on these relationships. The findings of this study support the differential 




roles of peripheral hormones in depressive symptoms, as leptin and dopamine 
accounted for unique variance in problematic eating behaviours and serotonin 
accounted for unique variance in depressive symptom severity. Leptin also accounted 
for a significant quantity of variance in BMI, particularly in females. Study 5 provides 
additional support for the role of peripheral hormones in depressive symptoms, with the 
sex-based difference in adiposity, as indexed by BMI, linked to leptin levels. These 
findings, in combination with the sex-based differences in overeating and peripheral 
hormone patterns observed in the previous thesis studies, indicate that MDD symptom 
presentations and peripheral hormones should be considered with respect to the risk of 
depressogenic weight gain, particularly in females. 
 
6.2 Collective Implications 
This thesis has made several novel contributions to the knowledge and literature 
regarding the nature of and potential mechanisms related to problematic eating in MDD 
by systematically assessing the relationships between problematic eating behaviours, 
biometric health indices, depressive symptom profiles relating to appetite and weight, 
and peripheral hormones. This in turn provides novel information regarding the 
associations between MDD, obesity and cardiometabolic disease risk. As a result of this 
research program, several important conclusions about these relationships can be made. 
The results of the studies contained within this thesis indicate that there are 
distinct overeating patterns that occur in MDD relative to unaffected controls, which 
vary as a function of sex and depressive symptom profile. In all studies, emotional and 
restrained eating behaviours, as well as food addiction symptoms, were consistently 
higher in those with MDD compared to controls, in females overall compared to males, 
and in females with MDD compared to males with MDD. Problematic eating 
behaviours were also higher in individuals reporting increased appetite and weight 




during a depressive episode and in individuals with MDD who met the YFAS criteria 
for food addiction. These patterns are consistent with the atypical subtype of MDD, 
which is more prevalent in females and is characterised by hyperphagia and weight gain 
during a depressive episode (American Psychiatric Association, 2013). The present 
research was also the first to identify prevalence rates of food addiction in MDD, of 24-
29% (Mills et al., 2018; Mills et al., 2019; Mills et al., 2020), which is much higher than 
the current prevalence rates reported in obese or control populations (Meule & 
Gearhardt, 2014). Despite the high prevalence rates observed in the present thesis, the 
underlying biopsychosocial motivations for problematic eating in MDD remain to be 
elucidated. It has been suggested that problematic eating behaviours may be used by 
individuals with MDD in order to improve mood (Finch & Tomiyama, 2015). However, 
emerging evidence suggests that mood improving effects associated with highly 
palatable food intake are transient (Finch et al., 2019), and that problematic eating 
behaviours may therefore be used to mitigate physiological stress; including HPA axis 
activity which is elevated in MDD (Dallman et al., 2003; Keller et al., 2016). 
Interpreting the current results in the broader context of previous research, the increased 
emotional eating observed in those with MDD, including females and those with an 
atypical symptom profile, may be reflective of greater attempts to improve mood or 
physiological stress during a depressive episode (Finch & Tomiyama, 2015; Finch et 
al., 2019), which is supported by the positive correlations between problematic eating 
behaviours, depressive symptom severity and psychological stress in Studies 2, 3 and 4. 
The potentially transient nature of the mood improving effects may contribute to the 
repeated and excessive food intake experienced in MDD (Finch et al., 2019). These 
effects may reinforce highly palatable food intake patterns in some individuals, which 
may eventually manifest as food addiction (Martins et al., 2019). Alternatively, 




hormonal changes such as increased leptin or dopamine concentrations may lead to 
changes in hunger and associated eating behaviours. Such changes overlap with several 
types of problematic eating, such as food addiction, as observed in Study 4. The greater 
restrained eating observed in those with MDD may be indicative of increased binge 
eating following caloric restriction, or attempts to correct changes to weight following 
such binges (van Strien et al., 2016). The fact that external eating did not differ across 
groups in any study indicates that interoceptive hunger signals such as peripheral 
hormones relating to hunger and satiety, rather than environmentally derived food 
intake signals, may predominate in MDD. This contrasts with the increased sensory 
food intake that occurs in obesogenic environments in individuals unaffected by MDD 
(Hidaka, 2012). Collectively, these findings contribute to the understanding of the 
prevalence of overeating patterns in MDD, with the greater instances of emotional 
eating, restrained eating and food addiction observed in Studies 1-4 suggesting that 
these problematic eating behaviours related to mood and possibly to stress-relief, 
particularly food addiction, may be a more common occurrence in MDD than 
previously recognised. In addition to those with MDD, females and those specifically 
with an atypical MDD symptom profile characterised by overeating and weight gain 
may be more prone to engaging in these behaviours.  
Despite the popular perception that problematic eating behaviours are 
psychologically motivated (Finch & Tomiyama, 2015), this thesis highlights that 
peripheral hormones related to hunger, satiety, weight, energy balance and sympathetic 
stress are related to depressogenic overeating. Leptin levels were positively associated 
with emotional eating, restrained eating and food addiction, and were significant 
predictors of problematic eating behaviours across sexes and adiposity particularly in 
females. Due to the usual role of leptin in satiety, positive associations between leptin 




and overeating are consistent with an interpretation of leptin resistance or insensitivity 
to the expected satiety cues (Pan et al., 2014). If this was the case, higher leptin levels, 
particularly in females and those with MDD reporting increased appetite and weight, 
were not signalling the expected satiety response, resulting in increased appetite and 
increased food intake, particularly emotional eating. This may have in turn influenced 
weight gain risk due to the relationship between food intake and weight, in addition to 
the role of leptin in promoting adipogenesis to store excess energy following consistent 
overeating (Maffei et al., 1995). It is also possible that due to its moderating effect on 
HPA axis activity, leptin may be implicated as a signalling molecule for emotional 
eating in order to promote stress relief (Roubos et al., 2013).  
Ghrelin levels were negatively associated with restrained eating only, which 
may indicate increased ghrelin secretion. Due to the roles of ghrelin in hunger (Wren et 
al., 2000) and promoting adipogenesis during times of insufficient energy to ensure 
adequate energy stores (Tschop et al., 2001), individuals with higher ghrelin levels may 
have been experiencing greater hunger and therefore increased food intake. This may 
have resulted in dieting related behaviours and a greater vulnerability to compensatory 
binge eating, which may influence weight gain risk.  
The correlations between plasma dopamine and problematic eating behaviours 
varied by sex, as plasma dopamine correlated positively with emotional eating and food 
addiction, and predicted problematic eating behaviours, in females only. In contrast, 
plasma dopamine negatively correlated with restrained eating in males only. Further, 
plasma dopamine predicted Emotional eating across sexes. These relationships suggest 
that peripheral dopamine may be implicated in the differential regulation of problematic 
eating in males and females. Similarly to leptin, it is possible that plasma dopamine may 
act as a signalling molecule for highly palatable food intake as part of emotional eating 




and food addiction in order to promote stress relief, due to its links to the sympathetic 
stress response (Rubi & Maechler, 2010). As a result, females with higher and males 
with lower plasma dopamine levels may have been more likely to overeat and have a 
lower degree of control over food intake. However, the link between plasma dopamine 
and eating-related behaviours has not been previously reported in the literature and 
warrants further research.  
In contrast to leptin, ghrelin and dopamine, serotonin was not significantly 
associated with problematic eating behaviours or physical health indices. However, 
serotonin accounted for unique variance in depressive symptom severity across sexes, 
and was positively correlated with other depressive symptoms related to mood, 
depressogenic thinking and insomnia in males and agitation in females. While plasma 
serotonin has been previously linked to higher BMI values and obesity (Young et al., 
2018), it is possible that plasma serotonin may have a greater role in broader 
psychopathology in MDD, including symptom severity, with effects varying by sex. 
Similarly to dopamine, the link between plasma serotonin and depressive symptoms 
warrants further research to understand the nature of the identified associations. 
Taken together, the associations observed in this research indicate that 
depressogenic problematic eating behaviours are related to several hormone measures. 
Previous research has indicated that MDD is associated with neuroendocrine changes, 
particularly in relation to cortisol and HPA axis activity (Keller et al., 2016; Thomas & 
Larkin, 2018; 2020). This thesis provides new indications of further neuroendocrine 
involvement in MDD which has meaningful associations with specific symptoms, 
particularly problematic eating behaviours. As such, the risk for depressogenic weight 
gain, obesity and cardiometabolic disease may be linked to neuroendocrine changes in 
hunger, satiety, weight regulation and energy balance hormones, particularly leptin. 




Further, the fact that leptin predicted greater indices of adiposity in females, that leptin 
and dopamine were associated with overeating in females, and that plasma serotonin 
predicted depressive symptom severity in males supports the importance of peripheral 
hormones in depressive symptom patterns which vary by sex. The associations observed 
across all studies of this thesis suggest that upregulation in leptin, ghrelin and plasma 
dopaminergic pathways, along with hormone resistance or insensitivity, in MDD may 
be risk factors for depressogenic overeating and weight gain in females, and 
upregulation in serotonin may be a risk factor for more severe depressive symptoms in 
males, however further research is required to assess the temporal nature of these 
relationships. 
This thesis has contributed to the understanding of the physiological and 
psychological factors which may explain depressogenic overeating and associated 
health risks by identifying significant associations between problematic eating 
behaviours, peripheral hormones and indices of obesity and cardiometabolic disease 
risk. Previous studies have considered the individual contributions of problematic eating 
behaviours and hormones to weight gain in MDD, however interrelationships had not 
yet been assessed (Milaneschi et al., 2017a; Paans et al., 2018). In the cohorts in the 
current research program, emotional eating, restrained eating and food addiction 
symptoms were associated with greater BMI and waist circumference values. Leptin 
and dopamine were positively, and ghrelin negatively, associated with indices of 
adiposity, whereas serotonin was not related to overeating or adiposity measures. These 
relationships provide new information that problematic eating behaviours and distinct 
peripheral hormone profiles may act as potential risk factors for depressogenic weight 
gain, with overweight-obesity risk varying by sex. Weight gain and obesity are known 
risk factors for additional health complications, which compound the risk for chronic 




disease onset including obesity and cardiometabolic disease (Zhao et al., 2009; Kearns 
et al., 2014). As such, problematic eating behaviours and peripheral hormones may need 
to be carefully considered in the treatment of depressogenic weight gain. Importantly, 
this thesis also indicates that sex differences in these factors need to be carefully 
considered, as the greater prevalence of overeating and associated hormonal patterns in 
females and absence of such patterns in males may have important implications in that 
interventions for these issues may need to vary by sex (Smith et al., 2008). 
The interrelationships between problematic eating behaviours, hormones and 
indices of obesity suggest that integrated biopsychosocial approaches may show 
promise in future approaches to addressing depressogenic weight gain. There is 
currently a lack of holistic approaches to understanding weight gain in MDD as existing 
perspectives are predominantly either psychological or physiological in nature (Arora & 
Anubhuti, 2006; Paans et al., 2018). This is reflected in existing intervention methods 
oriented on either therapy for underlying emotional issues or a perceived lack of 
willpower, or generic weight loss approaches such as dieting, exercise or 
pharmacotherapy regimes (Jacka & Berk, 2012). However, these perspectives are 
limiting as potential interactions between variables may be overlooked. This research 
program has shown that an integrated approach incorporating biological, psychological 
and behavioural measures provides new information which can potentially increase the 
understanding of the risks of additional health burdens in affected individuals. Further 
integrated research is needed to better understand depressogenic overeating, which may 
lead to novel integrated interventions to assist in the prevention of this issue and 
associated health risks. 
Given the high prevalence of problematic eating in MDD, and the observed 
associations with indices of obesity in this research program, problematic eating 




behaviours and peripheral hormones may represent potential targets for integrated 
treatment approaches. From a practical perspective, a biopsychosocial approach to 
address depressogenic weight gain may consist of the development of a 
multidisciplinary health team to assess the specific psychological and physiological 
symptoms that an individual with MDD presents with, and subsequently tailoring 
therapeutic and behavioural interventions for the individual based on their symptom and 
behavioural profile. Such interventions may include a combination of tailored cognitive-
behavioural therapy, exercise or addressing eating behaviours with a dietician. A 
pharmacological element may also be included to address hormonal changes that occur 
in association with problematic eating behaviours and weight gain (Abizaid et al., 
2006). Further, given their greater susceptibility to MDD and adiposity (Blaak et al., 
2001; Rainville et al., 2018; Smith et al., 2008), females may also require different or 
more tailored interventions compared to males. The results of this thesis have provided 
further information indicating that overeating and select hormone patterns are more 
prevalent in females, which may be relevant to treatments for atypical MDD. Atypical 
MDD, characterised by appetite and weight gain, is more prevalent in females (Woelfer 
et al., 2019). As such, females may need to be more carefully assessed if they present 
with depressive symptoms related to weight gain risk, such as problematic eating 
behaviours. Leptin insensitivity could be assessed as a potential risk factor for weight 
gain in females, and leptin and dopamine levels in females could also be assessed as 
potential biomarkers of risk for problematic eating behaviours. Such assessments may 
lead to early preventative measures to reduce obesity and cardiometabolic disease risk 
in affected individuals, however, as this is one of the first programs of research to assess 
the interrelationships between problematic eating behaviours, hormones and weight 
gain in MDD, more research is required to assess the nature of the identified 




relationships in more depth. Given that the prevalence rates of MDD and chronic 
disease are increasing annually (World Health Organisation, 2017), this area of research 
is a priority in order to assist in reducing the likelihood of chronic disease risk in 
affected individuals. 
 
6.3 Thesis Limitations 
The findings from this thesis should be viewed in light of some methodological 
limitations. Firstly, cross-sectional study designs were utilised in all four studies, 
therefore causation cannot be inferred from the identified results and an understanding 
of the temporal nature of the identified relationships is limited. For example, it is not 
clear whether weight gain causes changes in peripheral hormones, or whether peripheral 
hormones affect appetite and eating behaviours, which can then cause weight gain. As 
such, longitudinal research is warranted to provide more specific indications about the 
directionality of the identified pathways between problematic eating behaviours, 
biological factors and weight in MDD, which will assist in further elucidating the 
pathways between MDD, obesity and cardiometabolic disease risk. 
Secondly, the sub-group analyses in Studies 2 to 4 were conducted in small 
groups of participants, and despite promising results from these investigations with 
respect to MDD symptom profile and sex differences in problematic eating behaviours, 
peripheral hormones and physical health indicators, these findings should be considered 
preliminary in nature and therefore interpreted tentatively. Further research replicating 
these analyses in larger groups will provide greater statistical power and may provide a 
clearer indication of the relationships between the variables of interest. 
 Thirdly, participants were not required to fast prior to blood collection. Previous 
studies have indicated that fasting levels of leptin and ghrelin are not significantly 
different to non-fasting levels (Hancox & Landhuis, 2011; Natalucci et al., 2005), 




whereas fasting differences in peripheral serotonin and dopamine have not been 
reported. In the thesis studies, no significant differences were observed in any 
peripheral hormone levels between participants who elected to fast and those who did 
not. Given the natural endocrine fluctuations in response to hunger and satiety, further 
research utilising fasting protocols may provide more detailed information regarding 
endocrine changes in the context of problematic eating in MDD. 
Further, several potential confounding variables such as participant diet, 
physical activity levels and current subjective hunger levels were not accounted for. 
Because of the role of dietary preferences and subjective hunger levels in eating 
behaviour, and the moderating influence of exercise on body weight, such covariates 
should be considered in future research. While measures of increased and decreased 
appetite were included in all studies, hunger scales may be useful in future studies to 
provide a quantitative index of hunger levels. In addition, data about menstrual cycle 
was not collected; menstrual cycle phase in females should also be considered in future 
research to account for any potential interactions between monthly fluctuations in 
female hormones, such as oestrogen, with the peripheral hormones of interest. 
 
6.4 Directions for Future Research 
Following the outcomes of the studies included in this research program, 
longitudinal research is warranted in order to understand the nature of the identified 
associations in more depth. A longitudinal study has commenced within the research 
group which aims to address the aforementioned limitations and include further 
variables. Additional survey measures have been included to measure physical activity 
levels and obtain a subjective rating of hunger. A semi-structured diet history interview, 
conducted by a dietician, has also been included to measure participant diet and food 




intake preferences. It is anticipated that this new study will assist in providing a clearer 
understanding of the pathways between MDD and chronic disease risk. 
In addition to replicating the studies conducted in this thesis, further studies 
should examine the possible role of other biological factors in problematic eating 
behaviours and weight gain, in order to provide a more thorough understanding of the 
relationship between MDD and chronic disease. Cortisol may be of interest due to its 
close associations with HPA axis activity, energy metabolism and food intake (George 
et al., 2010). Insulin and neuropeptide-Y may also be of interest due to their roles in the 
regulation of hunger and satiety (Loh et al., 2017; Steiner et al., 2019). Oxytocin may 
also be relevant due to its roles in stress attenuation and learning, particularly in the 
context of addiction (Sarnyai & Kovacs, 2014). Pro-inflammatory cytokines such as 
tumour-necrosis-factor alpha (TNF-a) and interleukin-6 (IL6) should also be considered 
due to the role of inflammation in the onset and maintenance of chronic health 
conditions such as cardiovascular disease (Shajib & Khan, 2015). Similarly, the role of 
genetic factors in weight gain and MDD may assist in elucidating these relationships 
(Milaneschi et al., 2017b). Due to the potential role of physiological stress in 
problematic eating behaviours, future studies would benefit from including additional 
measures of physiological arousal, such as skin conductance or electroencephalography, 
in order to assess the relationships between physiological stress indices and overeating. 
Further, despite the difficulties in quantifying hormone levels directly in the brain of 
living humans (Andrews et al., 2015), it may be of interest for future research to 
evaluate CNS measures of these hormones using CSF or neuroimaging techniques and 
compare them to peripheral levels in blood. Such studies may provide a better 
understanding of the relationships between the central and peripheral roles of these 
hormones in MDD, particularly in relation to obesity and cardiometabolic disease risk. 





6.5 Concluding Remarks 
To conclude, this thesis aimed to systematically investigate problematic eating 
behaviours and specific peripheral hormones, with a view of better understanding 
depressogenic weight gain and associations between MDD, obesity and cardiometabolic 
disease risk. It was identified that there is a high incidence of problematic eating 
behaviours, particularly food addiction, in those with MDD and in females. Differences 
in levels of hormones related to hunger, satiety, weight regulation, energy balance and 
the sympathetic stress response which aligned with the patterns of problematic eating 
behaviours were also observed; particularly leptin and dopamine in females. Despite the 
popular perceptions of ‘comfort eating’, these findings suggest that problematic eating 
behaviours in MDD are not purely psychological as they are associated with 
physiological factors. Peripheral hormone levels, particularly leptin, may have potential 
utility in acting as risk factors for problematic eating behaviours and weight gain in 
those affected by MDD, particularly females. This leads to the suggestion that 
integrated models and treatment perspectives be applied to depressogenic overeating 
and weight gain, which may lead to the development of more integrated and effective 
interventions in order to reduce the risk of obesity and cardiometabolic conditions in 
affected individuals. It is hoped that this program of research, and future research 
extending from it, may help address the increased risk of chronic health conditions in 
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“It’s like a game of chess – it’s one move at a time, and bit by bit everyone 
makes a contribution. Even if you do 10%, it’s something.” 
~ Nano 
 
 
 
